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1 Introduction 
The mitogen-activated protein kinase (MAPK) pathways are ubiquitous and highly conserved 
in all eukaryotic cells. They consist of a large enzyme network that contributes to the 
amplification and specificity of a signal by sequential activation of cytoplasmic and nuclear 
proteins and finally initiates cellular processes like gene transcription, protein synthesis, 
proliferation, differentiation or apoptosis (145, 157, 199).    
MAPKs are activated by different stimuli acting through diverse receptor families, 
including cytokines, hormones, growth factors and environmental stress. After ligand binding, 
activated receptors recruit adaptor proteins and activate small GTP-binding proteins. 
Subsequently, a three-tiered signalling module is turned on, consisting of MAP3Ks 
(MKKKs), MAP2Ks (MKKs) and MAPKs. So far, there are 20 defined MKKKs that activate 
7 MKKs which in turn activate 11 MAPKs (89). They represent the three major MAPK 
pathways: the extracellular signal-regulated kinase (ERK) pathway, the p38 kinase pathway 
and the c-Jun N-terminal kinase (JNK) pathway (Fig. 1). 
Fourteen of the 20 defined MKKKs activate the c-Jun N-terminal kinase (JNK) pathway 
(like apoptosis signal-regulating kinase 1 (ASK-1), dual leucine zipper kinase (DLK), 
mitogen-activated protein/extracellular signal-regulated kinase kinase (MEKK-1) and mixed 
lineage kinases 1-4 (MLK-1-4)), demonstrating the importance and versatility of JNK 
signalling in the cellular response to stimuli (72). Some of them phosphorylate both JNK 
activators, MKK4 and MKK7, and some of them are specific for a single MKK only. In turn, 
activated MKK4 and MKK7 phosphorylate JNKs (JNK1-3). Thus, a diversity of stimuli turns 
on a variety of MKKKs, which activate three JNK isoforms with only two MKKs as 
intermediates. How can MKK4 and MKK7 transfer, as well as multiply and ensure signal 
specificity? This problem is underestimated and often simplified as linear sequential 
bimolecular signalling. The number of published studies about MKK4, MKK7 and their 
upstream kinases is much less addressed (~ 1,400) compared to publications on JNKs (~ 
15,000). The introduction of this thesis focuses on the present knowledge of molecular and 
functional characteristics of MKK4 and MKK7. In addition, different ways of JNK regulation 
via MKK4 and MKK7 are presented and as yet unknown aspects are revealed. 
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Fig. 1: Simplified model of the JNK signalling cascade.  
The three-tiered core module of MKKKs, MKKs and MAPKs induces a multiplicity of cellular 
processes. 
 
1.1 Mitogen-activated protein kinase kinase 4 
The mitogen-activated protein kinase kinase 4 (MKK4) was first identified in a cDNA library 
from Xenopus laevis embryos by a PCR-based screen and called XMEK2 (211). Thereafter, 
Drosophila, mouse, rat and human homologs were cloned and named stress-activated protein 
kinase/extracellular signal-related protein kinase kinase 1 (SEK1), MKK4 and c-Jun N-
terminal kinase kinase 1 (JNKK1), respectively (46, 73, 115, 128, 154).  
Molecular characteristics- The mkk4 gene is located on human chromosome 17 
(mouse chromosome 11; rat chromosome 10; Drosophila chromosome 3R) and encodes a 
protein of 399 amino acids. So far, only one mkk4 gene product has been described. The 
human MKK4 shares 94% homology with the mouse and rat MKK4 protein (79% with 
Drosophila; mouse and rat share 100% homology).  
The kinase domain of the serine/threonine kinase MKK4 contains two phosphorylation 
sites in the S-I-A-K-T (Ser-Ile-Ala-Lys-Thr) motif (209). MKK4 is activated by the majority 
of MKKKs, such as ASK-1, MEKK, MLK, and transforming growth factor-β activated kinase 
(TAK) (145). Additionally, MKK4 contains a domain of versatile docking (DVD) located at 
the C-terminus (Fig. 2), where upstream MKKKs and other MKKs can bind (173, 204). 
Association with upstream kinases affects the activity of MKK4 and leads to conformational 
changes (27, 173). Furthermore, MKK4 binds via its DVD to scaffold proteins such as JIP-3.  
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Similar to other MAPKs, MKK4 contains motifs for binding of upstream and 
downstream signalling components. The D-domain type docking site in the N-terminal region 
of MKK4 binds to its MAPK substrates JNKs and p38 (78). In the ability to phosphorylate 
both MAPKs, MKK4 is unique among all known MKKs. In particular the JNK activation is 
well examined. In vitro studies revealed that MKK4 preferentially phosphorylates the tyrosine 
residue of JNKs (115, 154). Moreover, some stressors were found, where MKK4 is the main 
JNK activator such as anisomycin and arsenite (188). Other stimuli only require MKK4 for 
complete/optimal JNK activation, whereas MKK7 is essential for triggering JNK activity 
(178).  
Functions- MKK4 is involved in a variety of physiological and pathophysiological 
processes. Until embryonic day 10 (E10) in mice, mkk4 mRNA is exclusively expressed in the 
central nervous system (CNS) (110). By E12 the mkk4 transcript can be detected in several 
tissues of the developing embryo, with high mkk4 mRNA levels in the liver. Mice with a 
targeted deletion of the mkk4 gene die between E11.5 and E13.5 of anemia and abnormal 
hepatogenesis (62). Thus, MKK4 fulfils essential functions that cannot be compensated by 
other MKKs. Similarly, MKK4 is relevant in the heart, immune system and the development 
of cancer. In a mice model of hypertrophy, gene transfer of a kinase-inactive MKK4 inhibited 
JNK signalling and blocked cardiac hypertrophy (28). Studies on the function of MKK4 in the 
immune system were mostly carried out on chimeric sek1-/-/rag2-/- mice and brought up 
conflicting data. On the one hand, these mice developed smaller thymi with decreased 
proliferation of peripheral T cells (133). On the other hand, mice had no impaired B and T cell 
development but generated massive lymphadenopathy (169). This discrepancy could be 
ascribed to the missing constancy of different mkk4-/- embryonic stem cell clones. The human 
mkk4 gene is located proximal to the p53 tumour suppressor gene on chromosome 17, 
suggesting that MKK4 is involved in the inhibition of tumour formation. Indeed, studies on a 
wide spectrum of primary cancers demonstrated a loss-of-function mutation in mkk4 in 5% of 
especially lung and pancreatic tumours (99, 130, 167, 175, 205). Additionally, endogenous 
expression of MKK4 could reduce metastasis of pancreatic and ovarian tumours in mice (206, 
214). However, an equal number of studies revealed a pro-oncogenic role for MKK4. 
Knockdown of MKK4 by siRNA increased apoptosis of breast cancer cells after serum 
deprivation and suppressed tumour growth in a mouse model (194). Furthermore, injection of 
mkk4-/- pancreatic cell line into mice reduced lung metastases of the primary pancreatic 
tumour and caused a longer tumour volume-doubling rate compared to mkk4+/- cell injection 
(38). 
Introduction  4 
MKK4
MKK7
JNK
D
D D D
kinase domain DVD
kinase domain DVD
kinase domain CDED
P P
P P
P P
 
Fig. 2: Schematic illustration of the MKK4, MKK7 and JNK structures. 
All three kinases contain several functional domains for activation and binding of other proteins. They 
are activated by phosphorylation of two residues in their kinase/catalytic domain (Ser and Thr for 
MKK4 and MKK7; Thr and Tyr for JNK). CD, common docking domain; D, docking domain; DVD, 
domain of versatile docking; ED, glutamate/aspartate domain; P, phosphorylation site.  
 
 
1.2 Mitogen-activated protein kinase kinase 7 
The mitogen-activated protein kinase kinase 7 (MKK7), also called stress-activated protein 
kinase/extracellular signal-regulated protein kinase kinase 2 (SEK2) or c-Jun N-terminal 
kinase kinase 2 (JNKK2) was first cloned from cDNA of murine testis with primers based on 
the sequence coding for the Drosophila mitogen-activated protein kinase kinase hemipterous 
(hep) (180). Subsequently, MKK7 was cloned from human and rat (80, 129, 209, 210).  
Molecular characteristics- The human mkk7 gene is located on chromosome 19 
(mouse chromosome 8; rat chromosome 12; Drosophila (hep) chromosome X). By alternative 
splicing its transcript generates a group of protein kinases with three different N-termini (α, β 
and γ) and two different C-termini (1 and 2) (Fig. 3). So far, four human, six murine, one rat 
and three MKK7 splice variants from Drosophila have been described (60, 123, 180, 181, 
209). They encode for proteins ranging from 347 to 469 amino acids. Human MKK7γ1 shares 
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98% homology with the mouse and rat protein (mouse and rat 99% homology; Drosophila 
hep transcript variant C with human 85% homology). 
 The S-K-A-T (Ser-Lys-Ala-Thr) motif in the kinase domain of MKK7 is 
phosphorylated at the serine and threonine residues by several MKKKs. Interaction of MKK7 
with those upstream kinases is mediated by the domain of versatile docking (DVD) at the C-
terminus (Fig. 2). MKKK binding also facilitates phosphorylation of MKK7 through 
conformational changes of the activation loop (173). According to the size of the N-terminus, 
different MKK7 splice variants contain 2 or 3 docking (D) domains for JNK binding. A 
comparative study on the basal activities of different murine MKK7 splice variants revealed 
that MKK7β and -γ have higher catalytic activities towards JNKs than MKK7α (181). This 
might be due to the shorter N-terminus of MKK7α, which lacks a third docking domain (79). 
Further in vitro studies showed that each MKK7 splice variant has different biochemical 
properties, but little is known about the functional relevance. 
Functions- During embryogenesis, the mkk7 transcript is mainly found in epithelial 
tissues such as skin, lung and epithelium (210). In adult humans, the mkk7 mRNA is widely 
expressed in various tissues with high functional expression in the heart, liver, skeletal 
muscle, kidney and pancreas (209). Thus, embryos from mkk7 knockout mice die between 
E11.5 and E13.5 with a disorganized liver, which contains less parenchymal hepatocytes 
(178, 187). Therefore, most studies were done with mkk7-/- mouse embryonic fibroblasts 
(MEFs) or chimeric mouse models. The loss of mkk7 leads to decreased proliferation and 
premature cellular senescence beginning with passage 4-5 and G2/M cell cycle arrest in MEFs 
(187). Interestingly, knockout of mkk4 in MEFs showed a similar phenotype but 
overexpression of mkk4 in mkk7-/- MEFs could not compensate for the loss of mkk7 (187). 
Additionally, loss of jnk1 also has an anti-proliferative effect on MEFs and inactivation of c-
jun caused premature senescence. This indicates that the effect of mkk4 and mkk7 knockout is 
mediated by JNKs and that both MKKs are important for these processes but carry out 
different tasks (179). In contrast, studies with B and T lymphocytes from chimeric           
mkk7-/-/rag2 mice showed that loss of mkk7 enhances cell cycle progression of mast cells 
(155). Missing conditional and cell type specific mkk7 knockout approaches limit the 
investigations of MKK7 functions in vivo and functional studies on single MKK7 splice 
variants are needed to examine further molecular characteristics. 
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Fig. 3: Schematic illustrastion of the six murine MKK7 splice variants.  
Alternative splicing of the mkk7 transcript generates six MKK7 proteins with different C- and N-
termini. 
 
1.3 The c-Jun N-terminal kinases 
The c-Jun N-terminale kinases (JNKs), also called stress-activated protein kinases (SAPKs), 
have first been discovered in a c-Jun binding assay with extracts from UV-stimulated HeLa 
cells (76). In rapid succession, all three JNK isoforms from human, mouse and rat were 
identified and cloned (46, 107). Drosophila has only one JNK (DJNK, Basket) protein, which 
is encoded by basket (bsk) (163).  
Molecular characteristics- In mammalian genomes three genes (jnk1, jnk2 and jnk3) 
encode a family of three JNK isoforms (JNK1-3) with a total of ten splice variants. The jnk1 
gene is located on human chromosome 10 (mouse chromosome 14, rat chromosome 16), jnk2 
on chromosome 5 (mouse chromosome 11, rat chromosome 10) and jnk3 on chromosome 4 
(mouse chromosome 5, rat chromosome 14). Each jnk gene encodes for four, or two in the 
case of jnk3, alternatively spliced transcripts, which differ in subdomain IX (α and β) and 
their C-termini (1 and 2). All ten mRNAs are translated into proteins of 381 to 464 amino 
acids with molecular weights of 46 and 54 kDa. Mouse and rat JNK2α2 are identical and 
share 98% homology with the human protein (73% with Drosophila). 
 JNKs are activated by concomitant phosphorylation at a threonine and a tyrosine 
residue within a conserved T-P-Y (Thr-Pro-Tyr) motif in the activation loop of the kinase 
domain by MKK4 and MKK7 (106, 199). Like all other MAPKs, JNKs have a common 
docking (CD) domain in their C-terminus and a glutamate/aspartate (ED) domain in their N-
MKK7γ2
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terminus (Fig. 2), which enable interactions with activators (MKK4 and MKK7), inhibitory 
proteins (e.g., mitogen-activated protein kinase phosphatases (MKPs)) and substrates (e.g., c-
Jun) (69).  
 JNKs themselves phosphorylate multiple targets. In the nucleus, various transcription 
factors such as c-Jun, c-Myc, activating transcription factor 2 (ATF-2) and p53 are activated 
by JNKs (70, 91, 125, 135). Some of these transcription factors form homo- or heterodimers 
to induce transcription as the activator protein-1 (AP-1) complex, a key inducer of genes 
encoding proteins involved in proliferation (e.g., CyclinD1), differentiation (e.g., c-Jun) and 
cell death (e.g., Fas ligand (Fas-L)) (75, 159).  
 Cytoplasmic proteins constitute the second major pool of JNK substrates. As JNKs are 
involved in apoptosis, they modulate many pro- and anti-apoptotic proteins, e.g., B-cell 
lymphoma 2 (Bcl-2), Bcl-2-associated death promoter (Bad), Bcl-2-associated X protein 
(Bax), B-cell lymphoma extra large (Bcl-xl) or Bcl-2-interacting mediator of cell death (Bim) 
(29, 113, 143). Furthermore, superior cervical ganglia 10 (SCG10) and tau, which are 
involved in microtubule (de-)stabilization are phosphorylated by JNKs (147, 174).  
However, some targets are not only regulated by phosphorylation, but also by binding 
to JNKs. On the one hand, JNK-mediated phosphorylation or JNK binding activates and 
stabilizes substrates like transcription factors against ubiquitin-dependent degradation (111, 
160); but on the other hand, JNKs also mediate ubiquitin-dependent degradation of some of 
their targets. These ubiquitination-dependent actions of JNKs involve their interaction with 
ligases, such as Itch (63).  
 Functions- Looking at the tissue distribution of jnk transcripts in humans, jnk1 and 
jnk2 are widely expressed, whereas expression of jnk3 is mainly confined to brain, heart and 
testis. This restriction gave first hints for an important role of JNK3 in the nervous system.   
Mice with the deletion of a single jnk gene are viable. Only a combined deletion of 
jnk1 and jnk2 in mice is lethal due to changes in specific natural apoptosis in the brain and a 
defect in neural tube morphogenesis (104, 152). Studies on jnk knockout mice have shown 
that JNKs are involved in a diversity of pathologies like diabetes, obesity, cancer, Parkinson’s 
disease or Alzheimer’s disease (14, 24, 77, 87, 88). In contrast, negative effects of jnk 
knockout on brain development, long-term potentiation, cancer, neural differentiation and 
regeneration have been observed (10, 20, 22, 25, 95, 104, 132, 152). Regarding the question 
how JNKs mediate this plethora of partially opposing functions, specificity of JNK isoforms 
and their targets have been investigated for a long time (11, 12). However, the last years have 
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provided evidence that especially signalosome assembly, cellular localisation and 
environmental stimuli trigger distinct JNK effects (10, 193, 216). 
 
1.4 Regulation of JNKs by MKK4 and MKK7 
Apart from phosphorylation and dephosphorylation, JNKs and their upstream kinases are 
regulated by post-translational modifications and they form complexes with upstream kinases 
or downstream targets, so called signalosomes. Scaffold proteins, repeat-motif extended 
proteins, often function as couplers of those complexes and determine their composition and 
cellular localisation. 
Phosphorylation- The most obvious regulation of JNKs by MKK4 and MKK7 is their 
activation by phosphorylation. MKK4 and MKK7 differ in their preference for JNK 
phosphorylation sites. Whereas MKK4 induces phosphorylation of the tyrosine residue, 
MKK7 phosphorylates the threonine residue in the activation motif (100, 178). Importantly, 
full activation of JNK requires phosphorylation of both residues. Therefore, phosphorylation 
by MKK7 seems to be essential for JNK activation, while phosphorylation by MKK4 is only 
required for optimal JNK activation (178, 217). Furthermore, MKK7 splice variants show 
differences in their activation potency towards JNKs. Due to their N-terminal extension, 
MKK7β and –γ are strong JNK activators, whereas MKK7α only weakly phosphorylates 
JNKs (181).  
JNK activation following different types of cellular stress can be mediated by one 
MKK or both activators. MKK4 is the major activator of JNKs in response to anisomycin, 
arsenite or heat-shock stimulation, while MKK7 strongly activates JNKs under basal 
conditions and after tumour necrosis factor α (TNF-α), IL-1β and thapsigargin stimulation 
(178). During UV irradiation and cadmiumchloride stimulation, both MKKs equally 
contribute to the activation of JNKs (134, 178, 208). 
To stop signal transduction, mitogen-activated protein phosphatases (MKPs), also 
known as dual-specificity phosphatases (DUSPs), can inactivate or at least modulate JNKs, 
MKKs and MKKKs via dephosphorylation. 
Interactions- The formation of multiple protein complexes is necessary for the 
regulation of JNK signalling by MKK4 and MKK7. These protein complexes consist of 
different combinations of MKKKs, MKKs and JNKs and can include further modulators like 
phosphatases or other cofactors. Some of those signalling complexes are assembled by 
scaffold proteins. 
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MKK4 and MKK7 bind to JNKs via their D-domains in the N-terminal region (78, 79, 
127). This binding is very specific, as JNK1 and JNK2 do not interact with the D-domains of 
other MKKs (5). The intercellular concentrations of binding partners apparently determine the 
inhibitory or activating effect of MKKs on JNKs (97). However, interactions with MKKs 
enhance JNK phosphorylation but concurrently inhibit the activity of JNKs towards their 
downstream substrates for the time of binding. 
Efficient modulation/action of JNKs requires scaffold proteins that bring MKK4 and 
MKK7 together with MKKKs and JNKs. The best studied group of scaffolds are the JNK-
interacting proteins 1-4 (JIP-1-4) which also contribute to signal specificity. JIP-1 and JIP-2 
only bind to MKK7 (198, 212), whereas JIP-3 and JIP-4 additionally bind to MKK4 (94, 109, 
121). Signalosomes of JIP-1 or JIP-2 and MKK7 are found under basal conditions and 
increase following different types of stress like ischemia, UV irradiation or cytokine 
stimulation (127, 164, 198). Their abundance is always connected with a strong activation of 
JNKs and complexes with all three JNK isoforms have been reported.  
While some biochemical properties of interactions between MKK4, MKK7 and JNKs 
have already been characterised, cellular functions and molecular conditions of those 
complexes are still to be determined. Most studies were done using in vitro systems, i.e., 
independent of physiological and pathophysiological conditions. Further studies that link 
MKK:JNK interactions to a distinct cellular effect are necessary to understand the multiplicity 
of JNK-mediated functions.  
 
1.5 PC12 cells- a versatile model for peripheral mammalian neurons 
The PC12 cell line was established in 1976 by Lloyd Greene and Arthur Tischler and 
represents a single clonal cell line from a male rat pheochromocytoma, a tumour arising from 
chromaffin cells of the adrenal medulla (68). The cells synthesize and store the 
neurotransmitters dopamine and norepinephrine, but no epinephrine. They have a 
homogenous and near-diploid chromosome number of 40. PC12 cells grow adherent on 
collagen-coated dishes. One cell has a diameter of 15 to 30 µm. Cultured in medium that 
contains serum, PC12 cells have a round or polygonal shape and are comparable to adrenal 
chromaffin cells or sympathetic neurons. They have a doubling time of 48 to 72 h. No major 
changes were detected in cell growth characteristics, morphology, noradrenergic properties or 
growth factor sensitivity after cultivating the cells for 70 generations (68). 
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When cultured with serum-free medium, PC12 cells cease to proliferate (150). By 
addition of nerve growth factor (NGF) to serum-free medium, PC12 cells differentiate into a 
neuron-like phenotype (67). They undergo at least one round of division before they begin to 
extend branching varicose processes similar those of primary sympathetic neurons. If 
maintained in serum containing medium, NGF-induced differentiation is reversible. Removal 
of NGF is followed by degeneration of processes within 24 h and by resumption of cell 
multiplication within 72 h. Therefore, PC12 cells have been widely used in studying different 
aspects of growth factor-mediated differentiation. To induce differentiation, NGF binds to the 
tyrosine receptor kinase A (TrkA) and the p75 neutrophin receptor (p75) on the cellular 
surface (8, 102). These receptors activate different intracellular signalling cascades that 
usually involve the Ras/ERK1/2 pathway (144). 
Apart from differentiation, apoptotic processes in PC12 cells have been examined 
intensively (23, 54, 144). Since it is of major interest to understand the mechanisms of 
neuronal cell death in several diseases, it was first necessary to establish reliable cell culture 
systems: only under stable conditions, it is possible to elucidate signal transduction processes 
that are responsible for the induction of cell death. Due to the neuronal characteristics of 
PC12 cells, they have been frequently used in various situations that induce neuronal 
apoptosis. 
Another advantage of PC12 cells is that they can be transfected by various methods 
with high transfection efficiency and without affecting their ability to differentiate. Therefore, 
PC12 cells are a useful model system for many neurobiological studies. 
 
1.6 Aims of the study 
Many studies have investigated the functions of JNKs in neurons. However, it is largely 
unknown how this multiplicity of various and partially opposite functions is regulated. The 
aim of this thesis was to examine the effect of MKK4 and MKK7 on JNK signalling in 
neurons. Therefore, the coding sequences of MKK4 and MKK7 had to be isolated and cloned 
into a mammalian expression vector. As a cellular model system, PC12 cells were chosen, 
that should be stably transfected with MKK4 or MKK7. 
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In particular the following questions were addressed: 
 
• Does overexpression of a single MKK4 or MKK7 splice variant provoke a distinct 
phenotype in PC12 cells?  
 
• Which effect has a single MKK4 or MKK7 splice variant on basic cellular processes like 
proliferation, apoptosis or differentiation under basal and stress conditions? 
 
• Which effect has a single splice variant of MKK4 or MKK7 on JNKs? Does it affect the 
activation, protein levels and localization of distinct JNK isoforms?  
 
• Which effect has a single MKK4 or MKK7 splice variant on downstream JNK signalling, 
such as the activation and level of target proteins? 
 
• Which effect has a single MKK4 or MKK7 splice variant on JNK signalosomes? Does it 
change the assembly or abundance of JNK signalosomes? 
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2 Materials and methods 
2.1 Materials 
Unless otherwise indicated, all solutions and dilutions were prepared in double-distilled water 
(DDW). All chemicals were molecular biology or pro analysi (p.a.) grade, and cell culture 
reagents had endotoxin levels of less than 0.01 ng/ml lipopolysaccharide. Apart from 
antibodies used for Western blots, Tab. 1 includes all materials together with the respective 
manufacturer. 
 
Tab. 1: Materials. 
Material Manufacturer / Supplier 
Acetic acid Carl Roth; Karlsruhe, Germany 
Acrylamide / bis-acrylamide solution 
37.5:1 Bio-Rad; München, Germany 
Agarose SeaKem LE Biozym; Oldendorf, Germany 
6-Aminocaproic acid Merck-Schuchardt; Hohenbrunn, Germany 
Ammonium persulphate (APS) Merck; Darmstadt, Germany 
Ampicillin Stratagene; Amsterdam, Netherlands 
Aprotinin Sigma; München, Germany 
Bacto-tryptone BD Biosciences; Heidelberg, Germany 
Bacto-yeast BD Biosciences; Heidelberg, Germany 
BamHI Fermentas; St. Leon-Rot, Germany 
β-Glycerolphosphate Sigma; München, Germany 
Bovine serum albumin (BSA) Boehringer; Mannheim, Germany 
Boric acid Sigma; München, Germany 
BrdU incorporation assay Roche; Mannheim, Germany 
Broad Range Prestained Protein Marker New England Biolabs; Frankfurt, Germany 
Bromophenol blue Merck; Darmstadt , Germany 
Calcium chloride Merck; Darmstadt, Germany 
CASYton buffer Schaerfe System; Hamburg, Germany 
Cell culture plates (20 cm) Sarstedt; Nümbrecht, Germany 
Cell culture plates (10 cm) Sarstedt; Nümbrecht, Germany 
Cell culture plates (6 wells) Sarstedt; Nümbrecht, Germany 
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Material Manufacturer / Supplier 
Cell culture plates (12 wells) Sarstedt; Nümbrecht, Germany 
Cell culture plates (24 wells) Sarstedt; Nümbrecht, Germany 
Cell culture plates (96 wells) Sarstedt; Nümbrecht, Germany 
Cell scraper Sarstedt; Nümbrecht, Germany 
Chamber slides Nunc; Karlsruhe, Germany 
3-[(3-Cholamidopropyl)dimethyl-
ammonio]-1-propanesulfonate (CHAPS) Merck; Darmstadt, Germany 
ChIP-IT Control kit rat Active Motif; Rixensart, Belgium 
ChIP-IT Express Enzymatic kit Active Motif; Rixensart, Belgium 
Collagen Biochrom; Berlin, Germany 
Coomassie blue Carl Roth; Karlsruhe, Germany 
Cryotubes (2 ml) Sarstedt; Nümbrecht, Germany 
Cuvettes Sarstedt; Nümbrecht, Germany 
Diethyl pyrocarbonate (DEPC) Sigma; München, Germany 
Dimethylsulfoxide (DMSO) Carl Roth; Karlsruhe, Germany 
1,4-Dithiotheit Carl Roth; Karlsruhe, Germany 
dNTP set (10 mM each) Fermentas; St. Leon-Rot, Germany 
DreamTaq DNA Polymerase Fermentas; St. Leon-Rot, Germany 
DreamTaq Buffer (10 x) Fermentas; St. Leon-Rot, Germany 
DTT (0.1 M) Invitrogen; Karlsruhe, Germany 
Dye Reagent Biorad; München, Germany 
ECL Plus Reagents Amersham Biosciences; Freiburg, Germany 
Ethylene-diamine-tetra-acetic acid 
(EDTA) Carl Roth; Karlsruhe, Germany 
Ethanol p. a. Carl Roth; Karlsruhe, Germany 
Ethanol, technical (denatured) Bundesmonopol für Branntwein (BfB); Offenbach, Germany 
Ethidium bromide solution (10 mg/ml) Carl Roth; Karlsruhe, Germany 
Ethylene glycol-bis(2-aminomethyl)-
N,N,N ,N -tetraacetic acid (EGTA) Merck; Darmstadt, Germany 
ExactaCruz reagents Santa Cruz; Heidelberg, Germany 
Fetal calf serum (FCS) Biochrom; Berlin, Germany 
Filter paper Whatman; Maidstone, UK 
Filter unit 0.22 µm, syringe-driven Qualilab; Bruchsal, Germany 
Formaldehyde Merck; Darmstadt, Germany 
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Material Manufacturer / Supplier 
Formamide Carl Roth; Karlsruhe, Germany 
G418, sulfate (solution) Biochrom; Berlin, Germany 
Glucose Carl Roth; Karlsruhe, Germany 
Glycerol Merck; Darmstadt, Germany 
Glycine Merck; Darmstadt, Germany 
HEPES Merck; Darmstadt, Germany 
HindIII Fermentas; St. Leon-Rot, Germany 
Horse serum Biochrom; Berlin, Germany 
Hydrochloric acid (HCL) Carl Roth; Karlsruhe, Germany 
Hyperfilm ECL Amersham Biosciences; Freiburg, Germany 
Immobilon P transfer membrane Millipore; Eschborn, Germany 
Kaiser’s glycerol gelantine Merck; Darmstadt, Germany 
Kanamycin Carl Roth; Karlsruhe, Germany 
LB-Agar Sigma; München, Germany 
1 kb DNA Ladder Invitrogen; Karlsruhe, Germany 
Leupeptin Sigma; München, Germany 
Ligation buffer (10 x) Roche; Mannheim, Germany 
Magnesium chloride (RT-PCR) Invitrogen; Karlsruhe, Germany 
Magnesium chloride (MgCl2) Carl Roth; Karlsruhe, Germany 
β-Mercaptoethanol Sigma; München, Germany 
Methanol Carl Roth; Karlsruhe, Germany 
MinElute PCR Purification kit Qiagen; Hilden, Germany 
4-Morpholino-propane-sulfonic acid 
(MOPS) Merck; Darmstadt, Germany 
Mycoplasma Stain kit Sigma; München, Germany 
NGF (2.5 S) Alomone labs; Jeruslaem, Israel 
Non-fat dry milk Uelzena; Uelzen, Germany 
Nonidet P40 Fluka Chemie; Buchs, Switzerland 
NucleoBond PC 100 kit Macherey & Nagel; Düren, Germany 
NucleoBond EF 500 kit Macherey & Nagel; Düren, Germany 
NucleoSpin Plasmid QuickPure kit Macherey & Nagel; Düren, Germany 
Paraformaldehyde Merck; Darmstadt, Germany 
Phosphate buffered saline 
w/o Ca2+ and Mg2+ (10 x) PAA; Cölbe, Germany 
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Material Manufacturer / Supplier 
PCR buffer (10 x) (RT-PCR) Invitrogen; Karlsruhe, Germany 
pEGFP-C3 Clontech; Heidelberg, Germany 
Penicillin/Streptomycin solution           
(10,000 U/ml / 10 mg/ml) PAA; Cölbe, Germany 
Pepstatin Sigma; München, Germany 
Phenylmethylsulfonyl fluoride (PMSF) Carl Roth; Karlsruhe, Germany 
Phosphatase Inhibitor Cocktail II Sigma; München, Germany 
Pifithrin-α Santa Cruz; Heidelberg, Germany 
Piperazine-N,N’-bis(2-ethanesulfonic 
acid) (PIPES) Carl Roth; Karsruhe, Germany 
Pipettes  
(serological, sterile; 5 / 10 / 25 ml) Sarstedt; Nümbrecht, Germany 
Pipette tips (10 / 200 / 1,000 µl) Sarstedt; Nümbrecht, Germany 
Ponceau S Sigma; München, Germany 
Potassium chloride (KCL) Carl Roth; Karlsruhe, Germany 
Potassium dihydrogen phosphate Carl Roth; Karlsruhe, Germany 
Potassium disulfate Carl Roth; Karlsruhe, Germany 
2-Propanol Carl Roth; Karlsruhe, Germany 
Propidium iodide Carl Roth; Karlsruhe, Germany 
Protease Inhibitor (Complete) Roche; Mannheim, Germany 
Protein marker, prestained, broad range New England Biolabs; Frankfurt, Germany 
QIAquick Gel Extraction kit Qiagen; Hilden, Germany 
QIAquick Nucleotide Removal kit Qiagen; Hilden, Germany 
QIAshredder Qiagen; Hilden, Germany 
Random primers Promega; Mannheim, Germany 
RNase H Invitrogen; Karlsruhe, Germany 
RNeasy Plus Mini Kit Qiagen; Hilden, Germany 
RPMI-1640 medium PAA; Cölbe, Germany 
T4 DNA Ligase Roche; Mannheim, Germany 
SalI Fermentas; St. Leon-Rot, Germany 
Sodium hydrogen carbonate Sigma; München, Germany 
di-Sodium hydrogen phosphate Merck; Darmstadt, Germany 
Sodium hydroxide Merck; Darmstadt, Germany 
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Material Manufacturer / Supplier 
Sodium thiosulfate Merck; Darmstadt, Germany 
SuperScript II Reverse Transcriptase Invitrogen; Karlsruhe, Germany 
SP600125 Alexis; Grünberg, Germany 
Sodium acetate Sigma; München, Germany 
Sodium carbonate Sigma; München, Germany 
Sodium chloride (NaCl) Carl Roth; Karlsruhe, Germany 
Sodium citrate Carl Roth; Karlsruhe, Germany 
Sodium dodecyl sulphate (SDS) Carl Roth; Karlsruhe, Germany 
Sodium hydroxide (NaOH) Carl Roth; Karlsruhe, Germany 
T4 DNA ligase Roche; Mannheim, Germany 
TaqMan Low-Density Array Applied Biosystems; Darmstadt, Germany 
TaqMan Universal PCR Mastermix Applied Biosystems; Darmstadt, Germany 
Taxol Calbiochem; Darmstadt, Germany 
TEMED Carl Roth; Karlsruhe, Germany 
Thapsigargin Calbiochem; Darmstadt, Germany 
TNF-α Millipore; Schwalbach. Germany 
Tris Carl Roth; Karlsruhe, Germany 
Triton X-100 Merck; Darmstadt, Germany 
Trypan blue solution, cell culture tested Sigma; München, Germany 
Tubes (0.5 / 1.5 / 2.0 ml) Sarstedt; Nümbrecht, Germany 
Tubes for PCR Sarstedt; Nümbrecht, Germany 
Tubes, sterile (15 ml) Sarstedt; Nümbrecht, Germany 
Tubes, sterile (50 ml) Sarstedt; Nümbrecht, Germany 
Tunicamycin Calbiochem; Darmstadt, Germany 
TurboFect Fermentas; St. Leon-Rot, Germany 
Tween-20 Calbiochem; Schwalbach, Germany 
Ultrapure water Biochrom; Berlin, Germany 
 
2.2 Centrifuges, cell culture equipment and sterilization 
Centrifugation parameters are documented as “time; relative centrifugal force; temperature”, 
e.g., “5 min; ca. 2,000 ×g; 4°C”. The following centrifuges were used: Biofuge fresco, 
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Varifuge 3.0 (all from Heraeus; Osterode, Germany), Centrifuge 5804 R (Eppendorf; 
Hamburg, Germany) and Mikrofuge (Neolab; Heidelberg, Germany). The Mikrofuge created 
a relative centrifugal force (RCF) of 2,000 ×g maximum. The Varifuge 3.0 and Centrifuge 
5804 R displayed RCF’s automatically, and the RCF’s in the Biofuge fresco (maximum 
radius (rmax): 85 mm) were calculated using the following equation: 
 
×g = 1.118 × rmax [mm] × (rpm/1,000)2. 
 
Cell culture experiments were performed under sterile conditions (70% ethanol) in a 
laminar flow unit (LFU; HERAsafe; Heraeus). The cells were cultivated at 37°C and 5% CO2 
in an incubator (HERAcell; Heraeus; Osterode, Germany) and examined using an Olympus 
CK 2 inverted microscope (Olympus; Hamburg, Germany). All tubes and pipette tips were 
autoclaved (134°C, 2.2 bar, 20 min). Solutions for cell culture were either obtained sterile or 
autoclaved in a DS 202 autoclave (Webeco; Bad Schwartau, Germany) at 120°C and 2.0 bar 
for 30 min. 
 
2.3 Culture, staining, stimulation and transfection of cells 
Cells were purchased from the American Type Culture Collection (Manassas, VA, USA). 
Cell culture was maintained by passaging the confluent cells on 10 cm cell culture plates. 
Prior to use, horse serum and fetal calf serum (FCS) were inactivated by incubation at 56°C 
for 30 min, aliquoted and stored at –20°C. The penicillin/streptomycin solution was also 
stored at –20°C, while the medium was stored in a cooling chamber (4°C). The cells were 
provided with fresh medium every 2–3 days. The absence of mycoplasma contamination was 
confirmed by routine tests performed with the Mycoplasma Stain kit according to the 
manufacturer’s instructions. After the cells had been passaged 20 times, the cultures were 
discarded.  
 
2.3.1 PC12 cells 
The rat PC12 pheochromocytoma cell line was derived from a transplantable rat 
pheochromocytoma (68). The cells were grown in RPMI-1640 medium supplemented with 
10% horse serum, 5% fetal calf serum (FCS) and 1% penicillin/streptomycin solution. 
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Medium for transfected PC12 cells was additionally supplemented with 500 µg/ml G418 
sulfate.  
PC12 cells, like many other adherent cells, need a structured substrate for growing. 
Therefore, all plates used for cultivation and experiments were coated with collagen (0.1 
mg/ml in 1x phosphate buffered saline (PBS) for proliferation; 0.01 mg/ml for 
differentiation). The bottom of the cell culture plates was covered with a thin layer of collagen 
solution, placed in the incubator for at least 1 h and then washed with PBS to remove collagen 
that had not adhered to the plate. Air-dried plates were stored under sterile conditions. 
Since PC12 cells grow adherent, they were treated with passage EDTA before 
passaging. EDTA is a chelator of bivalent cations like Ca2+ and therefore helps to reduce cell-
substrate adhesion. After washing with PBS (37°C), cells were rinsed with 2 ml passage 
EDTA and placed for 2 min in the incubator (37°C, 5% CO2). Five ml of medium (37°C) was 
added, cells were scraped off the cell culture plate and transferred to a 15 ml tube. After 
centrifugation (10 min; 1000 ×g; r.t.), pelleted cells were first completely re-suspended in a 
syringe with a 21G needle attached in 2 ml of medium. Then 5 ml of medium were added and 
the cells were re-suspended again. After resuspension, electronic cell counts were carried out 
(section 2.3.2).The amount of cells, which were aliquoted into new cell culture plates 
depended on cell density and the diameter of the cell culture plate (Tab. 2).  
For cell cycle analysis, cultures were transferred to serum-free medium for 24 h to 
stop proliferation (150). Cell growth was restarted by returning the cells to normal growth 
medium supplemented with FCS, resulting in a synchronised cell cycle.  
For the production of PC12 stock aliquots, cells were harvested as described above 
and re-suspended in 1 ml of medium. An aliquot of the cell suspension was diluted in normal 
medium and cells were counted electronically. Freezing medium (RPMI-1640 supplemented 
with 10% FCS and 10% DMSO) was added to a final concentration of 5 × 106 cells/ml. The 
resulting suspension was aliquoted (1 ml) in 2 ml cryotubes which were incubated for 10 min 
at r.t., transferred to ice for 35 min, incubated at –20°C for 45 min and finally stored at –80°C. 
For cell culture initiation, a stock aliquot was quickly thawed in a 37°C water bath. In 
the LFU, the cell suspension was transferred to a 10 cm plate with fresh medium (37°C). 
After 24 h at the latest, the medium had to be changed. 
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Tab. 2: PC12 cell numbers on cell culture plates. 
Cell culture plate Cells [x 106] 
Ø 20 cm 1.5-2.5 
Ø 10 cm 0.8-1.25 
6-well 0.3 
12-well 0.1 
24-well 0.05 
96-well 0.01 
 
2.3.2 Electronic cell counting 
Electronic cell counting analysis were performed by CASY TT cell counter (Schaerfe System; 
Hamburg, Germany). An aliquot of the cell suspension was mixed with CASYton buffer and 
cell number and viability were determined according to manufacturer’s instructions. The 
CASY TT cell counter can determine the complete cell number, the ratio of cells with 
damaged cell membrane and the mean volume of one cell.  
 
2.3.3 Trypan blue viability staining 
Various manipulations of cells, including passaging, freezing and numerous stimulations 
result in cell death. To determine the number of surviving cells in a population, exclusion of 
the dye trypan blue can be used. Healthy cells are able to exclude this dye for a certain time, 
but trypan blue will quickly diffuse into cells which have lost their membrane integrity. 
For trypan blue staining, control and stimulated cells were washed with PBS (37°C), 
rinsed with 2 ml of passage EDTA and placed for 2 min in the incubator (37°C, 5% CO2). 
Five ml of medium (37°C) were added and cells were scraped off the cell culture plate and 
transferred to a 15 ml tube. After centrifugation (10 min; 1000 ×g; r.t.), the resulting pellet 
was thoroughly resuspended in an appropriate amount of PBS. Twenty µl of the cell 
suspension were mixed with 20 µl of trypan blue solution and transferred to a hemocytometer 
twin chamber (Omnilab; Hamburg, Germany). For reasons of accuracy, cells were not 
allowed to stay in the dye solution for longer than 5 min. Living cells in the 16 squares of 
both chambers were counted, and the percentage of viable cells was determined. 
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2.3.4 Flow cytometric analysis 
Flow cytometry was used to determine the distribution of cells to cell cycle phases. The DNA 
intercalator propidium iodide binds to DNA of permeabilized cells. The amount of dye bound 
correlates with the content of DNA within a given cell. The relative content of DNA indicates 
the distribution of a population of cells throughout the cell cycle phases. Cells in the G1-phase 
of the cell cycle have a DNA content of 2n. Cells within the G2/M phases of the cell cyclöe 
have a DNA content of 4n and cells in the S-phase of the cell cycle have a DNA content 
greater than 2n and less than 4n.  
One x 106 cells were harvested as described in section 2.3.1 and centrifuged at 200 xg 
and 4°C for 5 min. The medium was discarded and the cells were resuspended in 400 µl 
hypotonic propidium iodide solution [50 µg/ml propidium iodide; 0.1% (w/v) sodium citrate 
and 0.1% Triton-X-100 in Ultrapure water]. Afterwards cells were kept at 4°C in the dark 
until measurements. Stained cells were analysed using a FACSCalibur flow cytometer and 
CellQuest software (Becton Dickinson; Mountain View, CA, USA). The WinMDI 
(http://facs.scripps.edu/software.html) application was used for data analysis. 
 
2.3.5 5-bromo-2-deoxyuridine (BrdU) incorporation assay 
Cell proliferation was measured using a BrdU incorporation assay according to the 
manufacturer’s instructions. 5-bromo-2-deoxyuridine is incorporated in the cellular DNA like 
thymidine. The immunoassay enables the quantification of cell proliferation based on the 
BrdU incorporation during DNA synthesis. Cells grown in a 96-well-plate (Tab. 2) were 
incubated with BrdU for 4 h and fixed. After incubation with an anti-BrdU-POD-antibody and 
the subsequent substrate reaction, absorbance at 370 nm (reference wavelength 492 nm) was 
measured using an ELISA reader (Model 680 microplate reader; Biorad; München, 
Germany). 
 
2.3.6 Differentiation 
In response to nerve growth factor (NGF), growth arrest is induced and PC12 cells 
differentiate into neuron-like cells with formation and elongation of neurites (67). PC12 cells 
were plated on collagen-coated plates (0.01 mg/ml in PBS). After 24 h, the cells were serum-
starved for 72 h using medium containing 0.5% FCS and 1% penicillin/streptomycin to 
synchronize the cell cycle activity of the cells (150). With synchronized cells, the 
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differentiation process is more reproducible due to a comparatively similar NGF receptor 
expression on the cell surface. After 72 h, the medium was changed and supplemented with 
50 ng/ml of 2.5 S NGF. The differentiating cells were provided with fresh medium containing 
NGF every 2–3 days. For monitoring differentiation in terms of morphological and molecular 
processes, cells were cultured for 5 days. 
 
2.3.7 Neurite outgrowth 
For the documentation of neurite formation and elongation, cells were photographed on day 5 
of the differentiation process. To avoid artifacts of the documentation system, cells were 
either photographed using an Olympus CK 2 inverted microscope (Olympus; Hamburg, 
Germany) with a corresponding camera system (JVC; Tokio, Japan) or stained with 
Coomassie blue (section 2.3.8). Images were analysed using a DMR microscope (Leica; 
Solms, Germany) with a camera system (JVC; Tokio, Japan). The percentage of cells with 
neurites longer than 1.5 diameters of the cell body were counted using the software ImageJ 
(http://rsbweb.nih.gov/ij/).  
 
2.3.8 Coomassie blue staining 
PC12 cells at day 5 of the differentiation process (section 2.3.6) were stained with Coomassie 
blue to visualize the formation of neurites. Cells were plated on chamber slides (10 µl of cell 
solution/250 µl of medium per well) and treated with NGF (50 ng/ml) for 5 days. The 
medium was discarded, and the cells were rinsed with paraformaldehyde (4% in PBS, 37°C) 
and incubated at r.t. for 15 min. The paraformaldehyde was then discarded, and the cells were 
washed two times with DDW. Subsequently, the ready-to-use Coomassie blue solution was 
added and incubated for at least 30 min. After discarding the staining solution and washing 
two times with DDW, the cells were incubated in de-staining solution (10% methanol, 10% 
acetic acid in DDW) for at least 30 min. Finally, the cells were washed two times with DDW. 
 
2.3.9 Incubation with inhibitors and stressors 
For stimulation experiments, cells below passage number 20 were plated on 10 cm, 6-well 
cell culture plates or on chamber slides (250 µl of medium per well). The JNK inhibitor 
SP600125 (2 µM, 30 min) was added before incubation with stressors. The lyophilized 
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substance was dissolved in dimethyl sulfoxide (DMSO) to make up a 10 mM stock solution 
which was aliquoted, protected from light and stored at –20°C. The p53 inhibitor pifithrin-α 
(30 µM) was dissolved in DMSO to make up a 30 mM stock solution which was aliquoted 
and stored at -20°C. Subconfluent cells were incubated with 1.4 µg/ml tunicamycin (0.2 
µg/ml stock in DMSO), 50 ng/ml TNF-α (0.1 mg/ml stock in ultra pure water), 5 µM taxol 
(10 mM stock in DMSO) or 5 µM thapsigargin (10 mM stock in DMSO). After the respective 
incubation periods, RNA or proteins were extracted. 
 
2.3.10 Transfection 
Expression of foreign genes in mammalian cells is an important technology in molecular 
biology for merely biochemical purposes (e.g., to study protein structure-function 
relationships and to produce proteins at a larger scale that are normally only available in 
limited quantities) or for the examination of cellular processes (e.g., to confirm that cloned 
genes can direct the synthesis of the desired proteins and to evaluate the physiological 
consequences of the expression of regulatory proteins). The choice of a particular expression 
vector and the transfection method depends on the objectives of the study. In this work, an 
enhanced green fluorescent protein (EGFP)-tagged vector was used so that transfected cells 
could easily be identified due to their green fluorescence. To deliver the nucleic acids into 
PC12 cells, a sterile solution of a cationic polymer (TurboFect) was used. The polymer forms 
compact, stable, positively charged complexes with DNA. These complexes facilitate gene 
delivery into eukaryotic cells and protect DNA from degradation. 
 For transfection PC12 cells were plated on 96-well plates (section 2.3.1). After 2 days 
0.1 µg DNA per well was diluted in 10 µl RPMI-1640 medium and 0.2 µl TurboFect per well 
were added. This solution was incubated for 20 min at r.t.. During that time the cells on the 
96-well plate were provided with fresh medium. Than 10 µl of the DNA/Turbofect mix were 
pipetted in each well and the plate was gently rocked to achieve an even distribution of the 
complexes. After 24 hours the medium was removed and replaced by fresh medium 
containing 500 µg/ml G418 sulfate for selection of transfected cells.  
There are two possibilities of expressing foreign DNA in mammalian cells: Cells can 
either be transfected transiently or stable clones can be generated. However, to examine 
effects of the recombinant proteins, the transfection efficiency has to be high, which is usually 
not the case with PC12 cells. Therefore, stable cell clones were established in this study by 
selection with G418 (section 2.3.1). 
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2.4 Processing of PC12 cells for RNA extraction 
2.4.1 Experimental precautions to minimize RNA degradation 
To minimize RNase activity during RNA extractions, several precautions were taken. 
Molecular biology grade chemicals were used to prepare buffers. All solutions were made up 
in DDW containing 0.1% diethylpyrocarbonate (DEPC) and were autoclaved prior to use. All 
tubes, pipette tips etc. were bought RNase-free. Samples were kept on ice wherever possible 
and all reagents were added on ice, since RNases are less effective at low temperatures. 
 
2.4.2 Harvesting cells 
PC12 cells were harvested from the respective cell culture plates. The medium was discarded 
and the cells were washed with PBS (37°C). After removing the PBS very carefully, an 
appropriate amount of RLT Plus buffer (including 1% β-mercaptoethanol) (RNeasy Plus kit, 
Qiagen) was pipetted on the plates (1 ml for 6 cm plates, 3 ml for 10 cm plates) and the PC12 
cells were scraped off the plates using a sterilized (70% ethanol) rubber cell scraper. The 
resulting cell extracts were transferred to 1.5 ml tubes and either immediately processed for 
RNA extraction (section 2.5) or stored at -80°C until extraction. 
 
2.5 Isolation of RNA 
2.5.1 RNA extraction 
RNA extraction from cells was performed using the RNeasy Plus Mini kit with an optimized 
protocol. The cell lysates were pipetted into a QIAshredder spin column placed in a 2 ml 
collection tube, and centrifuged (2 min; 16,000 xg; r.t.) to homogenize the lysate. For DNA 
removal, the homogenized lysate was transferred to a gDNA Eliminator spin column and 
centrifuged (30 sec; 16,000 xg; r.t.). One volume of 70% ethanol was added to the flow-
through, and mixed by pipetting. The sample was transferred to an RNeasy spin column and 
centrifuged (30 sec.; 16,000 xg; r.t.) for precipitation of RNA. The precipitated RNA on the 
column membrane was washed once with 700 µl RW1 buffer, and twice with 500 µl RPE 
buffer (including ethanol) (30 sec.; 16,000 xg; r.t.) to remove salts. After the RNeasy spin 
column has been transferred to a clean collection tube, the membrane was dried by 
centrifugation (3 min; 16,000 xg; r.t.). For elution of RNA, the RNeasy spin column was 
transferred to a clean collection tube and 40 µl RNase-free water was directly pipetted on the 
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spin column membrane. After 1 min. incubation at r.t. the RNeasy spin column was 
centrifuged for 1 min at 16,000 xg and r.t.. The isolated RNA was stored at -80°C. 
 
2.5.2 RNA quantification and quality control 
The RNA sample was diluted 1:25 in RNase-free water. RNA concentrations were determined 
by measuring the absorbance at 260 nm (A260) against a blank of RNase-free water in a 
photometer (BioPhotometer; Eppendorf; Hamburg, Germany). An absorbance of 1 unit at 260 
nm corresponds to 40 µg/ml of RNA in water. Therefore, the RNA concentration cRNA could 
be determined using the following equation: 
 
cRNA = 40 × A260 × dilution factor (e.g., 25) 
 
The ratio of the absorbances at 260 nm and 280 nm (A260/A280) allows to estimate the 
purity of RNA with regard to protein contaminants that also absorb in the UV. A ratio of 1.6–
2.0 indicates pure RNA (in water). In order to exclude genomic DNA contamination, control 
reverse transcription polymerase chain reaction (RT-PCR) experiments were performed in 
which no reverse transcriptase (RT) was added prior to a PCR step with primers for H2A.z 
(section 2.6). 
 
2.5.3 RNA agarose gel 
To assess the integrity of isolated RNA, an aliquot of the RNA sample was analysed with a 
denaturing agarose gel. Intact total RNA run on a denaturing gel has sharp, clear 28S and 18S 
rRNA bands. The 28S rRNA band should be approximately twice as intense as the 18S rRNA 
band. This 2:1 ratio (28S:18S) is a good indication that the RNA is completely intact. 
Partially degraded RNA has a smeared appearance, lacks the sharp rRNA bands, or does not 
exhibit the 2:1 ratio of high quality RNA. Completely degraded RNA appears as a very low 
molecular weight smear.  
Formaldehyde agarose gels (1.5%) were performed with MOPS buffer [40 mM 4-
morpholino-propane-sulfonic acid (MOPS; pH 7.0), 10 mM sodium acetate, 1 mM EDTA] 
and 20% formaldehyde. Two µg of RNA was filled up to 10 µl with ultrapure water and 10 µl 
of RNA loading buffer [40% (v/v) formamide, 20% (v/v) saturated bromophenol blue 
solution, 5% (v/v) formaldehyde and 0.75% ethidium bromide in MOPS buffer] were added. 
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The RNA samples were incubated for 5 min. at 65°C to denaturate the RNA. The gels were 
run in MOPS buffer at a current voltage of 60 V for 3 h. Bands were visualized with 312 nm 
UV light (Image Master VDS; BioRad; München, Germany). 
 
2.6 Reverse transcription polymerase chain reaction (RT-PCR) 
2.6.1 Reverse transcription of mRNA 
Reverse transcription polymerase chain reaction (RT-PCR) is a method in which a RNA-
dependent DNA polymerase (the reverse transcriptase, RT) is used to selectively transcribe 
mRNA into complementary DNA (cDNA). The RT can start from random primers binding to 
the polyadenylated tail of the mRNAs. The resulting cDNAs can then be selectively amplified 
by PCR. In this study, the SuperScript II First-Strand Synthesis System for RT-PCR was used 
to produce cDNA.  
The RT reaction was carried out in a final volume of 20 µl. For each sample, 500 ng of 
RNA (section 2.5) were diluted in a volume of 11.5 µl with ultrapure water in a single PCR 
tube. The Random primer solution (0.5 µl) was added to each sample, incubated for 5 min at 
65°C in a thermocycler (Personal Cycler; Biometra; Göttingen, Germany) and chilled on ice 
in order to eliminate RNA secondary structures and to allow binding of the Random primers 
to the polyadenylated tails of the mRNAs. Meanwhile, the RT master mix was prepared on ice 
as described in Tab. 3. After the samples had been chilled on ice, 7 µl of the RT master mix 
was added to each sample. 
 
Tab. 3: Composition of the RT-PCR master mix. 
Component Quantity (for 7 µl per sample) 
PCR Buffer (10 x) 2 µl 
dNTP Mix (10 mM) 1 µl 
DTT (0.1 M) 2 µl 
MgCl2 (25 mM) 2 µl 
 
 
Samples were incubated in the thermocycler at 25°C for 2 min, then 1 µl SuperScript 
II RT was added to each sample. Subsequently, incubation in the thermocycler at 25°C was 
continued for 10 min followed by 42°C for 50 min and 70°C for 15 min. This rise in 
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temperature inactivated the RT and denatured RNA-cDNA hybrids. After addition of 1 µl 
RNase H for a final 20 min incubation in the thermocycler at 37°C, samples were either used 
immediately in subsequent PCRs or stored at –20°C until required. 
 
2.6.2 PCR 
The cDNA produced in the RT reaction (section 2.6) was amplified in a total volume of 50 µl 
in a thermocycler. 1 µl of the cDNA sample was pipetted into single PCR tubes and placed on 
ice. The PCR master mix (Tab. 4) was prepared on ice, and the respective amount of the 
master mix was added to each sample. The final PCR mix contained 1 µl of the RT products, 
0.2 mM of each dNTP, 0.2 µM of each primer and 2.5 units of Taq DNA Polymerase. 
 
Tab. 4: Composition of the PCR master mix. 
Component Quantity (for 50 µl per sample) 
Autoclaved DDW 40.75 µl 
DreamTaq buffer (10 x) 5 µl 
dNTP solution (10 mM) 1 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
DreamTaq DNA Polymerase 0.25 µl (1 unit) 
 
All primers were designed using the software Primer 3 Software Distribution 
(Whitehead Institute/Howard Hughes Medical Institute; Boston, MA, USA). The size of the 
amplicons ranged from 129 bp to 835 bp with different annealing temperatures depending on 
the DNA sequence (Tab. 5). Therefore, different PCR programs had to be used for most 
PCRs. 
Initially, one incubation at 94°C for 5 min was performed to denature the cDNA 
template. The denaturation step was followed by repeated cycles, each consisting of a 
denaturation step in which double-stranded DNA was melted to single strands (94°C for 
1 min), an annealing step for binding of the primers to their specific recognition sites on the 
template (1 min), and an extension step (72°C) where new strands of DNA were produced by 
DNA polymerase extension of the primers. Finally, an additional extension step (72°C, 
10 min) was carried out to ensure that all DNA produced was double-stranded. 
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For each RT-PCR experiment, a primer pair which was specific for the target sequence 
and a primer pair which resulted in amplification of an ubiquitously occuring endogenous 
cellular component, the histone H2A.z, were selected. H2A.z is the only histone which is not 
regulated in its expression during the differentiation of rat neurons (139), and it was amplified 
to normalize for varying efficiencies in RNA isolation and reverse transcription. The absence 
of contamination was checked by negative control assays, in which RNA in the RT reaction 
and cDNA in the PCR were replaced by DEPC-DDW. Genomic DNA contamination had 
already been excluded by PCR for H2A.z in minus-RT reactions. 
 
Tab. 5: Primer pairs and reaction conditions for PCR amplification. 
Primer Sequence (5’→3’) TA 
[°C] 
Cycles 
Amplicon 
[bp] 
H2A.z_for 
H2A.z_rev 
CGTATTCATCGACACCTGAAA 
CTGTTGTCCTTTCTTCCCAAT 
55 22 282 
GAPDH_for 
GAPDH_rev 
AACGACCCCTTCATTGAC 
TCCACGACATACTCAGCAC 
53 31 835 
p21/WAF_for 
p21/WAF_rev 
TGGACAGTGAGCAGTTGAGC 
ACACGCTCCCAGACGTAGTT 
54 27 129 
CyclinD1_for 
CyclinD1_rev 
ATTGAAGCCCTTCTGGAGTCAAGCC 
TCTATTTTTGTAGCACCCCCCCGTC 
58 27 420 
JNK1_for 
JNK1_rev 
ATGCTAAGCGAGCCTACCG 
TCTCAAAGCTATAGCCAGCG 
55 30 621 
JNK2_for 
JNK2_rev 
ACCTCCTCTACCAGATGCT 
TGAACTCTGCGGATGGTG 
58 27 357 
 
The specificity of the primer pairs was verified by comparative alignment using the 
BLAST database (http://www.ncbi.nlm.nih.gov/BLAST/) at the National Center for 
Biotechnology Information (NCBI; Bethesda, MD, USA). All amplicons were cloned and 
sequence verified using the GATC Biotech AG (Konstanz, Germany) sequencing service. 
RT-PCR products were visualized by agarose gel electrophoresis. One % (w/v) or 1.5% 
(w/v) agarose gels were prepared with 1 × Tris-boric acid-EDTA buffer [TBE; 0.9 M Tris, 0.9 
M boric acid and 20 mM EDTA]. The 1 × TBE buffer was set up by diluting a 10 × 
concentrate with DDW. After dissolving the required amount of agarose by heating in a 
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microwave oven, 5 µl/100 ml of a 10 mg/ml ethidium bromide stock solution was added (final 
concentration: 0.5 µg/ml). 10 × loading buffer [0.25% (v/v) bromophenol blue and 30% (v/v) 
glycerol in DDW] was prepared and added to all samples, resulting in a 1 × final 
concentration. The 1 kb DNA Ladder was used as a marker. The gels were run in 1 × TBE 
buffer at 80 mV for ca. 60 min (Wide Mini-Sub Cell GT, Biorad; München, Germany). Bands 
were visualized with 312 nm UV light (Image Master VDS; Biorad; München, Germany). 
 
2.7 TaqMan Real-Time-quantitative PCR (QRT-PCR) 
TaqMan Real-Time PCR gene expression profiling was done by using the Applied 
Biosystems 7900HT Fast Real-Time System with TaqMan Low-Density Arrays, which is a 
384-well micro-fluidic card pre-loaded with optimised probes and primers for selected genes. 
Relative quantification analysis was performed with ABI Prism SDS 2.1.1 software (Applied 
Biosystems; Darmstadt, Germany). All experiments were performed in technical triplicates 
for each of the three biological replicates in 384 well plates. The QRT-PCRs were performed 
in cooperation with Dr. Robert Häsler from the Institute of Clinical Molecular Biology at the 
University Hospital Schleswig-Holstein Campus Kiel. 
TaqMan probes depend on the 5'- nuclease activity of the DNA polymerase used for 
PCR to hydrolyze an oligonucleotide that is hybridized to the target amplicon. TaqMan 
probes are oligonucleotides that have a fluorescent reporter dye attached to the 5' end and a 
quencher moeity coupled to the 3' end. These probes are designed to hybridize to an internal 
region of a PCR product. In the unhybridized state, the proximity of the fluor and the quench 
molecules prevents the detection of fluorescent signal from the probe. During the elongation 
step of the PCR, the 5'- nuclease activity of the polymerase cleaves the probe. This leads to 
the release of the fluorescent dye from the quencher and to an increase in fluorescence that is 
proportional to the exponentially amplified amount of cDNA. The CT (cycle threshold)-value 
of a sample indicates the number of cycles needed to reach defined fluorescence intensity 
above background levels.  
All experiments were performed with TaqMan Universal PCR Mastermix. Mastermix 
(4.5 µl), fluorescently labeled probe (0.2 µl; 10 µM) and forward and reverse primers (0.15 
µl; 20 µM) were added to each plate well. The final reaction volume was set to 10 µl. The 
endogenous control 18s was used for normalization. Normalized delta (∆) cycle threshold 
(CT) values were then subjected to evaluation of statistical significance (p < 0.05) of 
differential expression compared to control using the Wilcoxon test. Fold changes were 
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calculated using the ∆∆CT method, whereby linoleic acid intervention values were used as 
reference (control). The relative expression of each sample was calculated using the 2-∆∆CT 
method: 
Relative expression = 2 ·(S∆CT- C∆CT) 
∆CT = (CT(GOI) – CT(HKG)) 
S∆CT - C∆CT = control value (C) is subtracted from sample value (S) 
 
GOI : gene of interest 
HGK: house keeping gene 
S: sample 
C: control 
 
2.8 Cloning of cDNA fragments 
2.8.1 General principles and procedure 
Molecular cloning is defined as the insertion of a DNA fragment – either genomic DNA or 
cDNA – into a vector which allows amplifying and modifying this fragment. Since this study 
focused on the effects of recombinant protein expression, cDNA was used.  
First, RNA was extracted from PC12 cells (section 2.5.1), transcribed into cDNA and 
amplified by PCR using Taq polymerase (section 2.6). The cDNA was purified and ligated 
into the mammalian expression vector pEGFP-C3, which was transferred into competent 
bacteria. Positive bacterial clones were used for endotoxin-free plasmid extraction, which 
finally yielded the plasmid for the transfection of PC12 cells.  
The choice of a particular expression vector depends on the cell culture system used. 
For neuronal cells, which are difficult to transfect, it is advisable to use expression vectors 
that encode fluorescence tagged fusion proteins to facilitate detection and selection of 
transfected cells. Therefore, the pEGFP-C3 vector was used in this study.  
 
2.8.2 Production of competent E. coli DH5α cells 
DH5α is a versatile E. coli strain that can be used in many cloning applications. For culturing 
DH5α, LB liquid medium was set up as follows: 10 g of Bacto tryptone, 5 g of Bacto yeast 
extract and 5 g of sodium chloride were dissolved in 1 l of DDW and the pH was adjusted to 
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7.2. LB agar medium for culture plates was produced by dissolving 16 g of purchased LB 
Agar in 500 ml of DDW and adjusting the pH to 7.2. Both LB medium and LB agar were 
autoclaved prior to use or plating the agar on Petri dishes, respectively. 
For the production of DH5α stock aliquots, single colonies were picked from a freshly 
streaked out plate and cultures were inoculated in 2–5 ml LB medium. The cultures were 
placed in the incubator (Innova 4000; New Brunswick Scientific; Amsterdam, The 
Netherlands) for 12–14 h at 37°C with vigorous shaking (200 rpm). Subsequently, 1.66 ml of 
the bacteria solution was transferred into cryotubes, mixed with 0.344 ml 86% (v/v) sterile 
glycerol. The cryotubes were snap-frozen in liquid nitrogen and stored at –80°C. 
For the production of competent DH5α, a starter culture was inoculated with bacteria 
from a stock aliquot (3 ml LB, 37°C and 200 rpm overnight). Subsequently, cells were 
streaked out on LB agar and placed in an incubator at 37°C overnight. A single colony was 
picked and another overnight culture was inoculated with bacteria from this colony (3 ml LB, 
37°C, 200 rpm). The overnight culture was diluted in LB medium (1:100) and incubated 
(37°C, 200 rpm) until an OD600 of 0.3–0.4 was reached. The OD600 was measured with 1 ml 
aliquots in disposable plastic cuvettes in a spectrophotometer (U-2000; Hitachi; Wiesbaden, 
Germany). The bacteria were placed on ice for 10 min before centrifugation (10 min; 1,000 × 
g; 4°C). The supernatant was discarded and the pellets were re-suspended in an appropriate 
amount of 100 mM MgCl2 (1 ml of MgCl2 solution for a pellet obtained from 25 ml of cell 
suspension). All bacteria were transferred into one tube and stored at 4°C overnight. 
Subsequently, sterile glycerol was added to a final concentration of 15% (v/v). The bacteria-
glycerol solution was distributed in pre-chilled 1.5 ml tubes (200 µl aliquots) and stored at      
-80°C. 
 
2.8.3 Generation of cloning primers and selection of restriction enzymes 
Before generating cloning primers, the coding sequences of mkk4 and mkk7 (Genbank 
accession numbers AY880882 and AY879265) were screened for restriction sites with the 
software WebCutter 2.0 (http://tools.neb.com/NEBcutter2/). Subsequently, the multiple 
cloning site of the vector was analysed, and two restriction sites that were absent in the 
respective mkk sequence were chosen. The sequence of the 5’-restriction site was placed at the 
front of the sense primer, and the 3’-restriction site was placed at the back of the antisense-
primer (Tab. 6). It was also important to match the annealing temperatures TA, which was 
done by using the following formula: 
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TA = 4 × (number of G and C) + 2 × (number of A and T) 
 
Restriction enzymes or restriction endonucleases are part of bacterial defence systems 
which recognize and cut foreign DNA. The recognition sites consist of palindromic sequences 
of 4–8 base pairs. Type II restriction enzymes reliably cut DNA sequences at defined sites and 
are therefore used for restriction digestion in molecular biology. Tab. 7 lists the restriction 
enzymes used in this study. 
 
Tab. 6: Cloning primers. 
Primer name Sequence (5’→3’) 
MKK4_rat_HindIII_for ATGGTAAAGCTTATGGCGGCTCCGAGCC 
MKK4_rat_BamHI_rev 
ATGGTAGGATCCCTAGTCGACATACATG
GGAGAGCTGG 
MKK7_rat_HindIII_for ATGGTAAAGCTTATGGCGGCGTCCTCCC 
MKK7_rat_BamHI_rev 
ATGGTAGGATCCCTACCTGAAGAAGGG
CAGATGGTG 
 
Tab. 7: Restriction enzymes. 
Restriction enzyme Recognition site 
Hind III A↓AGCTT 
Bam HI G↓GATCC 
 
2.8.4 Amplification and purification of a PCR product 
PCR (section 2.6.2) was always performed with two identical samples (50 µl each). Before 
pooling the samples, a 10 µl aliquot of each reaction was removed to verify the size of the 
amplicon and the absence of nonspecific bands on an agarose gel (section 2.6.2). For cloning, 
90 µl of the PCR reaction was purified by the MinElute PCR Purification kit to purify the 
DNA from primers, nucleotides, polymerases and salts. PB buffer (450 µl) was added to the 
PCR reaction (90 µl), mixed, loaded on a MinElute spin column and centrifuged (1 min; 
16,000 xg; r.t.). The flow-through was discarded and the column was washed with 750 µl PE 
buffer (including ethanol) (1 min; 16,000 xg; r.t.). After the flow-through was discarded, the 
MinElute spin column was centrifuged again (1 min; 16,000 xg; r.t.) to dry the column 
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membrane. For elution of cleaned DNA, the MinElute spin column was placed in a clean tube 
and 10 µl EB buffer was pipetted to the center of the column membrane. Before 
centrifugation (1 min; 16,000 xg; r.t.) the column was incubated for 1 min at r.t..  
DNA concentration was determined by measuring the absorbance of a diluted aliquot 
at 260 nm (A260) against a blank of ultrapure water. An absorbance of 1 unit at 260 nm 
corresponds to 50 µg of DNA per ml water. Therefore, the DNA concentration cDNA was 
determined as follows: 
 
cDNA = 50 × A260 × dilution factor (e.g., 200) 
 
Similar to RNA, the ratio of the readings at 260 nm and 280 nm (A260/A280) provides 
an estimate of the purity of DNA with respect to contaminants that absorb in the UV, such as 
proteins. A ratio of 1.6–2.0 indicates pure DNA in water. 
 
2.8.5 Restriction digestion 
For cloning as well as for insert analysis of the resulting plasmids, restriction digestions were 
performed. The volumes and amount of DNA used depended on the purpose of the 
experiment. All components (Tab. 8) were added in the indicated order to a single sterile 1.5 
ml tube. For mini preparation, test digestions and for general restriction digestions with 1 µg 
plasmid DNA, the samples were incubated for 1 h at 37°C. For preparative digestions, the 
incubation time was prolonged to 2.5 h. Subsequently, all samples were analysed on a 1% 
agarose gel. A 10 × concentration of loading buffer (see section 2.6.2) was prepared and 
added to all samples to result in a 1 × final concentration. The gels were run in 1 × TBE buffer 
at 100 mV for approximately 90 min and analysed as described above. 
 
 
Tab. 8: Composition of a general digestion reaction. 
Component Quantity (for 10 µl per sample) 
DDW (autoclaved) 7.5 µl 
Plasmid DNA (1 µg/µl) 1 µl 
Buffer (10 x) 1 µl 
Restriction enzyme (10 U/ml) 0.5 µl 
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2.8.6 Purification of a digestion reaction 
Before further enzymatic hydrolysis of digested PCR products (section 2.6.2) or plasmid 
DNA (section 2.8.9), the DNA was purified from restriction enzymes, nucleotides and salts 
using the QIAquick Nucleotide Removal kit. First, 10 volumes of PN buffer were added to 1 
volume of digestion reaction, mixed and pipetted on a QIAquick spin column. After 
centrifugation (1 min; 16,000 xg; r.t.) the bound DNA was washed with 750 µl PE buffer 
(including ethanol) (1 min; 16,000 xg; r.t.). The flow-through was discarded and the 
QIAquick spin column was centrifuged again to dry the membrane (1 min; 16,000 xg; r.t.). 
For elution of DNA, the QIAquick column was placed in a clean tube, 30 µl of EB buffer was 
pipetted to the center of the membrane and centrifuged (1 min; 16,000 xg; r.t.) after 1 min 
incubation at r.t.. 
After a second digestion, the digested PCR products and plasmid DNA were analysed 
on a 1% agarose gel to verify the digestion and isolate the DNA fragment of interest. For 
purification of DNA fragments, the QIAquick Gel Extraction Kit was used. After running the 
agarose gel (section 2.6.2), the DNA fragment is excised from the gel with a clean scalpel. 
The gel slice was weighted in a tube and 300 µl QG buffer were added per 100 mg gel. In 
order to dissolve the gel, the sample was incubated for 10 min at 50°C and vortexed every 
second minute. After the agarose has dissolved completely, 1 volume of isopropanol was 
added and the sample was mixed by pipetting. To bind the DNA, the sample was pipetted 
onto a QIAquick column and centrifuged (1 min; 16,000 xg; r.t.). After the flow-through was 
discarded, the DNA was washed with 750 µl PE buffer (1 min; 16,000 xg; r.t.). The column 
membrane was dried by centrifugation (1 min; 16,000 xg; r.t.). For DNA elution the 
QIAquick column was placed in a clean tube and 30 µl EB buffer were pipetted to the center 
of the membrane. After incubation for 1 min at r.t. the column was centrifuged for 1 min at 
16,000 xg and r.t.. 
 
2.8.7 Ligation of DNA fragments into the pEGFP-C3 vector 
For ligation of the pEGFP-C3 vector and a DNA fragment, both had to be cut by restriction 
enzymes and purified carefully to allow efficient ligation (sections 2.8.5 and 2.8.6). The 
optimum molar ratio of insert and vector was 3:1. The required amount of the DNA fragment 
(in ng) was determined as follows: 
 
100 ng vector × (kb insert / kb vector) × molar ratio of insert / vector = ng insert 
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The appropriate amounts of vector and insert were mixed and filled up with autoclaved 
DDW to 13 µl. The ligation buffer (1.5 µl; 10 x) and 0.5 µl T4 DNA ligase were added. 
Samples were placed in a thermocycler, incubated for 30 min at r.t., and subsequently for at 
least 12 h at 15°C. To avoid exonuclease activity of the T4 ligase, the ligation mix was stored 
at –20°C. 
 
2.8.8 Heat-shock transformation of E. coli DH5α cells 
For optimal transformation efficiency, 10 ng of plasmid DNA (section 2.8.9) or 1 µg of 
ligation product (section 2.8.7) were used. To validate the quality of the competent cells, an 
appropriate vector for the respective antibiotic was used as a positive control. Competent 
DH5α cells were slowly thawed on ice. The appropriate amount of plasmid DNA or ligation 
product was added and the cells were kept on ice for 30 min. Subsequently, the cells were 
incubated at 42°C for 2 min and immediately placed back on ice for another 2 min. After 
adding 800 µl of pre-warmed LB medium, the cells were incubated at 37°C and 200 rpm for 1 
h. The bacteria suspension (100 µl or 500 µl) was streaked out on agar plates which contained 
the selective antibiotic to inhibit growth of non-transformed bacteria. The plates were placed 
in the incubator (37°C) overnight. When single colonies were detected after overnight 
incubation, plates were stored at 4°C to inhibit further growth of the colonies. 
 
2.8.9 Preparation of plasmid DNA 
2.8.9.1 Mini preparation of plasmid DNA 
For small scale purification of plasmid DNA, 5 ml LB medium containing the selective 
antibiotic were inoculated with a single clone and incubated overnight (37°C, 200 rpm). 
Afterwards the plasmid DNA was isolated from 3 ml bacteria suspension with the NucleoSpin 
Plasmid QuickPure kit according to the manufacturer’s instruction. The procedure is based on 
a modified alkaline lysis that was first described in 1979 by Birnboim and Doly (9). The 
purity and concentration of isolated plasmid DNA was determined by measuring the 
absorbance at 260 nm in a photometer (section 2.8.4). Plasmid DNA was stored at -20°C. The 
remaining 2 ml bacteria suspension were stored at 4°C until analysis of the insert size had 
shown whether the clone contained the desired insert. In this case, the leftover bacteria 
suspension was used for producing glycerol stocks (see section 2.8.2). 
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2.8.9.2 Midi preparation of plasmid DNA 
For cDNA sequence verification by GATC Biotech AG (Konstanz, Germany) and further 
experiments, plasmid DNA was isolated using the NucleoBond PC 100 kit according to the 
manufacturer’s specifications. Since the plasmids used in this study had a high copy number, 
overnight cultures of 25 ml LB (37°C, 200 rpm) with the selective antibiotic were sufficient 
for midi preparation. 
The bacteria were harvested by centrifugation (15 min; 6,000 ×g; 4°C). The pellet was 
resuspended in 4 ml of Buffer 1, 4 ml of Buffer 2 were added and the tube was inverted 4–6 
times to gently mix its contents. After incubating the sample for 5 min at r.t., 4 ml of pre-
chilled Buffer 3 were added and the sample was mixed again by inverting the tube. The lysate 
was poured into the Qiafilter cartridge and incubated for 10 min at r.t.. During incubation, a 
Qiagen-tip 100 was equilibrated with 4 ml of Buffer QTB. After the 10 min incubation, the 
lysate was filtered using the Qiafilter cartridge and loaded on the equilibrated Qiagen-tip 100. 
After the lysate had passed through the resin by gravity flow, the Qiagen-tip was washed two 
times with 10 ml of Buffer QC. Subsequently, the plasmid DNA was eluted with 5 ml of 
Buffer QF, transferred to a fresh 15 ml tube and mixed with 3.5 ml of 2-propanol. To 
precipitate the plasmid DNA, the mixture was distributed into sterile 1.5 ml tubes (830 µl 
each) and centrifuged (30 min; 16,000 ×g; 4°C). The resulting pellets were washed with 100 
µl of ethanol (70%) and centrifuged again (10 min; 16,000 ×g; 4°C). After air-drying, the 
pellets were dissolved in 50–100 µl of ultrapure water and the yield was determined (section 
1.8.4.). The remaining DNA was stored at –20°C until use. 
 
2.8.9.3 Endotoxin-free maxi preparation of plasmid DNA 
For transfection experiments, plasmid DNA must be free of endotoxins. To obtain this 
standard, the NucleoBond EF 500 protocol for high copy plasmids was used. Overnight 
cultures in 100 ml LB containing the selective antibiotic were inoculated (37°C, 200 rpm). 
The bacteria were harvested by centrifugation (15 min; 6,000 ×g; 4°C) and the pellet was 
resuspended in 10 ml of Buffer P1. Subsequently, 10 ml of Buffer P2 were added and the tube 
was inverted 4–6 times for gentle mixing. The sample was incubated at r.t. for 5 min. Ten ml 
of pre-chilled Buffer P3 was added and the sample was mixed by inverting the tube. The 
lysate was poured into the Qiafilter cartridge and incubated for 10 min at r.t.. Subsequently, 
the lysate was filtered into a 50 ml tube, and 2.5 ml of Buffer ER were added to remove the 
endotoxins. The tube was inverted to mix its contents and placed on ice for 30 min. During 
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incubation, a Qiagen-tip 500 was equilibrated with 10 ml of Buffer QTB. The cleared 
endotoxin-free lysate was loaded on the equilibrated Qiagen-tip. The lysate was allowed to 
enter the resin by gravity flow. Subsequently, the Qiagen-tip 500 was washed twice with 30 
ml of Buffer QC. After elution with 15 ml of Buffer QN, the plasmid DNA was transferred to 
a fresh 50 ml tube and mixed with 10.7 ml 2-propanol. For precipitation, the plasmid DNA 
was distributed in sterile 1.5 ml tubes (830 µl each) and centrifuged (30 min; 16,000 ×g; 4°C). 
The resulting pellets were washed with 100 µl of 70% (v/v) ethanol and centrifuged again (10 
min; 16,000 ×g; 4°C). Air-dried pellets were dissolved in 50–100 µl of Ultrapure water, the 
yield was determined and the DNA was stored at –20°C. 
 
2.8.9.4 Plasmid purification 
After restriction digestion and analysis on an agarose gel, the fragments had to be purified for 
further use. To guarantee a high standard of purity, the QIAquick Gel Extraction kit was used 
(section 2.8.6). The agarose gels used for this extraction contained minimal amounts of 
ethidium bromide in order to avoid mutations caused by this dye.  
 
2.8.10 Sequence verification 
The Taq DNA polymerase synthesizes DNA very quickly, but it has a high error rate as 
compared to other DNA polymerases, such as Pfu. Therefore, it is necessary to verify the 
cloned sequences. In this study, all cloned cDNAs (ligated into pEGFP-C3) were sent to 
GATC (Konstanz, Germany) for sequence verification. The standard run was used. Before 
sequencing, the plasmid DNA was extracted by NucleoBond PC 100 plasmid preparation       
(section 2.8.9).  
 
2.9 Denaturing protein extraction and protein quantification 
2.9.1 Harvesting cells 
After discarding the medium and washing the cells with PBS, PC12 cells were rinsed again 
with 800 µl PBS and scraped off the plates using a 70% ethanol-sterilized rubber cell scraper. 
The cell suspension was transferred to a sterile 1.5 ml tube and centrifuged (1 min; 2,000 ×g; 
r.t.). The supernatant was discarded and the pellet was used for protein extractions. 
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2.9.2 Denaturing extraction of whole cell proteins 
Denatured protein extracts were prepared using a Tris-buffered sodium dodecyl sulfate (SDS) 
lysis buffer containing 1% (v/v) SDS, 10 mM Tris (pH 7.4), Protease Inhibitor complete (1 
tablet for 10 ml of extraction buffer) and 1% Phosphatase Inhibitor Cocktail II in autoclaved 
DDW. The cell pellet sitting in a 1.5 ml tube was resuspended in 50–300 µl of lysis buffer 
(depending on the size of the pellet), incubated for 5 min at 95°C in a heating block 
(Thermomixer 543; Eppendorf; Hamburg, Germany) and chilled on ice. The sample was then 
sonicated twice for 5 s using a MS 72 sonotrode in a Sonopuls GM 70 sonicator (Bandelin; 
Berlin, Germany) and placed on ice again. Insoluble material was removed by centrifugation 
(15 min; 16,000 ×g; 4°C). The supernatant was transferred to a new 1.5 ml tube, and an 
aliquot was removed for determining the protein concentration. Protein extracts were 
aliquoted (in order to avoid repeated freeze-thaw cycles which can lead to loss of phosphate 
groups from phosphorylated proteins), snap-frozen in liquid nitrogen and stored at –80°C. 
 
2.9.3 Denaturing extraction of nuclear proteins 
To analyse nuclear proteins or the translocation of cytoplasmic proteins to the nucleus, 
cytoplasmic and nuclear proteins were extracted separately. Cells were harvested and washed 
in lysis buffer without Nonidet [10 mM HEPES, 10 mM KCl and 1.5 mM MgCl2]. To lyse the 
cell membranes, cell pellets were resuspended in lysis buffer supplemented with Nonidet 
(0.1% v/v) and placed on ice for 10 min. The amount of lysis buffer was dependent on the 
size of the pellet (80–250 µl). After centrifugation (5 min; 12,000 ×g; 4°C), the supernatants 
containing the cytoplasmic proteins were transferred to a sterile 1.5 ml tube and SDS from a 
10% stock solution was added to a final concentration of 1% SDS. Nuclear proteins were 
extracted by resuspension of the nuclear pellets in denaturing lysis buffer (section 2.9.2). 
Again, the amount of lysis buffer (50–100 µl) depended on the size of the cell pellet. From 
this point onwards, the cytoplasmic and the nuclear samples were treated as described for 
whole cell lysates in section 2.9.2. 
 
2.9.4 Non-denaturating extraction of whole cell proteins 
To analyse cytoplasmic proteins for Caspase-3 cleavage, cells were extracted under non-
denaturating conditions. PC12 cells were harvested and lysed with CHAPS cell extract buffer 
[50 mM PIPES/NaOH (pH 6.5), 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 20 µg/ml 
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leupeptin, 10 µg/ml aprotinin, 10 µg/ml pepstatin, and 1 mM PMSF]. The cell pellet sitting in 
a 1.5 ml tube was resuspended in 20–30 µl of lysis buffer (depending on the size of the pellet) 
and snap-frozen in liquid nitrogen. After thawing, the pellet was snap-frozen in liquid 
nitrogen and thawed for another two times. Insoluble material was removed by centrifugation 
(15 min; 16,000 ×g; 4°C). The supernatant was transferred to a new 1.5 ml tube, and an 
aliquot was removed for determining the protein concentration. Protein extracts were 
aliquoted (in order to avoid repeated freeze-thaw cycles), snap-frozen in liquid nitrogen and 
stored at –80°C. 
 
2.9.5 Non-denaturating extraction of whole cell proteins for immunoprecipitations 
To analyse protein-protein interactions, cells were extracted under non-denaturating 
conditions to keep them in their native conditions. PC12 cells were harvested and resuspended 
in native lysis buffer [20 mM Tris (pH 7.6), 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 0,5% 
(v/v) Nonidet P40, 1% (v/v) phosphatase inhibitor, 1% (v/v) β-glycerolphosphate and 1% 
(v/v) protease inhibitor]. After incubation on ice for 30 min, the lysate was centrifuged to 
remove insoluble material (15,000 xg for 15 min). The supernatant was transferred to a new 
1.5 ml tube, and an aliquot was removed for determining the protein concentration. Protein 
extracts were aliquoted (to avoid repeated freeze-thaw cycles), snap-frozen in liquid nitrogen 
and stored at –80°C. 
 
2.9.6 Determination of protein concentrations 
Protein concentrations were determined using Dye Reagent (Bio-Rad; München, Germany), a 
variant of Bradford’s colorimetric assay. The Bradford assay is based on the shift of the 
absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 from 465 nm 
to 595 nm when the dye binds to proteins. The assay was performed in disposable plastic 
cuvettes. 
A protein standard was produced by serial dilution of a 1.2 mg/ml bovine serum 
albumin (BSA) stock solution in autoclaved DDW (0.1 to 0.6 mg/ml). Samples were diluted 
1:20 or 1:50 in autoclaved DDW. Afterwards, 20 µl of sample or standard were pipetted into a 
cuvette and one cuvette was blanked with 20 µl of DDW. To prepare the working solution, 
the Dye Reagent stock solution was diluted 1:5 with DDW. One ml of the working solution 
was added to each cuvette. All cuvettes were vortexed to start the reaction and incubated at r.t. 
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for 10 min. The absorbance at 595 nm (A595) was measured using a spectrophotometer (U-
2000; Hitachi; Wiesbaden, Germany). 
 
2.9.7 Immunoprecipitation (IP) and immunodepletion (ID) 
For immunoprecipitation (IP) and immunodepletion (ID), native cell lysates (section 2.9.5) 
were prepared from subconfluent cells. One hundred fifty µg of total proteins were used for IP 
and ID with the ExactaCruz reagents. All steps were performed at 4 °C if not mentioned 
otherwise. The samples were pre-cleared for 30 min with the appropriate pre-clearing Matrix. 
The antibody-IP matrix complex was formed by incubation of 1 µg primary antibody with 50 
µl of the appropriate IP matrix in 500 µl of PBS for 1 h. The IP antibody-IP matrix complex 
was washed twice with cold PBS, the pre-cleared sample was mixed with the antibody-IP 
matrix complex and incubated overnight. The negative control was prepared by incubation of 
the antibody-IP matrix complex with native lysis buffer. After centrifugation, the supernatants 
with the ID samples were collected for Western blots, while the pellets containing 
immobilized proteins with IP matrix complexes were washed three times with PBS. The 
immobilized proteins were dissociated with 5 x reducing electrophoresis buffer in 20 µl of 
ultra-pure water at 95 °C for 3 min. The supernatants from the dissociation were carefully 
loaded onto 12% (v/v) SDS-gels (section 2.10.1) whereas the matrix was removed by 
centrifugation. 
 
2.9.8 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) was performed using the ChIP-IT Express Enzymatic 
kit according to the manufacturer’s instructions. Chromatin samples were immunoprecipitated 
with a p53 antibody (Oncogene). An RNA polymerase II antibody was used as a positive 
control and an IgG antibody as a negative control following the protocol of the ChIP-IT 
control kit rat. PCR was performed on input DNA, DNA immunoprecipitated with the control 
antibodies and DNA immunoprecipitated with the p53 antibody. ChIP PCR was done using β-
Actin control primers and the following primers: 5’-GGGAGTGGTC ATTAGGTCTG-3’ and 
5’-GGGTGGTATTTGGAGTTCAG-3’. These primers flank a p53-binding site in the 
promoter region of the rat p21 gene. PCR was performed with the DreamTaq PCR reagent 
system and PCR fragments were analysed on a 1.5% (w/v) agarose gel (section 2.6.2). 
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2.10 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blot 
2.10.1 SDS-PAGE 
The principle of SDS-PAGE is based on the fact that SDS-treated proteins are denatured and 
negatively charged in proportion to their molecular weights, which allows electrophoretic 
separation of SDS-treated proteins according to their size in the molecular sieve of a 
polyacrylamide gel. Polyacrylamide gels were prepared by co-polymerization of acrylamide 
monomers with the cross-linker bis-acrylamide, which was catalyzed by ammonium 
persulphate (APS; 10% (w/v) in DDW, stored at 4°C in the dark) and initiated by N,N,N’,N’-
tetramethylethylenediamine (TEMED). For better resolution, a short stacking gel was set on 
top of the main resolving gel. Differences in composition between these two gels resulted in 
concentration of the protein samples into narrow bands in the stacking gel and separation of 
the bands according to their size in the resolving gel. 
Glass plates for a MiniProtean3 Vertical PAGE chamber (Biorad; München, 
Germany) were cleaned with warm water and 70% (v/v) ethanol. The glass plates were 
clamped together and placed in a vertical position on the benchtop. Depending on the 
molecular weight of the protein to be analysed, different acrylamide (Acrylamide/bis-
acrylamide solution 37.5:1) percentages were used for preparation of the resolving gels [4 x 
resolving buffer; 1.5 M Tris (pH to 8.8 with HCl), 0.4% SDS]. The catalyst TEMED was 
added last to the resolving gel mix (Tab. 9) prepared in a 15 ml tube, and after thorough 
vortexing, the gel mix was pipetted carefully between the gel plates using a 10 ml pipette. For 
a smooth interface between resolving and stacking gel, the resolving gel was overlayered with 
DDW and allowed to solidify for 10–30 min (depending on the acrylamide percentage).  
 
Tab. 9: Composition of resolving gels for SDS-PAGE. 
Target protein size 10-30 kDa 30–60 kDa 60–100 kDa > 100 kDa 
Components 15% gel 12% gel 10% gel 7.5% gel 
Acrylamide 5 ml 4 ml 3.3 ml 2.5 ml 
resolving buffer (4 x) 2.5 ml 2.5 ml 2.5 ml 2.5 ml 
Autoclaved DDW 2.4 ml 3.4 ml 4.1 ml 4.9 ml 
TEMED 10 µl 10 µl 10 µl 10 µl 
APS (10%) 100 µl 100 µl 100 µl 100 µl 
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The standard width of the resolving gel was 6 cm. When the gel had polymerized, the 
DDW layer was removed and residual liquid on the gel interface was carefully removed using 
strips of filter paper. Subsequently, the stacking gel [4 x stacking buffer; 0.5 M Tris (pH to 
6.8 with HCl), 0.4% SDS] was prepared and pipetted over the solidified resolving gel (Tab. 
10). A 15-well-comb was added, and the stacking gel was allowed to solidify for ca. 30 min. 
 
Tab. 10: Composition of 3% stacking gels for SDS-PAGE. 
Component Quantity 
Acrylamide 0.6 ml 
stacking buffer (4 x) 1.5 ml 
Autoclaved DDW 3.9 ml 
Bromophenol blue 5 µl 
TEMED 6 µl 
10% APS4 60 µl 
 
In the meantime, protein samples were diluted with autoclaved DDW in order to 
obtain 20 µg of total protein in a volume of 8 µl. 2 µl of 5 × SDS sample buffer were added, 
and the samples were heated to 95°C for 5 min (Thermomixer 543; Eppendorf; Hamburg, 
Germany). The 5 × SDS sample buffer contained 312.5 mM Tris (pH to 6.8 with HCl), 10% 
SDS, 10% β-mercaptoethanol, 50% glycerol and some crystals of bromophenol blue. After 
the final denaturation in sample buffer, samples were placed on ice until the gel was loaded. 
After the stacking gel had polymerized, the comb was removed and the gel plates were 
attached to the vertical SDS-PAGE chamber. The buffer reservoirs were filled with 1 × 
protein electrophoresis buffer [25 mM Tris (pH 8.3), 192 mM glycine, 0.1% SDS; diluted 
from a 10 × stock solution], and the wells of the stacking gel were rinsed with electrophoresis 
buffer using a pipette. After the wells were free of residual gel particles, the samples (10 µl of 
sample containing 20 µg of protein) were loaded into the wells. Broad range pre-stained 
protein marker (5 µl) was loaded into separate wells in order to estimate the molecular 
weights of bands detected by subsequent Western blotting. The samples were run through the 
stacking gel at a constant current of 15 mA per gel for 30 min (Power Supply 250 EX; 
Invitrogen; Karlsruhe, Germany). After the samples had entered the resolving gel, the current 
was raised to 30 mA per gel. Usually, gels were run for 30 min after the tracking dye had 
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passed the end of the gel. Finally, gels were removed from the gel plates, the stacking gel was 
discarded, and the resolving gels were used for Western blots. 
 
2.10.2 Western blot 
In Western blotting experiments, proteins are transferred from a SDS-PAGE gel (section 
2.10.1) to a synthetic membrane, on which specific proteins are subsequently detected by 
enzyme-tagged antibodies. In order to prevent non-specific attachment of antibodies to the 
membrane, the protein-binding capacity of the membrane is first saturated by incubation in 
non-fat milk or a BSA solution. After that, target proteins are labeled by hybridization with a 
primary IgG antibody (pAB; e.g., produced in mice) and detected by a secondary antibody 
directed against IgG (sAB; e.g., total mouse IgG). This secondary antibody is fused with an 
enzyme, e.g., a horseradish peroxidase (HRP), which converts a chemiluminescence substrate. 
The chemiluminescence detected by highly sensitive films is proportional to the amount of 
secondary antibody bound to the primary antibody, the binding rate of which is in turn 
proportional to the amount of target protein present on the Western blotting membrane. 
In the present study, proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane by semi-dry blotting using a semi-dry electroblotter. Three different transfer 
buffers were prepared, namely cathode buffer [25 mM Tris, 40 mM 6-aminocaproic acid, 
20% methanol], anode buffer 1 [30 mM Tris, 20% methanol] and anode buffer 2 [300 mM 
Tris, 20% methanol]. For each gel, 15 pieces of blotting paper were cut to the size of the gel 
(9 × 6 cm) and pre-soaked in cathode buffer (6 pieces), anode buffer 1 (3 pieces) and anode 
buffer 2 (6 pieces), respectively. The Immobilon P PVDF membrane was cut to the size of the 
gel, marked for orientation and pre-soaked in 100% methanol for 3 min. After rinsing the 
membrane in DDW for 2 min to elute the methanol, it was equilibrated in anode buffer 1 until 
use. The six cathode buffer-soaked filter papers were placed in a stack on a glass plate with 
the SDS-PAGE gel on top. The equilibrated membrane was then placed in close contact with 
the gel, taking care not to leave air-bubbles in between. The ‘sandwich’ was completed by 
stacking the remaining pieces of filter paper (pre-soaked in anode buffers 1 or 2, respectively) 
on the membrane. Finally, the blotting ‘sandwich’ was turned around and placed into the 
semi-dry transfer unit (Pegasus; Phase; Lübeck, Germany) in which the lid is the cathode. 
Proteins were transferred to the PVDF membrane using a constant current of 
0.8 mA/cm2 for 50 min (protein size 10-30 kDa), 1 h (protein size 30–80 kDa) or 1.5 h (> 80 
kDa). Following transfer, the membrane was washed for 15 min in TBST buffer [20 mM Tris, 
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137 mM sodium chloride, 0.1% Tween-20]. TBST was prepared by diluting a 10 × TBS stock 
solution [200 mM Tris, 1.37 M sodium chloride] in DDW and adding 0.1% (v/v) of the 
detergent Tween-20. 
Blocking, hybridization and washing steps were performed in petri dishes or smaller 
vessels (depending on the size of the blot membrane) on a rotator (Polymax 2040; Heidolph; 
Kehlheim, Germany). The membrane was placed in an appropriate vessel with the protein 
side up, and blocking solution (BS; 4% non-fat dry milk dissolved in TBST) was added. 
Membranes were incubated in this solution for 1 h at r.t. and subsequently hybridized with the 
primary antibody at 4°C overnight. The next morning, the primary antibody solution was 
discarded and unbound antibody was removed by washing the membranes once for 15 min 
and twice for 5 min each with TBST. Subsequently, the membrane was incubated with a 
dilution of secondary antibody (anti-rabbit (NEB/CST) or anti-mouse (Amersham 
Biosciences; Freiburg, Germany)) for 30 min at r.t.. After discarding the secondary antibody 
solution, the membrane was washed four times for 5 min each with TBST. All hybridization 
parameters are listed in Tab. 11. 
 
Tab. 11: Primary and secondary antibodies for Western blots. 
pAB Manufacturer1 Dilution and 
buffer 
sAB Dilution and 
buffer 
ATF-2 SC 1:500 in TBST rabbit 1:5000 in BS 
Bax SC 1:3000 in 1% BS rabbit 1:8000 in BS 
Bcl-2 SC 1:3000 in 1% BS mouse 1:2000 in 2% BS 
Bcl-xl CST 1:1000 in TBST rabbit 1:2000 in 2% BS 
Bim BD 1:2000 in 2% BS rabbit 1:2000 in 2% BS 
Caspase-3 SC 1:1000 in BS rabbit 1:6000 in BS 
c-Jun SC 1:1000 in TBST rabbit 1:2000 in BS 
Cleaved 
Caspase-3 
CST 1:1000 in BS rabbit 1:2000 in BS 
c-Myc SC 1:1000 in TBST rabbit 1:1000 in 2% BS 
Cyclin D1 BD 1:1000 in TBST mouse 1:6000 in BS 
Fas SC 1:1500 in 2% BS rabbit 1:5000 in 2% BS 
Fas-L SC 1:1000 in 1% BS rabbit 1:2000 in 2%BS 
JIP-1 SC 1:1000 in TBST rabbit 1:2000 in 2% BS 
JNK CST 1:1000 in TBST rabbit 1:2000 in 2% BS 
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pAB Manufacturer1 
Dilution and 
buffer 
sAB 
Dilution and 
buffer 
JNK1 BD 1:1000 in TBST mouse 1:3000 in 1% BS 
JNK2 E 1:5000 in TBST rabbit 1:3000 in 2% BS 
MKK4 SC 1:1000 in TBST rabbit 1:2000 in 1% BS 
MKK7 CST 1:1000 in 1% BS rabbit 1:2000 in 2% BS 
p21/WAF SC 1:1000 in TBST mouse 1:2000 in 2% BS 
p38 SC 1:1000 in BS rabbit 1:5000 in BS 
p53 BD 1:1000 in TBST mouse 1:1500 in 1% BS 
Phospho-ATF-2 CST 1:1000 in TBST rabbit 1:1000 in 2% BS 
Phospho-c-Jun CST 1:1000 in TBST rabbit 1:2000 in 2% BS 
Phospho-c-Myc CST 1:1000 in TBST rabbit 1:2000 in 2% BS 
Phospho-JNK P 1:2000 in BS rabbit 1:2000 in BS 
Phospho-
MKK4 
SC 1:1000 in TBST rabbit 1:5000 in 2% BS 
Phospho-
MKK7 
CST 1:1000 in 1% BS rabbit 1:2000 in 2% BS 
Phospho-p38 P 1:2000 in BS rabbit 1:2000 in BS 
Phospho-p53 CST 1:1000 in TBST mouse 1:1500 in 1% BS 
β-Actin S 1:5000 in TBST mouse 1:3000 in TBST 
1) Manufacturer: P (Promega; Mannheim, Germany); CST (New England Biolabs / Cell 
Signaling Technology; Frankfurt, Germany); SC (Santa Cruz Biotechnology; Heidelberg, 
Germany); S (Sigma; München, Germany); E (Epitomics; Hamburg, Germany); BD (BD 
Biosciences; Heidelberg, Germany).  
 
After the last washing step, TBST was allowed to drip off the membrane, and the 
membrane was placed with the protein side up on a glass plate. For a 6 × 9 cm (standard 
sized) membrane, 1 ml of ECL Plus HRP substrate was prepared immediately prior to use by 
mixing 0.975 ml of ECL Plus Reagent A with 25 µl of ECL Plus Reagent B. The membrane 
was carefully covered with the HRP substrate solution and incubated for 3 min. Subsequently, 
all HRP substrate was allowed to drip off the membrane and the membrane was placed inside 
the plastic pocket of a film cassette. The chemiluminescence on the membranes was detected 
by exposing the membranes to Hyperfilm ECL films in a darkroom. All membranes were 
exposed to film for varying lengths of time, and only films generating subsaturating levels of 
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intensity were selected for densitometrical and statistical evaluation. Films were developed 
and fixed by a film processor (Curix 60; Agfa, Köln, Germany). 
 
2.10.3 Stripping of Western blot membranes 
In order to allow repeated hybridizations of the same Western blotting membrane (section 
2.10.2) with different antibodies, e.g., ‘phospho-specific target’ antibodies and ‘total target 
protein’ antibodies, the membrane was stripped in between. The stripping stock solution 
consisted of 2% SDS and 62.5 mM Tris; 100 mM β-mercaptoethanol were added prior to use. 
Membranes were stripped for 20 min at 50°C and 25 rpm in an incubator (Innova 4000; New 
Brunswick Scientific; Amsterdam, The Netherlands) and washed at least twice for 10 min 
each with TBST. Subsequently, the membrane was blocked again with 4% milk and the next 
hybridzation was performed. 
 
2.10.4 Ponceau S staining of Western blot membranes 
Ponceau S is the only staining method which is completely compatible with all procedures of 
immunological probing, because the stain is transient and can be washed away so that it does 
not interfere with subsequent detection of antigens. Ponceau S is normally used for visual 
evidence that electrophorectic transfer of proteins has taken place. In the present study, it was 
also used to normalize for the amount of proteins in each lane, since there is no housekeeping 
protein which is reliable in every stage of neuronal differentiation. After the ECL reaction, 
membranes (section 2.10.2) were washed twice with TBST and then stained with Ponceau S 
for 20 min. The staining solution was re-used several times. Stained membranes were washed 
twice with DDW for 5 min each before air-drying. After scanning the stained membranes 
(ScanJet IIc; Hewlett Packard; Böblingen, Germany), the protein contents of the lanes were 
quantified using the densitometry software QuantityOne (Biorad, München, Germany). 
 
2.11 Statistical analysis and replication of the experiments 
Unless otherwise indicated, all experiments were carried out independently 3 to 6 times. 
Statistical analysis was performed with GraphPad Prism software (www.graphpad.com) using 
one-way analysis of variance with repeated measures. Means were compared using the post-
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hoc Bonferroni test, and significance was defined for p ≤ 0.05. Data were expressed as means 
± standard deviation. 
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3 Results 
3.1 Stable transfection of PC12 cell lines 
This first part deals with the preparatory work for the functional characterisation of MKK4 
and MKK7. It contains the cloning of different splice variants of mkk4 and mkk7 and the 
generation of stably transfected cell clones. As a cellular system, the rat pheochromocytoma 
cell line PC12 was used. Cultured in medium that contains serum PC12 cells are comparable 
to adrenal chromaffin cells or sympathetic neurons. By addition of nerve growth factor (NGF) 
to serum-free medium neuronal differentiation can be induced in PC12 cells (67). Stably 
transfected PC12 cells enable the investigation of MKK4 and MKK7 functions under naïve 
and differentiated conditions. 
 
3.1.1 Cloning of MKK4 and MKK7 expression vectors 
In order to study the influence of MKK4 and MKK7 on JNK activity and function, the coding 
sequences of rat mkk4 and mkk7 were cloned into the mammalian expression vector pEGFP-
C3. So far only one gene product of mkk4 was identified from all species (115). In the case of 
mkk7 four human and six murine MKK7 splice variants (α1; α2; β1; β2; γ1 and γ2) have been 
described so far, but only one rat MKK7 splice variant that is equivalent to MKK7β1 (60, 
123, 180, 209). 
For generation of MKK4 and MKK7 constructs, the coding sequences for both 
proteins were amplified from PC12 cell cDNA. Amplification of the complete coding 
sequences under optimized PCR conditions revealed the expected bands of 1191 bp (mkk4) 
and 1257 bp (mkk7) corresponding to protein sequences of 397 (MKK4) and 419 (MKK7) 
amino acids, respectively (Fig. 4A).  
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Fig. 4: Cloning of mkk4 and mkk7 into the expression vector pEGFP-C3.  
A, Amplification of coding sequences for mkk4 and mkk7 from PC12 cell cDNA. 
B, Plasmid DNA of single colonies of MKK4-pEGFP and MKK7-pEGFP clones. 
C, BamHI and HindIII enzymatically hydrolyzed DNA from MKK4-pEGFP and MKK7-pEGFP 
plasmid DNA. L, DNA ladder; E, pEGFP-C3; 1-10, number of the clone; 1H, enzymatically 
hydrolyzed DNA of clone 1. 
 
For expression of MKK4 and MKK7 in PC12 cells, the mammalian expression vector 
pEGFP-C3 was chosen. The pEGFP-C3 plasmid enables the expression of a gene of interest 
under the control of a strong SV40 early promoter. Additionally, genes cloned into the 
multiple cloning site of pEGFP-C3 are expressed as fusion proteins with EGFP at the C-
terminus, which entails a green fluorescence of the protein and allows its localization in vivo. 
Thereby, the green fluorescence is a marker for the transfection efficiency. 
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The enzymatically hydrolyzed mkk4 and mkk7 cDNAs were ligated into the 
enzymatically hydrolyzed mammalian expression vector pEGFP-C3. The PC12 mkk4 and 
mkk7 cDNA were cloned in-frame with the EGFP coding sequence without a stop codon. 
Transformation of the constructs into E. coli DH5α and plating of transformed bacteria 
resulted in 50-80 clones of every construct. Ten single colonies of every clone were picked 
and plasmid DNA was isolated. All plasmids of the 20 picked colonies had a larger size as the 
empty pEGFP vector (Fig. 4B).  
To confirm the presence of an insert in the plasmids, the DNA was enzymatically 
hydrolyzed with BamHI and HindIII. All clones showed the expected fragment (Fig. 4C). In 
order to verify the sequence of the clones, plasmid DNA was send to GATC Biotech AG. 
Sequencing revealed some clones with the right and in-frame sequence for mkk4 and mkk7 
from rat. 
 One cloned construct contained the known rat mkk4 sequence (MKK4) with an 
additional 30 bp segment within the 5’ coding region (MKK4∆). This 30 bp exon encodes a 
10 amino acid fragment (Fig. 5). 
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Fig. 5: Sequence alignment of MKK4.  
The primary sequence of the novel MKK4∆ from PC12 cells (rat) compared to MKK4 from PC12 
(rat), mouse and human. Differences between the species are highlighted in grey. 
 
Analyzing different amplicons from PC12 cDNA, the established MKK7 splice 
variant (MKK7β1) and a novel splice variant (MKK7γ1) were identified. Sequence analysis 
and alignment studies revealed a 99% homology to mouse MKK7γ1 (Fig. 6). Compared to the 
MKK7β1 sequence, the novel rat splice variant includes a fragment of 16 additional amino 
acids in the N-terminal region. Examination of the rat mkk7 genomic sequence shows that the 
unique 48 bp insert is a complete exon, indicating that this variant is not only expressed in 
PC12 cells, but also in the rat and is not a PCR artefact. 
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Fig. 6: Sequence alignment of MKK7. 
The primary sequence of the novel MKK7γ1 from PC12 cells (rat) compared to MKK7β1 from 
PC12 (rat) and both splice variants of MKK7 from mouse and human. Differences between the 
species are highlighted in grey. 
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3.1.2 Stable transfection of PC12 cells with MKK4 and MKK7 constructs  
First of all, PC12 cells were tested for G418 (Geneticin) sensitivity. At 500 µg/ml G418 all 
non-transfected PC12 cells died, while transfection with pEGFP-C3 (vector), MKK4-pEGFP, 
MKK4∆-pEGFP, MKK7β1-pEGFP or MKK7γ1-pEGFP protected the cells and allowed the 
selection of transfected cells, which usually took 6 weeks. Ten different cell clones for every 
construct were cultured until they arrived the maintenance culture state. After freezing some 
stocks of every cell line, 5 cell clones were screened for the expression of the transfected 
pEGFP constructs. Western Blot analysis revealed different protein levels for every construct 
(Fig. 7). 
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Fig. 7: Protein levels of the transfected pEGFP constructs in PC12 cells.  
Protein levels of endogenous and exogenous MKK4 and MKK7 in different stably transfected PC12 
cell clones were analysed by Western blots from whole cell extracts. v, vector (pEGFP-PC12); 1-5, 
number of the cell clone. 
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3.2 Functional analysis of MKK7γ1 in naïve PC12 cells 
After the generation of stably transfected PC12 cell lines, functional analysis of MKK4, and 
MKK7 and their splice-variants could be carried out. MKK7 is the only direct upstream 
kinase of JNKs that exclusively activates JNKs (181). Having identified a so far undescribed 
splice variant of MKK7 in rat, the first set of experiments was performed with MKK7γ1-
transfected naïve PC12 cells in order to address the influence of MKK7γ1 on JNK signalling.  
 
3.2.1 MKK7γ1 under normal cell growth conditions 
3.2.1.1 Characterisation of MKK7γ1-transfected PC12 cells 
First of all, vector- and MKK7γ1-transfected PC12 cells were monitored with regard to cell 
morphology, growth characteristics, and the expression status of MKK7. 
No morphological changes were detected (Fig. 8); under normal growth conditions, 
both vector- and MKK7γ1-transfected cells revealed a round or polygonal shape and did not 
spontaneously extend processes. However, the cell cultures transfected with MKK7γ1 
contained more cell debris and dead cells than the vector-transfected cell cultures.  
 
vector MKK7γ1
 
Fig. 8: Cell morphology of vector- and MKK7γ1-transfected PC12 cells.  
Light microscopic images of vector- and MKK7γ1-transfected PC12 cells. Both were kept under the 
same culture conditions. Bars, 50 µM. 
 
To examine whether this microscopic observation is reflected in cell numbers, 
electronic cell counting was carried out. Indeed, stable transfection of PC12 cells with 
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MKK7γ1 caused a significant decrease in viable cells by 29% compared with vector-
transfected cells under normal growth conditions (Fig. 9).  
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Fig. 9: Viability of vector- and MKK7γ1-transfected PC12 cells.  
Electronic cell counts of vector- and MKK7γ1-transfected PC12 cells. Both were kept under the 
same culture conditions. The data represents six independent experiments with ternary 
ascertainment. ###, p < 0.001 for effect of transfection with MKK7γ1 vs. vector. 
 
 
Additionally, stable clones were screened for MKK7 protein levels and activation by 
Western blot analysis. For activation of MAP2Ks/MAPKs, the characteristic Ser-Ile-Ala-Lys-
Thr/Thr-X-Tyr activation motives must be phosphorylated on both residues. Therefore, the 
antibodies used for detection of active MAP2Ks/MAPKs were specific for the dual-
phosphorylated forms. After determining phosphorylation levels of MAP2Ks/MAPKs, blot 
membranes were stripped and re-hybridized with antibodies directed against total kinase 
protein to normalize for kinase protein contents. 
The transfection with pEGFP or MKK7γ1-pEGFP did not change the amount and 
phosphorylation of endogenous MKK7 (Fig. 10). Furthermore, the amount of MKK7γ1 
protein produced by transfected cells was comparable with that of endogenous MKK7, 
whereas phosphorylation of exogenous MKK7γ1 was slightly reduced compared to 
endogenous MKK7 activation. 
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Importantly, the protein level of the second direct JNK activator MKK4 was reduced, 
but basal MKK4 activity was unchanged by transfection with MKK7γ1. The protein amounts 
and activation of JNKs, as the only direct downstream targets of MKK7, were investigated by 
Western blots. Importantly, PC12 cells only express JNK1 and JNK2, but not JNK3 (124). 
Whereas total JNK1 and JNK2 protein were only slightly increased after MKK7γ1-
transfections, the amount of phosphorylated JNK1 and JNK2 was substantially increased (Fig. 
10). 
Activated JNKs phosphorylate a multiplicity of proteins (reviewed by (12)). 
Transcription factors are the best known substrates thereof. Under normal cell growth 
conditions, both protein levels and phosphorylation of c-Jun and the tumour suppressor p53 
were increased after transfection with MKK7γ1. However, in the case of the proto-oncogene 
c-Myc, protein and activation level were decreased in MKK7γ1-transfected cells (Fig. 10) 
These results show that transfection with MKK7γ1 causes a high basal level of JNK 
activity and changes in protein levels and phosphorylation of associated transcription factors, 
which might induce a subsequent alteration in expression of target genes.  
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Fig. 10: Protein levels and phosphorylation of JNK1/2, their direct upstream kinases MKK4 and 
MKK7 and some of their direct downstream targets. 
Whole cell lysates (20 µg) from vector- and MKK7γ1-transfected PC12 cells were immunoblotted 
against JNK1/2, their upstream kinases (MKK4 and MKK7) and some of their downstream targets (c-
Jun, p53 and c-Myc). The Western blot membrane was first immunoblotted with phospho-specific 
antibodies (p-), than stripped and immunoblotted with an antibody directed against the total protein. 
Both cell lines were kept under the same conditions. β-Actin was used as a loading control. Western 
blots are representative for five independent experiments. 
 
3.2.1.2 Cell proliferation 
The next step was to verify if the MKK7γ1-induced decrease in cell number can be ascribed 
to changes in cell proliferation. Therefore, 5-bromo-2-deoxyuridine (BrdU) incorporation 
assays were performed. PC12 cells were transferred to serum-free medium for 24 h to stop 
proliferation. Cell growth was restarted by returning cells to normal growth medium 
supplemented with horse and fetal calf serum, resulting in a synchronized cell cycle (150). 
 The transfection with MKK7γ1 reduced BrdU incorporation to 78% compared to 
vector controls (Fig. 11). These findings indicate that an increase in MKK7γ1 protein inhibits 
cell proliferation in PC12 cells under normal cell growth conditions. Consequently, the 
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observed decrease in cell numbers of MKK7γ1-transfected PC12 cells is attributable to a 
lowered cell proliferation. 
Next, the protein levels of the cell cycle regulators p21WAF1/CIP1 (p21) and CyclinD1 
was examined. p21 negatively regulates the cell cycle by inhibiting the activity of cyclin-
dependent kinases (65, 98), whereas CyclinD1 is an important promoter of cell cycle 
progression (112). Indeed, the cell cycle inhibitor p21 was strongly up-regulated in MKK7γ1-
transfected cells, whereas CyclinD1 was down-regulated compared to vector-transfected cells 
(Fig. 12). 
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Fig. 11: Proliferation of vector- and MKK7γ1-transfected cells.  
Cell proliferation of vector- and MKK7γ1-transfected cells was determined by 5-bromo-2-
deoxyuridine (BrdU) incorporation assay. Both cell lines were kept under the same conditions. The 
data shown represent four separate experiments with ternairy ascertainment. ###, p < 0.001 for 
effect of transfection with MKK7γ1 vs. vector.  
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Fig. 12: Protein levels of the cell cycle regulators p21 and CyclinD1. 
Whole cell lysates (20 µg) from vector- and MKK7γ1-transfected PC12 cells were immunoblotted 
against p21 and CyclinD1. α-Tubulin was used as a loading control. Western blots are 
representative for five independent experiments. 
 
3.2.1.3 Apoptotic proteins 
Due to the detection of more dead cells and cell debris in MKK7γ1 cells (Fig. 8) and the fact 
that JNKs serve as mediators of cell death (reviewed by (47)), molecules that are implicated 
in apoptotic JNK signalling were also analysed.  
Western blots of whole cell extracts showed an up-regulation of Fas receptor protein in 
MKK7γ1-transfected PC12 cells under normal cell growth conditions, whereas the level of its 
ligand Fas-L was not altered (Fig. 13). Looking at the pro-apoptotic proteins, a distinct 
increase in Bim, but not Bax in MKK7γ1-transfected PC12 cells compared to vector-
transfected cells was also observed. The functional counterparts of Bim and Bax in apoptosis 
are the anti-apoptotic proteins Bcl-2 and Bcl-xl. Their protein levels were clearly reduced in 
MKK7γ1-transfected cells. 
The observed up-regulation of the death receptor Fas and pro-apoptotic proteins raised 
the question if spontaneous apoptosis of PC12 cells is induced by MKK7γ1 transfection. 
Therefore protein extracts from EGFP- and MKK7γ1-PC12 cells were blotted against cleaved 
(activated) effector Caspase-3 and total Caspase-3 (Fig. 13). Cleavage of Caspase-3 was 
increased by MKK7γ1 transfection, while the protein amount of Caspase-3 was unaffected. 
Taken together, the observed changes in protein levels and phosphorylation of JNK 
targets demonstrate distinct alterations in the JNK signalling pathway, caused by transfection 
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with MKK7γ1. These changes promote sensitivity of MKK7γ1-transfected PC12 cells 
towards cell death and a repression of cell proliferation under normal cell growth conditions. 
 
 
Fig. 13: Protein levels of JNK targets involved in apoptosis. 
Whole cell lysates (20 µg) from vector- and MKK7γ1-transfected PC12 cells were immunoblotted 
against Fas, Fas-L, Bim, Bax, Bcl-2, Bcl-xl, cleaved Caspase-3 and Caspase-3. Both cell lines were 
kept under the same conditions. β-Actin was used as a control for equal loading. Western blots are 
representative for four independent experiments. 
 
3.2.1.4 mRNA levels of targets 
The observed MKK7γ1-mediated effects on activity and protein levels of JNK targets 
suggested changes in mRNA levels. Therefore, mRNA levels of some selected targets were 
determined by quantitative real time PCR in vector- and MKK7γ1-transfected PC12 cells. 
Whereas the mRNA levels of the transcription factors c-Jun and p53 were increased 
by 37% and 8%, respectively, the c-Myc mRNA level was decreased by 50% in MKK7γ1-
transfected cells compared to vector-transfected cells. The Fas receptor mRNA level was 
strongly enhanced (by 139%) following MKK7γ1 transfection of PC12 cells. Furthermore, 
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MKK7γ1 increased the mRNA amounts of pro-apoptotic Bim (by 116%) and Bax (by 11%), 
but decreased the mRNA level of anti-apoptotic Bcl-2 (by 88%). 
 Summarizing, transfection of MKK7γ1 did not only affect JNK targets on protein, but 
also on mRNA level. The relative tendency of the observed changes on mRNA levels did 
mostly correlate with the effects on protein amounts (Fig. 10 and Fig. 13).  
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Fig. 14: Relative mRNA levels of JNK targets. 
mRNA levels of c-Jun, c-Myc, p53, Fas, Bim, Bax and Bcl-2 in vector- and MKK7γ1-transfected 
PC12 cells were quantified by real time PCR and normalized to the 18S mRNA level. Both cell lines 
were kept under the same culture conditions. The bars show the relative mRNA levels of targets in 
MKK7γ1-transfected cells compared to the mRNA levels in vector-transfected cells (set at 100%). 
The data shown represent three separate experiments with ternary ascertainment. ##, p < 0.01 for 
effect of transfection with MKK7γ1 vs. vector. 
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3.2.1.5 Summary I 
The following table gives a simplified overview of the observed MKK7γ1-mediated changes 
in PC12 cells under normal cell growth conditions. 
 
Tab. 12: MKK7γ1-mediated changes under normal cell growth conditions. 
▬
▲
- protein
- cleavageCaspase-3
apoptosis
cell cycle
transcription
factors
JNK
MKK
culture
parameter
cell number ▼
proliferation ▼
MKK7 - protein
- phosphorylation
▬
▬
MKK4 - protein
- phosphorylation
▼
▬
JNK1 - protein
- phosphorylation
▲
▲
JNK2 - protein
- phosphorylation
▲
▲
c-Jun
- mRNA
- protein
- phosphorylation
▲
▲
▲
c-Myc
- mRNA
- protein
- phosphorylation
▼
▼
▼
p53
- mRNA
- protein
- phosphorylation
▬
▲
▲
p21 - protein ▲
CyclinD1 - protein ▼
Fas - mRNA
- protein
▲
▲
Fas-L - protein ▬
Bim - mRNA
- protein
▲
▲
Bax - mRNA
- protein
▲
▬
Bcl-2 - mRNA
- protein
▼
▼
Bcl-xl - protein ▼
MKK7γ1
 
Relative changes (▲, increase; ▬, no change; ▼, decrease) in naïve MKK7γ1-transfected PC12 cells 
compared to vector-transfected PC12 cells under normal cell growth conditions. 
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3.2.2 MKK7γ1 under stress conditions 
Under normal cell growth conditions MKK7γ1 has an anti-proliferative and pro-apoptotic 
effect on PC12 cells (Fig. 11 and Fig. 13). This effect is accompanied by a high basal activity 
of JNK that leads to differences in the protein levels of transcription factors, cell cycle 
regulators and apoptotic proteins (Fig. 10, Fig. 12 and Fig. 13). 
In light of these observations, one could expect that MKK7γ1-mediated changes affect 
the cellular reaction towards stress. Regarding the decrease of proliferation and increased 
protein levels of pro-apoptotic proteins, a higher stress sensitivity could be assumed, which 
was addressed in the next set of experiments. To exclude that these effects were mainly 
caused by a general increased availability of any MKK7 protein, PC12 cells transfected with 
the so far only known rat splice variant MKK7β1 were additionally analysed. 
 
3.2.2.1 Cell death 
TNF-α is a pro-inflammatory cytokine that induces cell death in PC12 cells (117). The 
chemotherapeutic agent taxol suppresses mitotic spindle assembly and chromosome 
movement. Thapsigargin induces endoplasmatic reticulum (ER) stress by inhibiting Ca2+-
ATPase, which maintains Ca2+ homeostasis in the ER. Tunicamycin is an antibiotic that 
disrupts the N-glycosylation of newly-synthesized proteins. It is known that all these types of 
stress result in a strong JNK and c-Jun activation (45, 56, 162, 191).  
Vector-, MKK7γ1- and MKK7β1-transfected PC12 cells were synchronized and 
incubated with the stressors TNF-α (50 ng/ml), taxol (5 µM), thapsigargin (5 µM) or 
tunicamycin (1.4 µg/ml) for 24 h.  
Electronic cell counts revealed that stimulation with TNF-α only slightly reduced the 
number of viable vector-transfected PC12 cells by 12%, whereas taxol significantly decreased 
the number of viable cells by 51% (Fig. 15). The two ER-stressors thapsigargin and 
tunicamycin also reduced the number of viable vector-transfected PC12 cells by 32% and 
28%, respectively. MKK7β1-transfected cells showed no significant differences after 24 h 
incubation with TNF-α (11%), taxol (52%), thapsigargin (33%) and tunicamycin (24%) 
compared to vector-transfected cells. Interestingly, TNF-α, thapsigargin and tunicamycin 
evoked no significant change in the number of viable MKK7γ1-transfected cells, only 
incubation with taxol and thapsigargin significantly reduced the number of viable cells by 
15% and 8% but not as strongly as in the other cell lines.  
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Contrary to the assumption of higher stress sensitivity from basal conditions, 
transfection with MKK7γ1 protected PC12 cells from thapsigargin-, tunicamycin- and taxol-
induced cell death. This effect is exclusively triggered by MKK7γ1, but not by MKK7β1.  
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Fig. 15: Viability of vector-, MKK7γ1- and MKK7β1-transfected cells following stimulation with 
different stressors. 
Electronic cell counts of vector-, MKK7γ1- and MKK7β1-transfected PC12 cells after 24 h treatment 
with different stressors: TNF, 50 ng/ml TNF-α; TAX, 5 µM taxol; TG, 5 µM thapsigargin; TM, 1.4 
µg/ml tunicamycin. Control (unstimulated) = 100%. ∗, p < 0.1; ∗∗∗/###, p < 0.001 for effect of TNF, 
TAX, TG and TM/transfection with MKK7γ1 and MKK7β1 vs. vector. Data represent six independent 
experiments with ternary ascertainment. 
 
3.2.2.2 JNK signalling pathway 
Electronic cell counts showed, that MKK7γ1 transfection protected PC12 cells from cell death 
induced by different types of stressors (Fig. 15). As TNF-α only provoked a marginal cell 
death, it was excluded from further studies. From the two ER stressors, tunicamycin was 
further examined.  
Following the line of previous experiments, the phosphorylation and protein levels of 
JNKs, their upstream kinases and substrates after 6 h incubation with tunicamycin in whole 
cell lysates were investigated. The levels of endogenous MKK7 and exogenous MKK7γ1 or 
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MKK7β1 proteins were not influenced by tunicamycin in vector- and MKK7γ1-transfected 
PC12 cells (Fig. 16). However, phosphorylation of endogenous MKK7 increased after 6 h 
stimulation with tunicamycin in both cell lines to a similar degree. The activation of 
transfected MKK7γ1 and MKK7β1 was unaffected. Activation levels of the second JNK 
activator MKK4, were only elevated by tunicamycin in vector- and MKK7β1-transfected 
PC12 cells. The MKK4 protein amount was unaffected by tunicamycin treatment but reduced 
by transfection with MKK7γ1. In whole cell extracts, phosphorylation of JNK1/2 increased 
after incubation with tunicamycin in all three cell lines. The level of JNK1/2 that was 
generally increased in MKK7γ1-transfected cells was not further elevated by tunicamycin.  
 After activation, JNKs either remain in the cytoplasm or translocate to the nucleus and 
activate transcription factors (reviewed by (12)). The phosphorylation and protein levels of 
the exclusive JNK substrate c-Jun were increased after stimulation with tunicamycin in 
vector-, MKK7γ1- and MKK7β1-transfected PC12 cells (Fig. 16). Whereas the amounts of 
activated and absolute c-Jun were comparable in vector- and MKK7β1-transfected PC12 
cells, they were generally elevated in MKK7γ1-transfected PC12 cells. Tunicamycin had no 
impact on c-Myc phosphorylation and protein amount. Only transfection with MKK7γ1 
caused a down-regulation of c-Myc and phospho-c-Myc under basal and pathophysiological 
conditions. After 6 h incubation with tunicamycin, p53 phosphorylation and protein level 
were enhanced in vector- and MKK7β1-transfected cells. In contrast, MKK7γ1-transfection 
mediated an increase of phospho-p53 and absolute p53 in PC12 cells under normal cell 
growth conditions that was abolished after stimulation with tunicamycin.  
Taken together, both MKK7 splice variants increased phosphorylation of JNK1/2 
following tunicamycin treatment. Whereas protein and phoyphorylation levels of the analysed 
transcription factors were mostly unaffected by transfection with MKK7β1, MKK7γ1 
mediated distinct changes after stimulation with tunicamycin. 
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Fig. 16: Protein levels and phosphorylation of JNKs, upstream kinases and targets after 
stimulation with tunicamycin.  
Whole cell extracts (20 µg) from unstimulated (C) and tunicamycin-stimulated (TM, 1.4 µg/ml 
tunicamycin for 6 h) vector-, MKK7γ1- and MKK7β1-transfected PC12 cells were immunoblotted 
against JNK1/2, their upstream kinases (MKK4 and MKK7) and some of their direct downstream 
targets (c-Jun, p53 and c-Myc). The Western blot membrane was first immunoblotted with phospho-
specific antibodies (p-), than stripped and immunoblotted with an antibody directed against the total 
protein. Western blots are representative for five independent experiments. 
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3.2.2.3 Apoptotic proteins 
Under normal growth conditions, a reduced cell number accompanied by an increase of pro-
apoptotic and a decrease of anti-apoptotic proteins was observed in cultures from MKK7γ1-
transfected PC12 cells compared to vector-transfected cells (Fig. 9 and Fig. 13). So far, the 
results obtained from experiments under stress conditions surprisingly indicated an anti-
apoptotic JNK signalling mediated by MKK7γ1 transfection. Therefore, whole cell extracts 
were analysed by Western blots for pro- and anti-apoptotic JNK target proteins. 
After stimulation with tunicamycin, Fas protein was increased in vector-transfected 
cells, while it was decreased in MKK7γ1-transfected cells (Fig. 17). The amount of Fas-L was 
unchanged in vector-transfected cells, but slightly decreased in MKK7γ1-transfected cells. 
The level of the pro-apoptotic protein Bim was also decreased in MKK7γ1-transfected cells 
after cellular stress, whereas it was increased in vector-transfected PC12 cells. Stimulation 
with tunicamycin did not change the protein levels of Bax, Bcl-2 and Bcl-xl in both cell lines. 
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Fig. 17: Protein levels of pro- and anti-apoptotic proteins under stress conditions. 
Whole cell extracts (20 µg) from unstimulated (C) and tunicamycin-stimulated (TM, 1.4 µg/ml 
tunicamycin for 6 h) vector- and MKK7γ1-transfected PC12 cells were blotted against different 
proteins involved in apoptosis. β-Actin was used as a loading control. Western blots are 
representative for five independent experiments. 
 
Since MKK7γ1 seemed to reduce tunicamycin-mediated cell death (Fig. 15), Western 
blot analysis of the protein level and cleavage of effector Caspase-3 were performed. As 
expected, 18 h stimulation with tunicamycin strongly increased the cleavage of Caspase-3 in 
vector-transfected cells (Fig. 18). Indeed, transfection with MKK7γ1 decreased activation of 
Caspase-3 compared to vector-transfected cells. Surprisingly, cleavage of Caspase-3 was 
slightly reduced following tunicamycin stimulation in MKK7γ1-PC12 cells. In line with the 
observations above, Caspase-3 activation was increased in MKK7γ1-transfected cells 
compared to vector-transfected cells under normal cell growth conditions.  
Summarizing, MKK7γ1 transfection protects PC12 cells from apoptosis induced by 
tunicamycin. 
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Fig. 18: Protein level and cleavage of Caspase-3 after tunicamycin stimulation. 
Extracts (20 µg) from vector- and MKK7γ1-transfected PC12 cells after 18 h incubation with 
tunicamycin (TM; 1.4 µg/ml) were immunoblotted against Caspase-3 and cleaved Caspase-3. 
Western blots are representative for three independent experiments. 
 
3.2.2.4 Cell proliferation 
According to the observed changes in cell proliferation under normal cell growth conditions 
(Fig. 11), it was examined if the difference in cell survival is also caused by different cell 
division rates of the cell lines under stress conditions. Additionally to tunicamycin-stimulated 
cells, taxol-stimulated cells were analysed as this stressor interferes with the normal 
breakdown of microtubules during cell division.  
Monitoring proliferation in 5-bromo-2-deoxyuridine (BrdU) incorporation assays with 
stimulated cells showed that tunicamycin and taxol reduced proliferation of vector-transfected 
cells by 29% and 26%, respectively (Fig. 19). Again, MKK7β1-transfected PC12 cells 
showed similarly reduced proliferation rates as vector-transfected cells after stimulation with 
tunicamycin (30%) and taxol (34%). In contrast, no changes after taxol stimulation in 
MKK7γ1-transfected cells were observed and even a significant proliferation increase 
following tunicamycin by 43%.  
These findings indicate that only transfection with MKK7γ1, but not with MKK7β1, 
causes stress resistance in PC12 cells. 
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Fig. 19: Proliferation of vector-, MKK7γ1- and MKK7β1-transfected PC12 cells under stress 
conditions.  
BrdU incorporation was measured after 24 h stimulation in the different cell lines. Control, 
unstimulated; tunicamycin [1.4 µg/ml]; taxol [5 µM]. Control = 100%. ∗∗, p < 0.01; ∗∗∗/###,          
p < 0.001 for effect of tunicamycin and taxol/transfection with MKK7γ1 and MKK7β1 vs. vector. 
Data represent four independent experiments with ternary ascertainment. 
 
3.2.2.5 Cell cycle regulators 
To further characterise the changes in cell cycle regulation, p21 and CyclinD1 protein levels 
were monitored by Western blots. Twenty-four hours after stimulation with tunicamycin, the 
p21 amount of vector-transfected cells was increased, while it was decreased in MKK7γ1-
transfected cells (Fig. 20A). CyclinD1 protein levels did not change in both cell lines after 
incubation with tunicamycin.  
Afterwards the question came up, if the two cell cycle proteins are regulated on 
transcriptional or translational level. Therefore, RT-PCRs for p21 and CyclinD1 transcripts 
with cDNA isolated from both cell lines after 6 h incubation with tunicamycin were 
performed. Under normal cell growth conditions, MKK7γ1-transfection caused an up-
regulation of p21 mRNA (Fig. 20B). After stimulation with tunicamycin p21 mRNA was 
increased in vector-transfected cells and decreased in MKK7γ1-transfected cells. No changes 
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in mRNA levels could be observed for CyclinD1. Correspondingly, the observed difference in 
p21 protein levels was caused by MKK7γ1-mediated transcriptional changes, whereas the 
basal decrease in CyclinD1 protein seemed to be regulated on a different level, such as protein 
stability. 
p21
CyclinD1
C TM   C  TM
ve
cto
r
MK
K7
γ1
α-Tubulin
C   TM  C   TM
p21
GAPDH
ve
cto
r
CyclinD1
mRNA
MK
K7
γ1A B
 
Fig. 20: Protein and mRNA levels of p21 and CyclinD1 after tunicamycin stimulation.  
A, Whole cell extracts (20 µg) from unstimulated (C) and tunicamycin-stimulated (TM, 1,4 µg/ml 
for 6 h) vector and MKK7γ1-transfected PC12 cells was immunoblotted against p21 and CyclinD1. 
α-Tubulin was used as a loading control. Western blots are representative for five independent 
experiments. 
B, RNA was isolated from unstimulated (C) and tunicamycin-stimulated (TM, 1.4 µg/ml for 6 h) 
vector and MKK7γ1-transfected PC12 cells. The p21 and CyclinD1 mRNAs were detected by 
semiquantitative RT-PCR (mRNA). GAPDH was used as a loading control. Data are representative 
for three independent experiments. 
 
The transcription of p21 is activated by the tumour suppressor and JNK substrate p53 
(53). To further analyse the observed transcriptional changes in p21 mRNA, chromatin 
immunoprecipitaions (ChIP) with lysates of unstimulated and with tunicamycin stimulated 
vector- and MKK7γ1-transfected cells were performed. Precipitation with a p53 antibody and 
a PCR with primers flanking a p53 binding-site in the p21 promoter revealed that tunicamycin 
enhances p53 binding in vector-transfected cells. MKK7γ1-transfection caused a down-
regulation of the generally increased p53-binding to the p21 promoter after stimulation with 
tunicamycin (Fig. 21). This result shows that MKK7γ1 influences p21 transcription by p53 
binding to the p21 promoter. 
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Fig. 21: p53 binding to the p21 promotor.  
p53 binding to the p21 promoter was analysed by chromatin immunoprecipitations (ChIP). 
Chromatin was isolated from unstimulated (C) and tunicamycin-stimulated (TM, 1.4 µg/ml for 6 h) 
vector- and MKK7γ1-transfected PC12 cells and immunoprecipitated with an antibody directed 
against p53 and β-Actin (internal control). PCR was done using β-Actin control primers and primers 
specific for a p53-binding site in the p21 promoter. Data are representative for three independent 
experiments.  
 
3.2.2.6 Inhibition of JNKs by SP600125 
In the light of the observation that p53-binding to the p21 promoter is affected by MKK7γ1 
transfection (Fig. 21), it was investigated if this transcriptional regulation was JNK- 
dependent. One hour treatment with a low concentration (2 µM) of the ATP-competitive JNK 
inhibitor SP600125 slightly increased the p53 protein amount in vector-transfected cells (Fig. 
22). Concurrently, the cell cycle inhibitor p21 protein was enhanced after incubation with 
SP600125.  
 As described above, MKK7γ1 mediates a strong increase in p53 and p21 protein levels 
under normal cell growth conditions compared to PC12-EGFP cells (Fig. 10 and Fig. 12). 
Indeed, incubation with SP600125 reversed these effects. Inhibition of JNKs in MKK7γ1-
transfected cells reduced the amount of p53 and p21 proteins in MKK7γ1-transfected cells 
(Fig. 22).  
 Taken together, these results show that MKK7γ1 specifically up-regulates 
proliferation of PC12 cells via JNK, p53 and finally p21 under stress conditions. 
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Fig. 22: JNK-dependent protein levels and phosphorylation of JNK targets in vector- and 
MKK7γ1-transfected PC12 cells. 
Western blot analysis from whole cell extracts (20 µg) of vector- and MKK7γ1-transfected PC12 
cells with antibodies directed against phosphorylated c-Jun (p-c-Jun), c-Jun, p53 and p21. Cells 
were unstimulated (C) or incubated for 24 h with SP600125 (SP; 2 µM). β-Actin was used as a 
loading control. Data are representative for three independent experiments. 
 
3.2.2.7 Cell cycle distribution patterns 
Based on the observed MKK7γ1-mediated changes in cell cycle regulators and cell 
proliferation (Fig. 19 and Fig. 20), further cell cycle analysis by flow cytometry were 
performed to elucidate cell cycle phase distribution of PC12 cells. The chemotherapeutic taxol 
provokes a G2/M-phase arrest of PC12 cells leading to cell death (191). As mentioned 
previously, MKK7γ1 transfection partially protects PC12 cells from taxol-induced apoptosis. 
Possibly, this protection is accompanied by a shift in cell cycle phases. Therefore, vector- and 
MKK7γ1-transfected PC12 cells were incubated with 1.4 µg/ml tunicamycin (TM) or 5 µM 
taxol for 6 h. 
Under normal cell growth conditions, 55.2 ± 0.6% vector-transfected PC12 cells were 
in G1-, 19.6 ± 0.5% in S- and 25.2 ± 2% in G2-phase of the cell cycle (Fig. 23). Significantly 
more MKK7γ1-transfected cells were in G1-phase (61.4 ± 1.5%), whereas less cells were in 
G2-phase (18.7 ± 2.1%). Although after stimulation with taxol and tunicamycin, MKK7γ1 
mediated differences in cell cycle distribution. Taxol caused a typical G2/M cell cycle arrest 
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of vector-transfected cells (55.8 ± 2.3%). In contrast, only 41.5 ± 0.9% MKK7γ1-transfected 
PC12 cells arrested in G2/M-phase and the number of cells in G1-phase was increased by 
14.4%. Stimulation with tunicamycin caused a shift of vector-transfected cells, from G2/M 
(18.7 ± 1.6%) to G1-phase (60.2 ± 0.8%). MKK7γ1-transfected cells showed a contrary shift 
from G1- (56.5 ± 0.8%) to G2/M-phase (23.9 ± 2.3%). The number of cells in the S-phase of 
the cell cycle was nearly unaffected by stimulation and transfection. 
Summing up, MKK7γ1-mediated changes in the expression of cell cycle regulators 
culminated in a shift of PC12 cell cycle distribution. This shift was already detectable under 
normal cell growth conditions and was enhanced by stimulation with taxol and tunicamycin. 
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Fig. 23: Cell cycle distribution of vector- and MKK7γ1-transfected PC12 cells.  
Cell cycle distribution of vector- and MKK7γ1-transfected PC12 cells under different growth 
conditions. The DNA of vector- and MKK7γ1-transfected cells was stained with propidium iodide 
and the content was measured by fluorescence-activated cell sorting. Control, unstimulated; taxol, 5 
µM for 6 h; tunicamycin, 1.4 µg/ml for 6 h. Data represent the mean percentage of cells in G1, S, 
G2/M of 6 independent experiments with ternary ascertainments. ∗∗/##, p < 0.01; ∗∗∗/###, p < 
0.001 for effect of taxol and tunicamycin/transfection with MKK7γ1 vs. vector. 
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3.2.2.8 JNK protein levels, activation and localization 
Overexpression of MKK7γ1 in PC12 cells caused a general increase in JNK activity (Fig. 10 
and Fig. 23). As cellular localization is a determining factor in JNK functions (10), the 
distribution and phosphorylation levels of JNK isoforms in cytoplasmic and nuclear fractions 
were investigated.  
In both cell lines, the major part of total JNK1/2 and active JNK1/2 was localized in 
the cytoplasmic cell fraction (Fig. 24). Stimulation with tunicamycin caused a typical increase 
of phosphorylated JNK1 and JNK2 in vector transfected cells. In MKK7γ1-transfected cells, 
phosphyorylation and amounts of JNK1 and 2 were generally increased, in particular in the 
nuclear fractions, but was only slightly affected by tunicamycin stimulation. The use of 
isoform-specific antibodies showed that the increase of total JNK protein as described above 
in MKK7γ1-transfected PC12 cells resulted from an increased JNK2 protein level .  
 
 
Fig. 24: Changes in protein levels, phosphorylation and localization of JNK isoforms after 
tunicamycin stimulation in MKK7γ1-transfected PC12 cells.  
Western blots of nuclear (nucl) and cytoplasmic (cyto) extracts (each 20 µg) from vector- and 
MKK7γ1-transfected PC12 cells. Membranes were immunoblotted against phosphorylated (p-) and 
total JNK1/2 and single JNK isoforms. C, unstimulated control; TM, 1.4 µg/ml tunicamycin for 6 
h). Western blots are representative for five independent experiments.  
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To determine if the MKK7γ1-mediated increase in JNK2 protein (Fig. 24) was based 
on the up-regulation of mRNA levels, RT-PCRs for jnk1 and jnk2 transcripts were performed. 
Accordingly, jnk1 mRNA levels were not influenced by MKK7γ1 transfection or 
tunicamycin, but jnk2 mRNA level was enhanced in MKK7γ1-transfected PC12 cells (Fig. 
25). These results suggest an up-regulation of JNK2 in PC12 cells on both mRNA and protein 
level caused by transfection with MKK7γ1. 
 
 
Fig. 25: JNK1 and JNK2 mRNA levels after tunicamycin stimulation.  
RNA was isolated from unstimulated (C) and tunicamycin-stimulated (TM, 1.4 µg/ml for 6 h) 
vector and MKK7γ1-transfected PC12 cells. The jnk1 and jnk2 mRNAs were detected by 
semiquantitative RT-PCR (mRNA). GAPDH were used as a loading control. Data are representative 
for three independent experiments. 
 
The increase of a single JNK isoform might not account for the observed changes in 
cellular reactions. More important is the activity status of the protein. For that reason, 
immunodepletions (IDs) of JNK1 or JNK2 in whole cell extracts from vector- and MKK7γ1-
transfected PC12 cells were performed to dissect the activation of JNK1 and JNK2. The 
supernatants containing only one JNK isoform were subsequently analysed in Western blots 
with an antibody directed against phosphorylated JNK.  
First of all, the IDs confirmed that the basal JNK activity was higher in MKK7γ1-
transfected cells, mainly as a result of increased JNK2 phosphorylation (Fig. 26). It also 
became evident that JNK2 activation was more pronounced in MKK7γ1-transfected cells after 
stress. In contrast to unstimulated cells, transfection with MKK7γ1 resulted in an increase of 
phosphorylated JNK1 after stimulation with tunicamycin.  
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In summary, JNK activation and protein levels were increased in the cytoplasm and 
nucleus of MKK7γ1-transfected cells, which mainly consisted of up-regulated JNK2 under 
basal conditions and additionally up-regulated JNK1 after cellular stress. 
 
 
Fig. 26: MKK7γ1-mediated changes in phosphorylation of single JNK isoforms after 
tunicamycin stimulation. 
Single JNK isoforms were immunodepleted (ID) in native protein extracts (100 µg) from 
unstimulated (C) and tunicamycin-stimulated (TM, 1.4 µg/ml for 6 h) EGFP- and MKK7γ1-
transfected PC12 cells. The remaining extracts were first immunoblotted with an antibody against 
phosphoraylated JNK1/2, than stripped and incubated with and antibody against JNK1/2. Western 
blots are representative for three independent experiments. 
 
3.2.2.9 JNK signalosomes 
Presence and activation of JNK require the formation of signalosomes with their upstream 
kinases and scaffold proteins. The preferential activation of JNK2 (Fig. 26) raised the 
question for changes of JNK signalosomes. Therefore, whole cell extracts were 
immunoprecipitated with an antibody against MKK7 and blotted against JNK1, JNK2 and 
JIP-1.  
As shown in Fig. 27A, JNK1:MKK7 complexes were hardly detectable under normal 
cell growth conditions in MKK7γ1-transfected cells. Six hours stimulation with tunicamycin 
had no effect on JNK1:MKK7 complex formation in MKK7γ1-transfected cells, while it 
reduced JNK1:MKK7 complexes in vector-transfected cells.  
In contrast, JNK2:MKK7 complexes were present in MKK7γ1-transfected cells and 
decreased in both cell lines after incubation with tunicamycin (Fig. 27A). JIP-1 is one of the 
major scaffold proteins, which assembles MKK7 and JNK for activation. Transfection with 
MKK7γ1 substantially increased JIP-1:MKK7 complexes under normal growth conditions. 
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While JIP-1:MKK7 complex formation was slightly pronounced after tunicamycin 
stimulation in vector-transfected cells, it disappeared in MKK7γ1-transfected cells. JIP-
1:JNK1 complexes were unaffected by tunicamycin and MKK7γ1 transfection. Precipitates 
with an antibody for JIP-1 blotted against JNK2 confirmed the hypothesis that the major 
signalosome occurring in MKK7γ1 cells is formed by JIP-1, MKK7 and JNK2 under normal 
cell growth conditions. This complex is disrupted following cellular stress such as 
tunicamycin.  
The next step was to investigate if MKK7γ1 transfection has an impact on JNK2 
binding to substrates. Immunoprecipitations with a c-Jun antibody blotted against JNK2 
yielded no influence of MKK7γ1 transfection nor tunicamycin stimulation on JNK2:c-Jun 
complexes. 
From non-neuronal cell types it is known that JNKs can bind to p21 and, thereby 
control p21 stability and activation (98). The results from immunoprecipitation demonstrate 
that JNK:p21 complexes are also present in neuronal cells (Fig. 27B). According to previous 
results, MKK7γ1-transfected PC12 cells showed an increased amount of JNK2:p21 
complexes compared to vector-transfected cells. Stimulation with tunicamycin caused an 
increase of JNK2:p21 complexes in vector-transfected cells, while the amount was slightly 
attenuated in MKK7γ1-transfected cells. JNK1:p21 complexes were also observed but 
remained unchanged. 
Taken together the results show profound changes in JNK signalosomes subject to 
MKK7γ1 transfection. An increase of JIP-1:MKK7, JIP-1:JNK2, MKK7:JNK2 and JNK2:p21 
complexes under normal cell growth conditions was observed that almost disappeared after 
stimulation with tunicamycin. These findings indicate JIP-1:MKK7:JNK2 and JNK2:p21 as 
the major signalosomes regulating the switch between MKK7γ1-mediated anti-proliferation 
under normal and pro-proliferation under stress conditions. 
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Fig. 27: MKK7γ1-mediated changes in protein-protein interactions. 
Immunoprecipitations (IP) of native protein extracts (200 µg) from unstimulated (C) and tunicamycin-
stimulated (TM; 1.4 µg/ml for 6 h) vector (v)- and MKK7γ1 (7γ1)-transfected PC12 cells. ∅, mock; L, 
lysate. 
A, The native protein lysates were immunoprecipitated with antibodies raised against MKK7 or JIP-1 
and immunoblotted with antibodies against JNK1, JNK2 and/or JIP-1. 
B, The native protein lysates were immunoprecipitated with antibodies raised against p21 or c-Jun and 
immunoblotted with antibodies against JNK1 and/or JNK2. 
The data shown represent four independent experiments.  
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3.2.2.10 Summary II 
The following table gives a simplified overview of the MKK7γ1-mediated changes in PC12 
cells following tunicamycin treatment. 
 
Tab. 13: MKK7γ1-mediated changes following tunicamycin stimulation. 
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Tunicamycin (TM)-mediated changes (↑, increase; -, no change; ↓, decrease) in vector- and MKK7γ1-
transfected PC12 cells. Relative changes (▲, increase; ▬, no change;▼, decrease) in tunicamycin-
treated MKK7γ1-transfected PC12 cells compared to vector-transfected PC12 cells. 
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3.3 Functional analysis of MKK7γ1 in differentiated PC12 cells 
The next aim of this study was to characterise the effect of MKK7γ1 on NGF-induced 
neuronal differentiation of PC12 cells with regard to morphological changes, MAP kinase 
activity and the phosphorylation of central MAPK substrates. 
 
3.3.1 Characterisation of NGF-treated MKK7γ1-transfected PC12 cells 
Upon nerve growth factor (NGF) supplementation, PC12 cells cease to proliferate and start to 
differentiate into neuron-like cells with pronounced neurite formation (67). As described 
previously, MKK7γ1 has an anti-proliferative effect on PC12 cells under normal cell growth 
conditions (Fig. 11). For maintaining the MKK7γ1-specific effects during differentiation,    
0.3 x 106 vector- or MKK7γ1-transfected PC12 cells were grown on collagen-coated 6-well 
plates for 2 days with serum-supplemented medium. The cell cycle was synchronized for 3 
days by serum deprivation. Thereafter cells were treated for 5 days with 50 ng/ml NGF 
(called “NGF-treated” or “differentiated” below). Normally, this procedure results in almost 
100% differentiated PC12 cells (189). The cell numbers in vector- and MKK7γ1-transfected 
PC12 cultures were determined by trypan blue staining to avoid misleading results from 
electronic cell counts caused by differences in cell sizes. Surprisingly, MKK7γ1-transfection 
significantly increased the number of viable cells by 110%, compared with vector-transfected 
PC12 cells after 5 days of differentiation (Fig. 28).  
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Fig. 28: Viability of NGF-treated vector- and MKK7γ1-transfected differentiated PC12 cells. 
Cell counts of trypan blue-stained vector- and MKK7γ1-transfected PC12 cells after 5 days 
treatment with NGF (50 ng/ml). The data represents six independent experiments with ternary 
ascertainment. Control = 100%. ***/###, p < 0.001 for effect of NGF/transfection with MKK7γ1 
vs. vector. 
 
3.3.2 Cell numbers 
As previously described, the cell number of MKK7γ1-transfected PC12 cells is reduced 
compared to vector-transfected cells under normal cell growth conditions (Fig. 9). The 
increased number of MKK7γ1-transfected cells after 5 days of NGF treatment raised the 
question, when MKK7γ1 changed the phenotyp of PC12 cells from anti-proliferative to pro-
proliferative. Again, 0,3 x 106 cells were grown on collagen-coated 6-well plates and counted 
before serum depletion, after serum depletion before NGF (50 ng/ml) was supplemented, and 
after 5 days of NGF (Fig. 29). Whereas the number of vector-PC12 cells increased by        
1.34 x 106 cells (446%), the number of MKK7γ1-transfected cells only increased by          
0.87 x 106 (389%) during 5 days with normal serum-supplemented medium. Serum depletion 
almost stopped the proliferation of both cell lines (0.17 x 106 (10%) for vector- and 0.1 x 106 
(8%) for MKK7γ1-transfected PC12 cells). Following NGF supplementation, however, the 
number of EGFP-transfected PC12 cells was only elevated by 0.56 x 106 (41%). Interestingly, 
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the number of viable MKK7γ1-transfected cells further increased by 1.54 x 106 (178%). 
Therefore, proliferation of MKK7γ1-transfected cells occurred when least expected, namely 
during NGF supplementation. 
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Fig. 29: Cell numbers of vector- and MKK7γ1-transfected PC12 cells during differentiation. 
Cell counts of trypan blue stained vector- and MKK7γ1-transfected cells after 5 days with serum-
supplemeted medium (5), 3 days with serum-free medium (8) and 5 days with NGF-supplemented 
medium (50 ng/ml; 13). The data represents five independent experiments with ternary 
ascertainment.   
 
3.3.3 Sprouting 
Normally, NGF treatment induces the extension of neurites in PC12 cells. The observed 
proliferative effect of MKK7γ1 during NGF supplementation raised the question if neurites 
formation is blocked. Microscopical analysis revealed that NGF-differentiated vector- and 
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MKK7γ1-transfected PC12 cells showed a polygonal form and developed neurites (Fig. 30). 
Typically, both cell lines generated a monolayer of enlarged cell bodies with branched 
neurites on collagen-coated dishes. However, on top of the substrate-adhering MKK7γ1-
transfected PC12 cells were small round cells without processes. 
 
 
Fig. 30: Cell morphology of NGF-treated vector- and MKK7γ1-transfected PC12 cells. 
Light microscopic images of vector- and MKK7γ1-transfected PC12 cells after 5 days treatment 
with NGF (50 ng/ml). Bars, 50 µM. 
 
To assess the extent of neuronal differentiation, neurite outgrowth (sprouting) was 
examined in both cell lines. Therefore, 1x 105 vector- and MKK7γ1-transfected PC12 cells 
were grown on an object slide and differentiated for 5 days with 50 ng/ml NGF. The 
percentage of cells with neurites longer than 1.5 diameters of the cell body were counted with 
the ImageJ software. As expected, 98% of vector-transfected cells had developed neurites 
after 5 days of differentiation. In contrast, only 70.6% of MKK7γ1-transfected cells were 
sprouting (Fig. 31). 
 Summing up, MKK7γ1 prevented complete sprouting of PC12 cells during NGF 
supplementation. Indeed, a minor part of MKK7γ1 transfected cells remained naïve and 
exhibited no differentiation features. 
vector MKK7γ1
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Fig. 31: Sprouting of NGF-treated vector- and MKK7γ1-transfected PC12 cells. 
Cell counts of sprouting vector- and MKK7γ1-transfected cells after 5 days treatment with 50 ng/ml 
NGF. ###, p < 0.001 for effect of transfection with MKK7γ1 vs. vector. 
 
3.3.4 Activation of AKT, ERK1/2 and JNK pathways 
How does MKK7γ1 affect NGF-mediated PC12 cell differentiation? Normally, NGF 
supplementation enhances the expression of its high-affinity receptor TrkA and the low-
affinity receptor p75 in PC12 cells (146, 192). These increases in TrkA and p75 protein 
amount could only be observed in vector-transfected cells after 5 days of differentiation with 
50 ng/ml NGF (Fig. 32A). MKK7γ1-transfected cells, however, showed a general decrease in 
TrkA protein under naïve and differentiated conditions. NGF treatment mediated only a slight 
increase in TrkA protein amount compared to vector-transfected cells. Under normal cell 
growth conditions, p75 levels of vector- and MKK7γ1-transfected cells were equal. Again, 
NGF only mediated a slight elevation in p75 protein in MKK7γ1-transfected cells compared 
to vector-transfected cells. 
TrkA can activate the ERK1/2 pathway in PC12 cells, which is linked to 
differentiation (21, 144). While the levels of the ERK1/2 activator MEK-1 (mitogen-activated 
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protein kinase/extracellular signal-regulated protein kinase kinase 1) were comparable in 
vector- and MKK7γ1-transfected PC12 cells (Fig. 32B), MEK-1 phosphorylation was 
decreased after 5 days of differentiation in MKK7γ1-transfected cells compared to controls. 
Similar observations were made for the protein and activation levels of ERK1/2 in both cell 
lines. 
Phosphatidylinositol-3-kinase (PI3K), another kinase activated by TrkA, 
phosphorylates the serine/threonine-kinase protein kinase B (AKT) (3). Differentiation 
slightly reduced the protein level and activation of AKT in vector-transfected PC12 cells (Fig. 
32B). In MKK7γ1-transfected PC12 cells the amount AKT was unchanged, but 
phosphorylation of AKT was generally decreased and unaffected by differentiation. 
Finally, JNKs are also activated after NGF-binding to the TrkA receptor (90). This 
pathway includes mitogen-activated protein kinase/ERK kinase kinase-1 (MEKK-1) that in 
turn phosphorylates the MAP2Ks MKK4 and MKK7, which finally leads to JNK activation. 
The protein level of MEKK-1 was elevated in NGF-treated PC12 cells following MKK7γ1-
transfection (Fig. 32C). No differences could be observed for the amount of MKK4, only 
phosphorylation of MKK4 was slightly reduced by MKK7γ1-transfection, with subsequent 
reduction of p38 protein level in MKK7γ1-transfected cells. Activation of MKK4 was 
decreased in naïve and differentiated MKK7γ1-transfected PC12 cells compared to vector-
transfected cells. For MKK7 protein, no differences could be observed exempt an additional 
expression of exogenous MKK7γ1 in transfected PC12 cells. NGF mediated a slightly 
increased activity of endogenous MKK7 in both PC12 cell lines. As under normal cell growth 
conditions, phosphorylation of JNKs was increased by MKK7γ1 transfection and NGF 
treatment. The amount of JNK1/2 was also elevated by transfection with MKK7γ1, but 
seemed to be decreased after 5 days of differentiation. For JNK1 the amount was comparable 
in MKK7γ1-transfected PC12 cells after differentiation. However, JNK2 levels were slightly 
decreased after differentiation of MKK7γ1-transfected PC12 cells. 
Taken together, MKK7γ1 mediated a down-regulation of the two NGF receptors TrkA 
and p75 during differentiation, which attenuated the activation of MEK-1, ERK1/2 and AKT, 
all of them critical for differentiation of PC12 cells. In contrast, JNK signalling is strongly up-
regulated following NGF exposure in MKK7γ1-transfected PC12 cells. 
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Fig. 32: Protein and phosphorylation levels of NGF receptors and downstream pathways. 
Western blot analysis of whole cell extracts (20 µg) of naïve (N) and NGF-treated (D) vector- and 
MKK7γ1-transfected PC12 cells. Membranes were first immunoblotted against phosphorylated (p-) 
kinases or receptors of the NGF-pathway, then stripped and incubated with antibodies against the total 
protein. Equal loading was checked by Ponceau S staining of the membranes. Data are representative 
for three independent experiments. 
 
3.3.4.1 JNK protein levels, activation and localization 
The enhanced JNK activation in NGF-treated MKK7γ1-transfected PC12 cells brought up the 
question of isoform- and compartment-specific differences. Therefore, activated JNKs were 
detected in nuclear and cytoplasmic extracts from naïve and differentiated (5 days 50 ng/ml 
NGF) vector- and MKK7γ1-transfected PC12 cells by a phospho-specific antibody and 
membranes were stripped and re-hybridized with an antibody against total JNK.  
After NGF treatment MKK7γ1-transfected cells showed phosphorylation of JNK1/2 in 
both cellular fractions, with a marked activity in the nucleus. Total JNK protein levels were 
also increased in both fractions of MKK7γ1-transfected cells compared to vector-transfected 
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cells. Interestingly, the amount of 46 and 54 kDa JNK splice variants was enhanced in the 
nucleus of MKK7γ1-PC12 cells. Studies with isoform-specific antibodies directed against 
JNK1 and JNK2 revealed that this increase was due to high levels of JNK2 54 kDa splice 
variants in the nuclear fraction of MKK7γ1-transfected cells. In cytoplasmic fractions of 
MKK7γ1-tarnsfected cells, also 54 kDa splice variants of JNK2 were predominant. In contrast 
to JNK2, distribution and amount of JNK1 was comparable in vector- and MKK7γ1-
transfected PC12 cells. JNK1 only contributed to the 46 kDa JNK fraction. 
Summing up, MKK7γ1 mediated an increase in activation and protein levels of JNK1 
and JNK2 in the nucleus and cytoplasm of NGF-stimulated PC12 cells. Especially the 54 kDa 
splice variants of JNK2 (JNK2α2 and JNK2β2) showed a high level in MKK7γ1-transfected 
PC12 cells compared to control cells. 
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Fig. 33: Changes in amount, phosphorylation and localization of JNK isoforms after NGF 
treatment in MKK7γ1-transfected PC12 cells.  
Immunoblots of nuclear (nucl) and cytoplasmic (cyto) extracts (each 20 µg) from NGF-treated 
vector- and MKK7γ1-transfected PC12 cells. Membranes were immunoblotted against 
phosphorylated (p-) and total JNK1/2 and single JNK isoforms. Equal loading was checked by 
Ponceau S staining of the membranes. Western blots are representative for four independent 
experiments.  
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3.3.4.2 JNK targets 
The results so far and especially the strong nuclear JNK signal in MKK7γ1-transfected cells 
suggested an analysis of JNK substrates (Fig. 33). Therefore, the protein levels and 
phosphorylation of JNK targets involved in transcription, proliferation and apoptosis were 
investigated in naïve and differentiated (5 days 50 ng/ml NGF) vector- and MKK7γ1-
transfected PC12 cells by Western Blot analysis. 
c-Jun is known to be induced by NGF and to be involved in differentiation of PC12 
cells (52, 201). Similarly, the tumour suppressor p53 plays an important role in neuronal 
sprouting (4, 48, 140). NGF mediated an increase of c-Jun and p53 activation and amounts 
that were strongly pronounced in MKK7γ1-transfected cells compared to vector-transfected 
cells (Fig. 34). The transcription factor c-Myc and its targets can regulate the switch from 
proliferation to differentiation (32, 82, 186). Here, protein level and phosphorylation of c-Myc 
were differentially regulated in both cell lines dependent on NGF exposure. Differentiation 
caused an induction of c-Myc and its phosphorylation in vector-transfected PC12 cells. In 
naïve MKK7γ1-transfeceted PC12 cells c-Myc protein and phosphorylation were already 
down-regulated. NGF had no impact on the level and phosphorylation of c-Myc in MKK7γ1-
transfected cells. 
Due to the prolonged proliferation after NGF supplementation, the cell cycle 
regulators p21 and CyclinD1 were examined. NGF mediated an increase of the cell cycle 
inhibitor p21 in vector- and MKK7γ1-transfected PC12 cells (Fig. 34). However, the p21 
protein amount was more pronounced in vector-transfected cells compared to MKK7γ1-
transfected cells after differentiation. Inversely, the level of CyclinD1 was almost unaffected 
by NGF in vector-transfected cells but strongly increased in MKK7γ1-transfected cells. 
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Fig. 34: Protein amounts and phosphorylation of JNK targets in vector- and MKK7γ1-
transfected PC12 cells following NGF treatment. 
Whole cell extracts (20 µg) from naïve (N) and NGF-treated (D) vector- and MKK7γ1-transfected 
PC12 cells were analysed by Western blot. Membranes were first immunoblotted against 
phosphorylated (p-) transcription factors, then stripped and blotted against the total protein. Equal 
loading was checked by Ponceau S staining of the membranes. Data are representative for four 
independent experiments. 
 
 
3.3.4.3 Inhibition of JNKs 
To investigate the influence of JNKs on different substrates during NGF supplementation, 
two specific inhibitors were used. SP600125 is a small molecular weight, potent, cell-
permeable, reversible inhibitor that competes with ATP for binding to kinases and has a high 
specificity toward JNKs (7).  
Inhibition of JNKs after 24 h incubation with SP600125 (2 µM) reduced the protein 
amounts and phosphorylation of the eponymous target c-Jun in vector- and MKK7γ1-
transfected PC12 cells (Fig. 35). Whereas the JNK-inhibitor increased activation and protein 
levels of p53 in vector-transfected cells contrary effects were observed in MKK7γ1-
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transfected PC12 cells. p53 induction was reflected in the protein level of the cell cycle 
inhibitor p21. CyclinD1 was increased in both cell lines due to JNK inhibition. 
These results demonstrate that MKK7γ1 increased the NGF-mediated increase of c-Jun 
and p53 protein levels and activation via JNKs.  
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Fig. 35: JNK-dependent protein levels and phosphorylation of transcription factors and cell 
cycle regulators in NGF-treated vector- and MKK7γ1-transfected PC12 cells. 
Western blot analysis from whole cell extracts (20 µg) of vector- and MKK7γ1-transfected PC12 
cells with antibodies directed against phosphorylated (p-) c-Jun (p-c-Jun), c-Jun, p-p53, p53, p21 
and CyclinD1. Cells were naïve (N) or NGF-treated and unstimulated (D) or incubated for 24 h with 
SP600125 (SP; 2 µM). Equal loading was checked by Ponceau S staining of the membranes. Blots 
are representative of three independent experiments. 
 
 
3.3.4.4 p53 actions  
The proto-oncogene p53 is a transcriptional activator of p21. Furthermore, p53 was shown to 
be important for PC12 cell differentiation. As shown above, NGF-treatment increased 
activation of p53 and the protein level of p21 in vector-transfected cells, while transfection 
with MKK7γ1 enhanced p53 phosphorylation but decreased p21 protein levels. Both 
processes are JNK-dependent. This brought up the questions, (i) if p53 regulates p21 levels 
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during NGF-treatment and (ii) how MKK7γ1 and JNKs affects both proteins.  
 Pifithrin-α is a potent inhibitor of p53 actions (103). The mechanism, how Pifithrin-α 
blocks p53 is not identified yet. To investigate the effect of p53 on p21, vector- and MKK7γ1-
transfected PC12 cells were treated with NGF and incubated with Pifithrin-α for 24 h. 
Afterwards whole cell extracts from treated PC12 cells were immunoblotted against p21. As 
shown in Fig. 36A, inhibition of p53 reduced p21 protein levels in vector-transfected PC12 
cells. In contrast, stimulation with Pifihrin-α slightly enhanced the amount of p21 in 
MKK7γ1-transfected PC12 cells. Thus, p53 positively regulates p21 in control cells but 
negatively regulates p21 following overexpression of MKK7γ1. 
Apart from phosphorylation, JNKs bind to p53 (2, 84). To analyse JNK:p53 
complexes, whole cell extracts from naïve and NGF-treated vector- and MKK7γ1-transfected 
PC12 cells were immunoprecipitated with an antibody against p53 and immunoblotted with 
isoform-specific JNK1 and JNK2 antibodies. Transfection with MKK7γ1 mediated an 
increase in JNK1:p53 complexes (Fig. 36B). However, JNK1:p53 complexes were unaffected 
by NGF treatment. In contrast, JNK2:p53 complexes were enhanced in differentiated vector-
transfected PC12 cells and reduced in MKK7γ1-PC12 cells following NGF-treatment.   
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Fig. 36: Influence of MKK7γ1 on p53 actions in NGF-treated PC12 cells. 
A, Western blot against p21 of whole cell extracts (20 µg) from NGF-treated or vector- and 
MKK7γ1-transfected PC12 cells. C, unstimulated control; P, 2 µM Pifithrin-α for 24 h.  
B, Immunoprecipitation (IP) of native protein extracts (200 µg) from naïve (N) and NGF-treated 
(D) vector- and MKK7γ1-transfected PC12 cells. The native protein lysates were 
immunoprecipitated with an antibody against p53 and immunoblotted with antibodies against JNK1 
and JNK2. ∅, mock. 
3.3.5 MKK7γ1 under stress conditions in NGF-treated PC12 cells 
As MKK7γ1 mediated stress resistance in naïve PC12 cells (see section 3.2.2), the next set of 
experiments addressed the influence of MKK7γ1 on the reaction of NGF-trated PC12 cells 
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towards stress conditions. Therefore, experiments were carried out with taxol as a 
differentiation-dependent stimuli and tunicamycin that causes cell death in naïve and 
differentiated PC12 cells. The anticancer agent taxol binds to microtubules and provokes a 
cell cycle arrest during mitosis that leads to apoptosis. Thus, only proliferating cells, but not 
differentiated cells are susceptible for taxol. The observed proliferation of MKK7γ1-
transfected cells during NGF supplementation could maintain their responsiveness towards 
taxol. The ER stressor tunicamycin, however, should have a stronger apoptotic effect on 
vector-transfected cells, than MKK7γ1 cells. 
 
3.3.5.1 Cell death 
Vector- and MKK7γ1-transfected PC12 cells were differentiated for 5 days with 50 ng/ml 
NGF. Afterwards, the cells were incubated for 24 h with two different concentrations of taxol 
(2.5 or 5 µM) and counted by trypan blue staining. Stimulation with taxol did not affect the 
viability of vector-transfected PC12 cells (2.5 µM taxol; 103%) or even increased it (5 µM 
taxol; 127%) as shown in Fig. 37. In contrast, survival of NGF-treated MKK7γ1-transfected 
PC12 cells was decreased by 26% (2.5 µM taxol) and 24% (5 µM taxol). 
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Fig. 37: Viability of NGF-treated vector- and MKK7γ1-transfected cells following stimulation 
with taxol.  
Cell counts of trypane blue stained NGF-treated vector- and MKK7γ1-transfected PC12 cells. The 
cells were unstimulated (control) or stimulated with two different concentrations (2.5 or 5 µM) of 
taxol for 24 h. Stimulation with 2.5 or 5 µM taxol. Control = 100%. ∗∗, p < 0.01; ∗∗∗/###,               
p < 0.001 for effect of taxol/transfection with MKK7γ1 vs. vector. Data represent four independent 
experiments with ternary ascertainment. 
 
As a marker for apoptosis, cell extracts from both cell lines were blotted against 
cleaved and total effector Caspase-3. Differentiated vector- and MKK7γ1-transfected PC12 
cells were stimulated with taxol (5 µM), the JNK inhibitor SP600125 (2 µM) or both for 18 h 
and proteins were extracted. Protein amount and cleavage of Caspase-3 were unaffected by 
taxol as well as SP600125 in vector-transfected cells (Fig. 38). Even in MKK7γ1-transfected 
PC12 cells, the level of Caspase-3 did not change. However, differentiated MKK7γ1-
transfected cells showed an increase of activated Caspase-3 following taxol treatment. 
Pretreatment with SP600125 reduced Caspase-3 activity to basal levels, which means that 
transfection with MKK7γ1 caused a JNK-dependent increase of Caspase-3 cleavage in 
differentiated PC12 cells. 
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 Taken together, the chemotherapeutic taxol has no effect on differentiated vector-
transfected PC12 cells. The fact that MKK7γ1 did not stop proliferation during NGF 
treatment of PC12 cells promoted JNK-induced apoptosis of PC12 cells following taxol 
stimulation. 
Stimulation with 1.4 µg/ml tunicamycin for 18 h reduced the number of viable vector-
transfected PC12 cells by 27% (Fig. 39). Survival of MKK7γ1-transfected cells was only 
decreased by 9%.  
 
Fig. 38: Cleavage and protein levels of Caspase-3 in NGF-treated vector- and MKK7γ1-
transfected PC12 cells following stimulation with taxol and SP600125. 
Whole cell extracts (20 µg) from NGF-treated vector- and MKK7γ1-transfected PC12 cells were 
analysed by Western blot. Membranes were first incubated with an antibody directed against 
cleaved Caspase-3, then stripped and immunoblotted with a Caspase-3 antibody. C, unstimulated 
control, S, 2 µM SP600125 for 18 h; T, 5 µM taxol for 18 h and ST, 2 µM SP600125 30 min before 
18 h treatment with 5 µM taxol. Equal loading was checked by Ponceau S staining of the 
membranes. Western blots are representative for three independent experiments. 
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Fig. 39: Viability of NGF-treated vector- and MKK7γ1-transfected cells following stimulation 
with tunicamycin. 
Cell counts of NGF-treated vector- and MKK7γ1-transfected PC12 cells after 24 h stimulation with 
1.4 µg/ml tunicamycin. The cells were counted after trypane blue staining. Control = 100%. ∗∗∗/###, 
p < 0.001 for effect of tunicamycin/transfection with MKK7γ1 vs. vector. Data represent four 
independent experiments with ternary ascertainment. 
 
Also cleavage of Caspase-3 was increased in vector-transfected PC12 cells compared 
to MKK7γ1-transfected cells (Fig. 40). Inhibition of JNKs by incubation with SP600125 
decreased activation of Caspase-3 in both cell lines. Caspase-3 protein levels were unaffected 
by tunicamycin as well as SP600125. 
Taken together, taxol has no apoptotic effect on differentiated vector-transfected PC12 
cells. MKK7γ1 did not stop proliferation during differentiation of PC12 cells, and accordingly 
promoted JNK-induced apoptosis of PC12 cells following taxol stimulation. As in naïve PC12 
cells, MKK7γ1 mediated protection of NGF-treated cells against tunicamycin-induced 
apoptosis.  
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Fig. 40: Cleavage and protein levels of Caspase-3 in NGF-treated vector- and MKK7γ1-
transfected PC12 cells following stimulation with tunicamycin and SP600125. 
Whole cell extracts (20 µg) from NGF-treated vector- and MKK7γ1-transfected PC12 cells were 
analysed by Western blot. Membranes were first incubated with an antibody directed against 
cleaved Caspase-3, then stripped and immunoblotted with a Caspase-3 antibody. C, unstimulated 
control, S, 2 µM SP600125 for 18 h; TM, 1.4 µg/ml tunicamycin for 18 h and STM, 2 µM 
SP600125 30 min before 18 h treatment with 1.4 µg/ml tunicamycin. Equal loading was checked by 
Ponceau S staining of the membranes. Western blots are representative for three independent 
experiments. 
 
3.3.5.2 JNKs and their targets 
To further characterise the MKK7γ1-mediated susceptibility of NGF-treated PC12 cells to 
taxol, Western blots with antibodies directed against JNKs and their targets were performed. 
Taxol caused an increase of activated JNK1/2 in NGF-treated vector- and MKK7γ1-
transfected PC12 cells, which was more pronounced in MKK7γ1-transfected cells (Fig. 41). 
JNK1/2 protein levels were unaffected by taxol stimulation but slightly elevated by 
transfection with MKK7γ1. Similar to JNK activation, taxol increased c-Jun phosphorylation 
in both cell lines. Interestingly, the c-Jun protein level was down-regulated in MKK7γ1-
transfected cells after stimulation with taxol, whereas it was increased in vector-transfected 
cells. Furthermore, taxol evoked a strong activation of p53 in differentiated vector- and 
MKK7γ1-transfected cells. No change in p53 levels could be observed in vector-transfected 
cells. However, stimulation with taxol decreased the amount of p53 in MKK7γ1-transfected 
cells. Phospho-c-Myc and c-Myc levels were not affected by stimulation with taxol, but 
down-regulated by MKK7γ1 transfection. After application of taxol, changes in p21 and 
CyclinD1 protein levels were detected. In vector-transfected cells, taxol had only a slight 
effect on p21, whereas it was up-regulated in MKK7γ1-transfected PC12 cells. Taxol induced 
a down-regulation of CyclinD1 protein in both cell lines. 
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Fig. 41: Protein levels and phosphorylation of JNKs and their targets after taxol stimulation in 
NGF-treated PC12 cells. 
Western blot analysis from whole cell extracts (20 µg) of vector- and MKK7γ1-transfected PC12 cells 
with antibodies directed against phosphorylated (p-) JNK1/2, JNK1/2, p-c-Jun, c-Jun, p-p53, p53, p21, 
p-c-Myc, c-Myc and CyclinD1. Taxol-stimulated (24 h) differentiated PC12 cells. Equal loading was 
checked by Ponceau S staining of membranes. Western blots are representative of four independent 
experiments. 
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3.3.5.3 Summary III 
The following table gives a simplified overview of the MKK7γ1-mediated changes in PC12 
cells following NGF treatment. 
 
Tab. 14: MKK7γ1-mediated changes following NGF treatment. 
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NGF- mediated changes (↑, increase; -, no change; ↓, decrease) in vector- and MKK7γ1-transfected 
PC12 cells. Relative changes (▲, increase; ▬, no change;▼, decrease) in NGF-treated MKK7γ1-
transfected PC12 cells compared to vector-transfected PC12 cells. 
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3.4 Characterisation of MKK4 and MKK4∆ in naïve PC12 cells 
For characterisation of MKK4 and MKK4∆, electronic cell counts were carried out. 
Therefore, 0.3 x 106 cells were grown on collagen-coated 6-well plates for 5 days. 
Transfection with the established MKK4 splice variant decreased the number of viable PC12 
cells by 35% (Fig. 42). In contrast, transfection with the so far unknown MKK4∆ splice 
variant mediated an increase of viable PC12 cells by 40% compared to vector transfection. 
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Fig. 42: Electronic cell counts of vector-, MKK4- and MKK4∆-transfected PC12 cells.  
The three cultures were kept under the same conditions. The data represent six independent 
experiments with ternary ascertainment. ***/###, p < 0.001 for vector- vs. MKK4-/MKK4∆-
transfected cells/ transfection with MKK4∆ vs. MKK4. 
 
 Afterwards, stable cell clones were screened for the protein level and activation of 
MKK4, their counterpart MKK7, their substrates p38 and JNKs and other downstream 
targets. Transfection of PC12 cells with the pEGFP vector, MKK4-pEGFP or MKK4∆-
pEGFP did not change the amount and phosphorylation of endogenous MKK4 (Fig. 43). The 
protein levels and phosphorylation of exogenous MKK4 and MKK4∆ was slightly reduced 
compared to endogenous MKK4. Transfection with both MKK4 splice variants had no impact 
on the MKK7 protein levels. However, activation of MKK7 was reduced in MKK4-
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transfected cells and further decreased by transfection with MKK4∆ compared to transfection 
with the empty pEGFP vector. All three cell clones showed similar levels of JNK1/2 proteins. 
Activation of JNK1/2, especially the 54 kDa splice variants, was slightly elevated by 
transfection with MKK4 and MKK4∆. No changes could be observed in the amount and 
phosphorylation of the second direct MKK4 substrate p38. 
 The transcription factor p53 can be phosphorylated by p38 or JNKs, respectively (84, 
138). Whereas the protein amount of p53 was comparable in MKK4- and vector-transfected 
PC12 cells, transfection with MKK4∆ strongly induced p53. Activation of p53 was also 
increased in MKK4∆-transfected cells, while it was slightly decreased following MKK4 
transfection compared to vector-transfected PC12 cells. Protein amounts and phosphorylation 
of the transcription factor c-Jun were unaffected by transfection with MKK4 but decreased by 
transfection with MKK4∆.  
 The two cell cycle regulators p21 and CyclinD1 are targets of p38 and JNK signalling. 
The p21 protein level was unaffected by transfection with MKK4∆, whereas it was increased 
by transfection with MKK4 compared to vector-transfected cells. Furthermore the amounts of 
CyclinD1 were oppositely affected by MKK4 and MKK4∆ transfection. MKK4 transfection 
reduced and MKK4∆ transfection increased CyclinD1 levels. 
 Transfection with both MKK4 splice variants increased the levels of the anti-apoptotic 
BH3-only protein Bcl-2. However, the amounts of pro-apoptotic Bim were decreased by the 
transfection with MKK4∆ and further reduced by exogenous MKK4. 
 In summary, though the novel MKK4∆ only includes an additional exon compared to 
MKK4, overexpression of both MKK4 splice variants provoked different effects in PC12 
cells. Transfection with MKK4 slightly reduced the number of viable PC12 cells and the 
phosphorylation of p53. Furthermore, p21 levels were increased but CyclinD1 and Bim 
protein amounts were decreased. In contrast, MKK4∆ enhanced the number of viable PC12 
cells and the protein level and phosphorylation of p53. c-Jun and Bim were down-regulated 
and CyclinD1 protein increased following MKK4∆ transfection.   
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Fig. 43: Protein levels and phosphorylation of JNKs, upstream kinases and targets.  
Whole cell extracts (20 µg) from vector-, MKK4 and MKK4∆-transfected PC12 cells were 
immunoblotted against JNK1/2, their upstream kinases (MKK4 and MKK7) and some of their direct 
downstream targets (c-Jun, p53 and c-Myc). All three cell lines were kept under the same conditions. 
The Western blot membrane was first immunoblotted with phospho-specific antibodies   (p-), then 
stripped and immunoblotted with an antibody directed against the total protein. β-Actin was used as a 
loading control. Western blots are representative for five independent experiments. 
 
The next experiment addressed the question, if overexpression of MKK4 and MKK4∆ 
affects the survival of PC12 cells under cellular stress conditions. Vector-, MKK4- and 
MKK4∆-transfected PC12 cells were synchronized and incubated with the chemotherapeutic 
taxol (5 µM) for 24 hours. Electronic cell counting revealed that transfection with MKK4 
significantly increased the viability of PC12 cells by 15% following taxol stimulation (Fig. 
44). However, survival of taxol-stimulated MKK4∆-transfected PC12 cells was reduced by 
6% compared to vector-transfected PC12 cells. 
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Taken together, the observed differences between MKK4- and MKK4∆-transfected 
cells alter the cellular reaction following stimulation with the stressor taxol. 
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Fig. 44: Viability of vector-, MKK4- and MKK4∆-transfected PC12 cells following stimulation 
with taxol. 
Electronic cell counts of unstimulated (control) and taxol-stimulated (taxol, 5 µM for 24 h) vector-, 
MKK4- and MKK4∆-transfected PC12 cells. Control = 100%. #, p < 0.1; ∗∗∗/###, p < 0.001 for 
effect of taxol/transfection with MKK4 and MKK4∆ vs. vector. Data represent four independent 
experiments with ternary ascertainment. 
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3.4.1.1 Summary IV 
Table 15 gives a simplified overview of MKK4- and MKK4∆-mediated changes in naïve 
PC12 cells. 
 
Tab. 15: MKK4- and MKK4∆-mediated changes in naïve PC12 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relative changes (▲, increase; ▬, no change;▼, decrease) in naïve MKK4-/MKK4∆-transfected 
PC12 cells compared to vector-transfected PC12 cells. 
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4 Discussion 
The aim of this study was to investigate the functions of single MKK4 and MKK7 splice 
variants in proliferating and differentiated neuronal cells under physiological and pathological 
conditions. Their effect on activation and protein levels of JNKs and downstream targets was 
to be examined and the resulting consequences for basic cellular processes like proliferation 
and apoptosis. 
 
4.1 The cellular system 
PC12 cells were used for the functional characterization of MKK4 and MKK7 splice variants. 
The aim of this study was the evaluation of a stable neuronal model system, which could be 
used for determining the potential of MKK4 and MKK7 splice variants under different 
conditions, like cellular stress or neuronal differentiation. The physiological effects of 
overexpression approaches are rather moderate. Therefore, it was necessary to use a reliable 
system with a very low susceptibility to experimental interferences. The use of primary 
cultures of mice or rat sympathetic neurons would, of course, have come closer to the in vivo 
situation. However, not only the preparation and the varying physiological conditions of the 
animals, but also contaminations with other cell types (e.g., glia cells), influence the 
reproducibility of the experiments (13). Another disadvantage of primary neurons is their 
susceptibility to gene transfer. They are difficult to transfect with a maximal efficiency of 
30%, moreover, the majority of cells already die during the transfection procedure (39). 
It was not the aim of this study to examine the in vivo situation but rather to come closer 
to the understanding of signal transduction triggered by MKK4 and MKK7 splice variants. By 
characterizing such basic processes, it will be possible plan experiments for in vivo situations 
more accurately. In addition, a large amount of cell culture experiments was conducted in the 
present thesis. To carry out a comparable set of experiments with primary neurons would have 
been quite delicate from an ethical point of view, since numerous animals would have been 
sacrificed for addressing basic questions of signal transduction. 
  Apart from PC12 cells, other neuronal permanent cell lines, human or mouse 
neuroblastoma cells, for example, can also be differentiated by treatment with retinoic acid, 
but do not display the extent of neuritogenesis as PC12 cells (149). Furthermore, a loss of 
neuronal characteristics with increasing passage number has been described for permanent 
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neuroblastoma cells. In contrast, no major changes in cell growth characteristics or growth 
factor sensitivity were detected in PC12 cells even after 70 generations (68). 
An important feature of PC12 cells is that their biochemical properties have fairly well 
been characterized and their sets of MAPKs has been determined (124, 168, 170, 177, 189). 
Apoptotic processes and differentiation of PC12 cells have been extensively examined over 
several years. All these qualities render PC12 cells a well-defined cell culture system for the 
analysis of MAPK pathways under various environmental conditions. 
 
4.2 Methodology 
Functional analysis of proteins can be done by different methods. The most obvious one is to 
characterize and investigate knockout animals or primary cells from those animals. 
Unfortuntely, mkk7-/- mice are embryonic lethal and only embryonic fibroblasts of these 
animals can serve as a research object. However, splice variant-specific studies are impossible 
as gene deletion affects all transcripts. Another option is using RNA interference approaches. 
Efficient gene silencing without side effects can provide unequivocal information of protein 
functions. For a strong reduction of target mRNA levels a cocktail of 2 to 4 siRNAs (each ~21 
nucleotides) is necessary (37). Furthermore, more than 16 to 17 contiguous base pairs of 
homology to other coding sequences should be excluded. MKK4 and MKK4∆, or MKK7β1 
and MKK7γ1 splice variants only differ in a single exon of 30 or 48 base pairs, respectively. 
After extensive studies of gene and transcript sequences and consulting of siRNA 
manufacturers, RNA interference approaches had to be ruled out. Thus, overexpression was 
the method of choice for this thesis. Stable transfection, continuous validation of construct 
expression via microscope (GFP-Tag) or Western blot analysis enabled constant and reliable 
results. In addition, most experiments were done with several cell clones in parallel and 
multiple independent repetitions were performed of every experiment shown in this study. 
 All protein analyses of this thesis were done with specificity-evaluated mono- or 
polyclonal antibodies. Fortunately, most backround signals of individual antibodies, mainly 
the phospho-specific antibodies, could be prevented by using optimized dilutions and 
concentrations of blocking solution. The JNK antibodies used for immunoprecipitations and 
immunodepletions were tested on tissues from knockout mice (216). With negative controls 
and the ExactaCruz reagents, artefacts originated from the heavy chains of 
immunoprecipitation antibodies could be eliminated. 
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4.3 MKK7γ1 as a regulator of cell proliferation in PC12 cells 
4.3.1 Naïve PC12 cells 
Normal cell growth conditions- The results of the present study show that MKK7γ1 is 
a negative regulator of neuronal cell proliferation under normal cell growth conditions. The 
decrease in proliferation is accompanied by a high JNK activity, a reduced amount of 
CyclinD1 protein and a JNK-dependent increase in the cyclin-kinase inhibitor p21 on mRNA 
and protein level. CyclinD1 forms complexes with cyclin-dependent kinase (CDK) 4 and 6 
which promote the cell cycle transition from G1- to S-phase (195). p21 inhibits CDK2 and 
CDK4 and thereby stops cell cycle progression in late G1-phase (116, 122). The observed 
changes on the level of both cell cycle regulators and the increase of PC12 cells in G1 present 
a mechanism how MKK7γ1 can block cell cycle progression and decrease proliferation. 
Previous studies on the proliferative impact of total MKK7 revealed contradictory results and 
the effect of MKK7γ1 has not been addressed so far. Consistent with the results of this study, 
MKK7 was shown to be a negative regulator of haematopoietic cell proliferation, assumably 
via induction of the cell cycle inhibitor p16INK4a and down-regulation of CyclinD1 levels 
(50, 155). In contrast, studies on mkk7-/- MEFs revealed that MKK7 has no impact on 
proliferation in passages 1 to 3, but is a positive regulator of proliferation and an antagonist of 
senescence beginning with passage 4 to 5 (187). The expression of CyclinD1 and p21 was not 
altered in mkk7-/- MEFs. Thus, the effect of MKK7 on proliferation is dependent on the cell 
type, the age or number of passage. Furthermore, there is a difference between MKK7 splice 
variants. Expression of constitutive active MKK7β1 in the human embryonal kidney 
carcinoma cell line HEK293 demonstrated that MKK7β1 suppresses proliferation (200).  
Stress conditions- The chemotherapeutic agent taxol suppresses mitotic spindle 
assembly which leads to dysfunction of the cytoskeleton (118). Tunicamycin is an antibiotic 
that disrupts the N-glycosylation of newly-synthesized proteins (158). Cellular stress response 
to both stimuli involves JNK signalling in PC12 cells (162, 191). Stimulation with taxol and 
tunicamycin reduced proliferation of vector- and MKK7β1-transfected PC12 cells. Only 
transfection with MKK7γ1 increased proliferation of PC12 cells in response to tunicamycin. 
Treatment with taxol induces a G2-phase cell cycle arrest with an decrease of G1-phase cell 
population (41). Both, vector and MKK7β1 transfection showed this effect, whereas MKKγ1 
reduced G2 cell population. To a lesser extent tunicamycin shifts cells from G2- in G1-phase 
(119), as described for control and MKK7β1-transfected PC12 cells in this study. Again, 
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MKK7γ1-transfected cells showed an opposite reaction. The percentages of cells was 
decreased in G1- and increased in G2-phase and the distribution of tunicamycin-stimulated 
MKK7γ1-PC12 cells nearly reached that of unstimulated control cells.  
mRNA and protein levels of p21 confirm the observations from proliferation and cell 
cycle assays. Transfected MKK7γ1 selectively decreased the amount of p21 after stimulation 
with tunicamycin. In vector- and MKK7β1-transfected cells tunicamycin stimulation 
increased p21 levels. Results from chromatin immunoprecipitations show that p53, which is 
known to be an inducer of p21 transcription under various conditions (53), is involved in the 
transcriptional regulation of p21 in the used PC12 cell model. Additionally, MKK7γ1 
influences p21 promoter-binding of the transcription factor p53. The data from JNK inhibition 
experiments with SP600125 show that this regulation is triggered by JNKs. So far no other 
publication investigated the influence of single MKK7 splice variants on cellular growth 
behavior under conditions of stress. The results of this thesis demonstrate that MKK7γ1 
positively regulates neuronal proliferation by modulation of cell cycle regulators on mRNA 
and protein levels under stress conditions.  
 
4.3.2 NGF-treated PC12 cells 
In the presence of NGF, PC12 cells cease to proliferate and differentiate into a near-neuronal 
phenotype with neurite outgrowth and dramatic changes in mRNA and protein levels (176). 
Concerning the cell cycle, NGF induces the expression of the cell cycle inhibitor p21 and the 
G1-phase CyclinD1 (16, 207).  
During serum deprivation, vector-transfected PC12 cells stopped proliferation, but 
after 5 days of NGF supplementation a small increase in cell numbers was observed. Western 
blot analysis revealed a strong increase in p21 levels, which is required for the mitotic arrest 
mediated by NGF (64). The experiment with the p53 inhibitor Pifithrin-α showed that the 
NGF-mediated increase in p21 is p53-dependent. The increase of CyclinD1 confirmed several 
findings on mitogenic effects of NGF during early stages of differentiation in PC12 cells (17) 
and it also explains the slightly increased cell number of vector-transfected cells.  
The first part of this thesis on naïve PC12 cells showed that MKK7γ1 attenuates 
proliferation under normal cell growth conditions, increases p21 and suppresses CyclinD1 
levels. Therefore, I expected that overexpression of MKK7γ1 accelerate PC12 cell 
differentiation, too. Surprisingly, 5 days of NGF treatment strongly increased the number of 
MKK7γ1-transfected cells, reduced p21 protein levels and drastically enhanced CyclinD1 
Discussion  109 
 
levels. NGF-mediated cell cycle arrest is blocked and proliferation is sustained. In contrast to 
vector-transfected cells, inhibition of p53 slightly enhanced p21 protein in MKK7γ1-
transfected PC12 cells. Thus, MKK7γ1 interferes with the central process of neuronal 
differentiation by antagonising cell cycle arrest. 
 
4.4 MKK7γ1 is a negative regulator of neuritogenesis in PC12 cells 
NGF signalling through the receptor tyrosine kinase TrkA induces differentiation (92). NGF-
binding to the TrkA and p75 receptors activates several signalling pathways underlying the 
formation of neurites (reviewed by (85, 93)). Five days of NGF supplementation (50 ng/ml) 
following serum deprivation caused a pronounced differentiation of all vector-transfected 
PC12 cells. However, NGF treatment failed to induce sprouting of all MKK7γ1-transfected 
cells. Furthermore, differentiated cells were overgrown by naïve, proliferating PC12 cells. 
This non-physiological phenotype is accompanied by alterations in molecular signalling. In 
vector-transfected cells, NGF strongly enhanced TrkA and p75 levels and the activation of 
ERK1/2. In contrast, MKK7γ1 transfection attenuated a substantially lesser increase of TrkA, 
p75 and activated ERK1/2 levels, which explains the partially defective neurite formation (33, 
144, 148). 
The activation and protein levels of AKT, a co-effector of neuritogenesis (108, 120, 
131), were also examined in this study. As for TrkA, p75 and ERK1/2, AKT phosphorylation 
was markedly attenuated in MKK7γ1-transfected cells, which might further contribute to 
decreased neurite formation.  
Beyond stress response and cell death (31, 42), JNKs exert important functions in 
response to growth factors and regulation of neurite outgrowth (101, 190). ERK1/2 and JNKs 
interact to induce neurite formation and both are crucial for regeneration of damaged neurites 
in PC12 cells (189, 190). This study shows that MKK7γ1 potentiates JNK signalling by 
increased levels of MEKK-1 as well as activation of MKK7 and JNK1/2. Simultaneously, 
phosphorylation and amounts of MKK4 were down-regulated. Only in MKK7γ1-transfected 
cells, this decrease was reflected by reduction of active p38. What cellular consequences 
could that have? In cerebral granule neurons MKK4 was mostly associated with JNK-
mediated stress reactions and MKK7 with JNK-induced neuritogenesis (30). Furthermore, 
MKK7 activity is increased during neuroregeneration of injured PC12 cells, whereas 
phoshorylation of MKK4 is unaffected (190). In MKK7γ1-transfected PC12 cells, however, 
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the strong activation of the JNK pathway might not be sufficient for differentiation, especially 
when the activation of ERK1/2 and AKT are decreased. 
 
4.5 MKK7γ1 as regulator of PC12 cell stress response 
4.5.1 Naïve PC12 cells 
Normal cell growth conditions- Transfection with MKK7γ1 increased the mRNA and 
protein levels of the death receptor Fas and the pro-apoptotic BH3-only protein Bim. 
Furthermore, the cleavage of the effector Caspase-3 was enhanced under basal conditions. 
Concurrently, the amount of anti-apoptotic proteins Bcl-2 and Bcl-xl were decreased 
compared to vector-transfected PC12 cells. JNKs activate Bim and Bcl-2 and thereby promote 
apoptosis in neurons (113, 142). Therefore the reduced number of viable cells in response to 
transfection with MKK7γ1 could partially be caused by an increase of spontaneous apoptotic 
cell death via the JNK-Bcl-axis and a decrease in cellular proliferation, respectively. 
Stress conditions- In contrast to vector- and MKK7β1-transfected PC12 cells, 
transfection with MKK7γ1 significantly reduced cell death after stimulation with taxol, 
tunicamycin and thapsigargin. Interestingly, overexpression of MKK7γ1 prevented PC12 cells 
from death usually induced by TNF-α and tunicamycin. According to the results from vector- 
and MKK7β1-transfected cells, all tested stressors induce apoptotic cell death in PC12 cells 
(162, 172, 191). Thus, the observed neuronal death resistance is splice variant-specific for 
MKK7γ1.  
With regard to signal transduction, tunicamycin-triggered activation of the effector 
Caspase-3 was reduced in MKK7γ1-transfected PC12 cells. Additionally, the protein amounts 
of the death receptor Fas and its ligand Fas-L were decreased in MKK7γ1-cells. In vector-
transfected cells stimulation with tunicamycin caused an increase of Fas, while Fas-L was 
unaffected. Stress is known to increase the expression of Fas in PC12 cells and activation of 
Fas turns on a pathway leding to Caspase-3 cleavage (26, 58). Studies on Fas-deficient mice 
showed reduced apoptosis in neurons (1, 19). Interestingly, treatment with the Fas inhibitor 
protein Fas-Fc decreased neuronal regeneration of PC12 cells following injury (192). The 
results of this study suggest that the MKK7γ1-mediated down-regulation of the Fas-receptor 
is a relevant factor in promoting stress-resistance of PC12 cells.  
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4.5.2 NGF-treated PC12 cells 
The preceding section has shown that overexpression of MKK7γ1 protects PC12 cells against 
different types of stress, including taxol and tunicamycin. Normally, NGF also promotes cell 
survival in response to taxol, by with-drawl from mitosis (34). However, MKK7γ1 
transfection caused cell death of NGF-treated PC12 cells. This effect resulted from an 
incomplete differentiation caused by MKK7γ1. MKK7γ1-transfected PC12 cells still 
proliferated in spite of NGF supplementation, which rendered them susceptible to taxol, 
which blocks mitosis. 
Interestingly, reactions of MKK7γ1-transfected cells towards the ER-stressor 
tunicamycin were unaffected by NGF treatment. Whereas tunicamycin stimulation induced 
apoptosis in differentiated control cells, MKK7γ1 could antagonise cell death. Presumably, 
the observed resistance of NGF-treated PC12 cells is caused by a MKK7γ1-mediated down-
regulation of death receptor Fas as in naïve MKK7γ1-transfected cells. However, further 
analysis of apoptotic proteins will be necessary. 
 
4.6 MKK7γ1 activates a distinct JNK signalling pathway in PC12 cells 
4.6.1 Naïve PC12 cells 
Normal cell growth conditions- Comparable to the results from vector-transfected 
cells, naïve PC12 cells possess a low basal level of JNK, c-Jun and p53 activity (15, 124). 
Overexpression of MKK7γ1 strongly enhances the amount and phosphorylation of JNKs and 
their targets c-Jun and p53. Based on the high activation of JNK, it is conceivable that the 
observed changes are controlled by JNK. Apart from phosphorylation of c-Jun, JNKs activate 
a number of transcription factors in neurons that contribute to the c-Jun promoter activity, 
including c-Jun itself and ATF-2 (31). The results from experiments with the JNK inhibitor 
SP600125 confirm that both transcription factors and the cell cycle inhibitor p21 are JNK-
dependent up-regulated in PC12 cells following transfection with MKK7γ1. In contrast, the 
p53 protein level is slightly down-regulated via JNKs in control PC12 cells. p53 is suppressed 
by JNK1 in primary human fibroblasts (171). However, immunodepletions clearly showed 
that phosphorylated JNK2 forms the majority of activated JNK in MKK7γ1-transfected PC12 
cells. Interestingly, JNK2 deficiency leads to increased cell numbers of primary MEFs and 
immortalized 3T3 cells, due to enhanced proliferation (151). In addition to the ability of p53 
phosphorylation, activated JNK2 is a positive regulator of p53 (2, 171). The results of this 
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thesis show that regulation of p53 rather occurs on protein, than on mRNA level. On the one 
hand, p53 can mediate cell cycle arrest through p21 (53) and, on the other hand, p53 regulates 
apoptosis through the Bcl-2/Bax balance in neurons (184). Indeed, p53 is rather linked to anti-
proliferation than to differentiation and apoptosis in neuronal precursor cells (183). 
Overexpression of MKK7γ1 decreased c-Myc mRNA, protein and phosphorylation 
levels. A rapid down-regulation of c-Myc is often triggered by anti-proliferative signals (18, 
43). In jnk1-/- liver cancers, c-Myc and CyclinD1 expression are strongly reduced, while p21 
expression is increased (86, 153). Mechanistically c-Myc is a repressor of p21 transcription 
via binding to the p21 promoter (165). Furthermore, increased p21 protein levels negatively 
regulate CyclinD1 expression in liver cell proliferation following partial hepatectomy (166, 
203). Assumably, MKK7γ1 preferentially activates JNK2, thereby increases p53 and 
decreases c-Myc and CyclinD1 levels, which in turn positively regulates p21. 
JNKs are also involved in regulation of apoptotic proteins (reviewed by (47)). They 
can activate pro-apoptotic mediators such as Bax, Bad, and Bim (51, 74, 126, 142, 179) and 
de-activate anti-apoptotic proteins like Bcl-2 (96, 142, 156). Transfection with MKK7γ1 
caused an up-regulation of Bim and cleaved Caspase-3 and a down-regulation of Bcl-2 and 
Bcl-xl. As shown by previous studies, JNK2 positively regulates bim transcription in PC12 
cells (55). This mechanism involves nuclear activation of the transcription factor c-Jun (197). 
The regulation of cell survival by Bcl-2 is tightly linked to activated JNK1, which 
phosphorylates Bcl-2 (44). In contrast, JNK1, but not JNK2 knockdown via siRNA, leads to 
reduced Bcl-2 levels in human leukemic CEM cells (36). 
 Summarizing, MKK7γ1 triggers a distinct JNK signalling pathway in PC12 cells by 
modulation of JNK isoform acitivities. Thereby, MKK7γ1 mediates changes on mRNA (Fas, 
Bim and Bcl-2), protein (c-Jun, c-Myc, p53, Fas, Bim, Bcl-2 and Bcl-xl) and activity levels 
(c-Jun, p53, c-Myc) of JNK targets which alters the normal PC12 cell phenotype to an anti-
proliferative and pro-apoptotic one. 
Tunicamycin stimulation- Cellular stress induced by tunicamycin is known to cause 
cell death by activation JNK and c-Jun in PC12 cells (213). Additionally, tunicamycin 
mediates a cell cycle arrest of neuronal cells (81). In MKK7γ1-transfected PC12 cells, 
tunicamycin hardly induces cell death, but stimulates proliferation. The changes in cellular 
JNK signalling might provide an explanation for these individual splice-variant-specific 
actions. Stimulation with tunicamycin generally increased phosphorylation of endogenous and 
exogenous MKK7 and JNK1/2. The cellular pool of activated JNK was located in nucleus and 
Discussion  113 
 
cytoplasm and increased after transfection with MKK7γ1. Immunodepletion experiments 
revealed a strong increase of activated JNK1 in MKK7γ1-transfected cells. This shift in 
isoform-specific JNK activity could be a reason for changes in cellular proliferation and 
apoptosis. Several studies observed a positive function of JNK1 in proliferation (86, 137, 
196), putatively by JNK1-dependent down-regulation of p21 (86). Here, MKK7γ1 offers an 
explanation for the observed contrary effects of tunicamycin by activation of a distinct 
downstream signalling. 
 
4.6.2 NGF-treated PC12 cells 
Basal conditions- The multiplicity of pathophysiological and physiological JNK 
functions in neurons are dependent on different factors, such as isoform specificity and 
cellular localization (reviewed by (11, 12, 36, 72). Looking at the cellular distribution of 
activated JNKs after differentiation, transfection with MKK7γ1 strongly increased the nuclear 
JNK pool. Western blots with isoform-specific antibodies revealed that this increase could be 
ascribed to JNK2α2 and JNK2β2, whereas JNK1 only contributes to the 46 kDa JNK fraction. 
This suggests that MKK7γ1 mediates its effects through JNK2 splice-variants in NGF-treated 
PC12 cells. The described functions of JNK2 cover a wide spectrum such as induction of 
apoptosis and tumour growth and promotion of proliferation and neurite regrowth (31, 49, 54, 
190). In human neuroblastoma cells, nuclear JNK2 is involved in both promotion of apoptosis 
and proliferation (193). Only little is known about splice-variant specific effects of JNK2α2 
and JNK2β2, which are unique among JNKs in their ability of autophosphorylation (182). 
JNK2α2 was found to be the major isoform in human brain glioblastoma (35). Therefore, 
MKK7γ1 might be the upstream component underlying the activation of JNK2 isoforms in 
the cellular transition of pro-proliferation during NGF supplementation. 
 Several studies using inhibitors or siRNA approaches have suggested that the 
transcription factor c-Jun acts as a JNK substrate during neuronal differentiation (114, 189, 
215). In this study c-Jun is strongly induced and phosphorylated after differentiation of PC12 
cells. The fact that MKK7γ1 further increased c-Jun levels implies that c-Jun not only 
contributes to differentiation, but also to proliferation as reported previously (6). 
 It is known that neurite outgrowth is a p53-dependent process in PC12 cells (4, 48). 
Mutant p53 protein, which lost its transcriptional activity, inhibits neurite extensions (48, 57, 
202). Opposite findings, however, report that a lack of functional p53 does not prevent 
terminal differentiation of PC12 cells (185) and p53 is rather linked to down-regulation of 
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proliferation than to differentiation in murine neuronal precursors (183). This thesis shows 
that p53 phosphorylation is enhanced during differentiation of PC12 cells. Whereas its 
phosphorylation is increased after JNK inhibition in vector-transfected cells, it is decreased in 
MKK7γ1-transfected cells. Therefore, transfection with MKK7γ1 leads to an enhanced JNK-
dependent phosphorylation of p53 during differentiation of PC12 cells. Assumably, p53 is 
normally phosphorylated by other kinases (e.g., ERK1/2 or p38) during PC12 cell 
differentiation. MKK7γ1 down-regulates those pathways and concurrently triggers p53 
phosphorylation by JNK. As all three MAPK have distinct p53 phosphorylation sites this 
MKK7γ1-mediated changes could influence p53 transcriptional activities. JNKs regulate p53 
not only by phosphoryation but also by direct interaction (2). This interaction is not linked to 
p53 activation, but to p53 stability (2, 61). This thesis shows that p53 binds to JNK1 and 
JNK2 in NGF-treated PC12 cells. Furthermore, MKK7γ1 reduced p53:JNK2 complexes and 
increased p53:JNK1 complexes, which implies contrary isoform-specific JNK functions and 
partially explains the differential effects in MKK7γ1- and vector-transfected cells. Whereas 
increased levels of phosphorylated JNK1 cause a decrease in p53, enhanced phosphorylated 
JNK2 levels increase p53 amounts in primary human fibroblasts (171). 
The JNK target c-Myc is supposed to regulate around 15% of all genes of the genome 
(66). These genes are involved in apoptosis, cell cycle, adhesion and differentiation (32, 40). 
MKK7γ1-transfected PC12 cells showed decreased c-Myc levels that were not affected by 
differentiation. The constant down-regulation of c-Myc in naïve and differentiated MKK7γ1-
transfected cells could be an important mechanism of MKK7γ1-mediated effects. 
Two important JNK-dependent cell cycle regulators are p21 and CyclinD1. The results 
of the present study show that p21 regulation during NGF-mediated PC12 cell differentiation 
is JNK-dependent. JNKs modulate p21 on various levels, like transcription, activation or 
stability (59, 65, 98). Therefore, some studies describe JNK as a negative regulator of p21 or 
in contrast as an positive regulator of p21 (71, 83, 136, 141). This study shows that active 
JNK represses p21 in naïve and differentiated PC12 cells. Interestingly, MKK7γ1 caused a 
reversion of the JNK effects on p21. Thus, MKK7 splice-variants constitute a further level 
upstream of JNKs in p21 regulation. Additionally, a JNK-mediated repression of CyclinD1 in 
differentiated PC12 cells has been observed. MKK7γ1 transfection further enhanced 
CyclinD1 induction following NGF treatment. 
 In summary, NGF activates or induces specific JNK signalling modules in PC12 cells, 
such as of c-Jun, p21 and CyclinD1 that promote differentiation. MKK7γ1 partially enhanced 
JNK signalling (c-Jun activation and induction; CyclinD1 induction) but also triggered 
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additional JNK-dependent activities (p53 activation, induction and binding) or even inverted 
JNK effects (c-Myc and p21 repression), which all might help to reverse the NGF-mediated 
PC12 cell phenotype. 
Taxol stimulation- This thesis shows that MKK7γ1-transfected PC12 cells still 
proliferated in spite of NGF supplementation, which rendered them susceptible to taxol that 
blocks mitosis. On a molecular level, taxol repressed c-Jun and p53 and induced p21 in NGF-
treated MKK7γ1-transfected cells. This is contrary to stress reactions in naïve PC12 cells, 
where MKK7γ1 even increased c-Jun and p53 and repressed p21 under stress conditions. 
 
4.7 Conditional changes in MKK7-JNK complex formation in naïve PC12 
cells 
The composition of JNK signalosomes has been investigated for several years (reviewed by 
(12)). However, the link between defined signalosomes and their cellular function is often 
missing. This study strongly suggest an anti-proliferative and pro-apoptotic function for JIP-
1:MKK7:JNK2 signalosome (Fig. 45). Kukekov and colleagues already found a complex 
consisting of POSH, JIP-1, MLK, MKK7 and JNK and assumed a function in PC12 cell death 
for this signalosome (105). Complexes between MKK7 and JNK1 only revealed a strong 
signal in unstimulated vector-transfected PC12 cells. After stimulation with tunicamycin and 
transfection with MKK7γ1, the complex almost completely disappeared. Furthermore, 
binding of JIP-1 and JNK1 was absolutely unaffected by transfection and stimulation with 
tunicamycin. 
JNK1 is known to interact with p21 in T-lymphocytes (137). This study demonstrates 
the presence of JNK:p21 complexes in neuronal cells for the first time. The amount of 
complexes between JNK2 and p21 correlated with the amount of p21 protein in PC12 cells, 
whereas JNK1:p21 complexes did not change. The results suggest different functions for 
JNK1 and JNK2 in the regulation of the cyclin-dependent kinase inhibitor p21. As JNKs 
phosphorylate, bind and stabilize p21, it is conceivable that individual JNK isoforms 
contribute to distinct functions (98, 137, 161). Binding between JNK and p21 is a further 
mechanism for JNK-mediated cell cycle regulation.  
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Fig. 45: Schematic model of MKK7γ1-mediated protein interactions. 
Differential impact of MKK7γ1 on protein interactions under normal cell growth conditions and after 
stimulation with tunicamycin (stress conditions). The JIP-1:MKK7:JNK2 signalosome is involved in 
regulation of proliferation and death in PC12 cells. 
 
4.8 MKK4 and MKK4∆ differently affect naïve PC12 cells 
This thesis presents a novel splice variant of MKK4, called MKK4∆. So far, only one gene 
product of mammalian mkk4 genes has been described. MKK4∆ contains an additional exon 
of 30 bp. This exon is located directly in front of the region encoding the JNK-binding 
domain. Therefore, a functional relevance was assumable. 
The preliminary results from overexpression of both MKK4 splice variants in naïve 
PC12 cells, revealed different results. Whereas MKK4 transfection decreased the number of 
viable PC12 cells under basal conditions MKK4∆ transfection increased it. Those changes in 
cell numbers can be caused by altered proliferation or cell death. Indeed, MKK4 mediated an 
increase in p21 protein levels whereas CyclinD1 levels were down-regulated compared to 
vector transfection, which could reduce proliferation of PC12 cells (59, 65, 98). Transfection 
with MKK4∆, however, strongly increased CyclinD1 levels compared to control PC12 cells 
and did not affect the p21 protein amount. The increased levels of anti-apoptotic Bcl-2 and 
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decreased levels of Bim following MKK4- and MKK4∆-transfection could also attenuate 
spontaneous apoptosis of MKK4∆-PC12 cells (143), but do not explain the observed decrease 
in cell number of MKK4-PC12 cells. 
MKK4 is unique among all MKKs in its ability to phosphorylate two different MAPKs, 
p38 and JNKs. Nevertheless, some studies revealed that the MKK4 activity towards p38 is 
less pronounced than towards JNKs (38). For example, knockout of mkk4 in MEFs causes a 
decrease in phospho-JNK levels but not in phospho-p38 levels under basal and stress 
conditions (188). Indeed, overexpression of the MKK4 splice variants only enhanced JNK1/2 
phosphorylation, whereas phophorylated p38 was unaffected. Concurrently, the activity levels 
of MKK7 was decreased in MKK4- and MKK4∆-transfected PC12 cells which indicates that 
the increase of activated JNK1/2 was due to MKK4 and the observed changes are mediated by 
JNKs. 
Surprisingly, phosphorylation of c-Jun was unaffected by MKK4 transfection and even 
reduced following MKK4∆ transfection. Studies on the distribution of MKK4, JNKs and c-
Jun in primary neurons have shown that MKK4 and JNKs are mainly located in the 
cytoplasm, whereas c-Jun and MKK7 are mainly located in the nucleus under basal conditions 
(30).  
 In response to taxol treatment, MKK4- and MKK4∆-transfected PC12 cells showed 
dramatically opposite reactions. MKK4 caused an increase of viable cells, whereas MKK4∆ 
transfection mediated a reduced cell survival. To understand these MKK4/∆-triggered 
differences in cell survival under stress conditions, further analysis needs to be done. 
 Summarizing, MKK4 and MKK4∆ have different effects on naïve PC12 cells even 
though their coding mRNAs only differ in 30 bp. Some of the investigated effects are contrary 
(e.g., cell numbers, taxol-induced cell death, p21 and CyclinD1 protein levels) and others are 
comparable for both MKK4 splice variants and only differ from control PC12 cells (e.g., 
activation and protein levels of MKK7, JNKs, p38).  
 
4.9 Perspectives 
The results of the present thesis have provided a basis for further research. It is of interest to 
investigate the observed MKK7γ1-mediated effects in vivo. Viral gene transfer enables the 
expression of single splice variants linked to a cell type-specific promoter in mice. This could 
be an adequate approach to check if the in vitro findings can be applied to primary neurons. 
Apart from physiological conditions, mouse models for different pathologies provide a system 
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to investigate a putative impact of MKK7γ1 based on the results of this study. On the one 
hand, MKK7γ1 could be an important player in neurological diseases as it blocks 
neuritogenesis. On the other hand, its opposing effects on cell proliferation and apoptosis 
following taxol indicate a role of MKK7γ1 in tumourigenesis. 
With regard to the functional characterization of MKK4 and MKK7 splice variants, the 
effects of the so far unknown MKK4∆ should be examined and compared to MKK4. PC12 
cells have proved a useful model system for the analysis of parallel MAPK signalling, which 
will be necessary for MKK4 functions since they can activate JNKs and p38. Therefore, not 
only different substrates will be analysed, but also specific inhibitors for JNK (SP600125) and 
p38 (SB239063) will be used to distinguish between the different MAPK pathways. 
The only structural difference between MKK4 and MKK4∆ is an additional protein 
fragment of 30 amino acids in MKK4∆ in front of the JNK binding domain. It is conceivable 
that this domain has an impact on the binding properties of MKK4 towards JNKs. Therefore, 
protein interactions of MKK4 and single JNK isoforms will be investigated by 
immunopreciptitations. 
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5 Summary 
The mitogen-activated protein kinase (MAPK) pathways are ubiquitious and highly expressed 
in all eukaryotic cells. Diverse stimuli activate MAPKs, whose intracellular network translates 
and integrates those signals into complex cytoplasmatic and nuclear processes which lead to 
organized cellular responses, like proliferation, differentiation or apoptosis. The c-Jun N-
terminale kinases (JNKs), one subfamily of MAPKs, are considered as essential signalling 
molecules for the differentiation, regeneration and programmed cell death of neurons. Apart 
from those physiological functions, JNKs mediate neurodegeneration and are involved in a 
number of pathologies such as Alzheimer’s or Parkinson’s disease. In answering the question, 
how JNKs regulate this functional dichotomy, their upstream activators, mitogen-activated 
protein kinase kinase (MKK) 4 and MKK7 are largely underestimated. The aim of this thesis 
was to use stable overexpression of MKK4 and MKK7 to investigate their effects on JNK 
functions in the rat adrenal pheochromocytoma cell line PC12. During cloning of both known 
JNK activators in the rat, MKK4 and MKK7β1, two so far unknown splice variants, MKK4∆ 
and MKK7γ1, were identified. Overexpression of MKK7γ1 in PC12 cells mediated distinct 
changes in activation and protein levels of JNK isoforms. Consequently, JNK signalling was 
changed at mRNA, protein and phosphorylation levels of JNK targets, such as transcription 
factors (c-Jun, p53, c-Myc), cell cycle regulators (p21WAF-1/CIP-1, CyclinD1) and apoptotic 
proteins (Fas, Bim, Bcl-2, Bcl-xl). Additionally, the assembly of JNK signalosomes was 
affected. These alterations promoted the sensitivity of PC12 cells towards cell death and 
repressed proliferation under normal cell growth conditions. After stimulation with taxol and 
tunicamycin, MKK7γ1 but not MKK7β1 transfection, reduced cell death and even increased 
cell proliferation.  
Furthermore, MKK7γ1 partially blocked nerve growth factor (NGF)-induced 
differentiation of PC12 cells via additional down-regulation of the NGF receptors TrkA and 
p75 as well as of the differentiation-promoting extracellular signal-regulated kinase 1/2 
(ERK1/2) and phosphatidylinositol-3-kinase (PI3K) pathways. These MKK7γ1-triggered 
effects induced an escape from cell cycle arrest and rendered PC12 cells sensitive to taxol-
mediated cell death. 
Overexpression of MKK4 and MKK4∆ caused opposite effects in PC12 cells. MKK4 
decreased the viability of cells under basal conditions and enhanced cell survival following 
taxol stimulation. In contrast, MKK4∆ increased the number of viable cells under basal 
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conditions, but reduced the viability of taxol-treated cells. Thus, single MKK4 and MKK7 
splice variants are powerful inductors of distinct and contrasting JNK actions depending on 
the cellular context and are at least partially responsible for the dichotomy of JNK signalling.  
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6 Zusammenfassung 
Die Mitogen-aktivierten Proteinkinasen (MAPK) sind zentrale Elemente der 
Signaltransduktion bei allen Eukaryoten. MAPK werden von einer Vielzahl verschiedenster 
Stimuli aktiviert. In der Zelle bilden sie ein Enzymnetzwerk, dass die Signale aufnimmt und 
in zytoplasmatische und nukleäre Vorgänge übersetzt, die schließlich zu organisierten 
zellulären Reaktionen, wie Proliferation, Differenzierung oder Apoptose führen. Eine 
wichtige Unterfamilie der MAPK sind die c-Jun N-terminalen Kinasen (JNK), die eine 
entscheidende Rolle bei der Differenzierung, Regeneration und beim programmierten Zelltod 
von Neuronen spielen. Abgesehen von diesen physiologischen Funktionen, vermitteln JNK 
auch Neurodegeneration und sind an einer Vielzahl von Krankheitsbildern wie Morbus 
Alzheimer oder Morbus Parkinson beteiligt. Bei der Beantwortung der Frage, wie JNK diese 
funktionelle Dichotomie bewirken, hat man der Bedeutung ihrer Aktivatoren, der Mitogen-
aktivierten Proteinkinasekinase (MKK) 4 und MKK7, bisher zu wenig Aufmerksamkeit 
geschenkt. Das Ziel dieser Arbeit war es, den Effekt von MKK4 und MKK7 auf JNK-
vermittelte Funktionen zu untersuchen. Dazu wurden sie in Phäochromozytom (PC12)-Zellen 
aus der Ratte stabil überexprimiert. Bei der Klonierung der beiden JNK-Aktivatoren, MKK4 
und MKK7β1, wurden zwei bisher unbekannte Spleißvarianten, MKK4∆ und MKK7γ1, in 
PC12 Zellen identifiziert. Überexpression von MKK7γ1 in PC12-Zellen veränderte die 
Phosphorylierung und die Proteinmenge von JNK-Isoformen. Infolgedessen war die Wirkung 
der JNK auf ihre Substrate verändert. Effekte konnten auf mRNA-, Protein- und 
Aktivitätsebene von Transkriptionsfaktoren (c-Jun, p53, c-Myc), Zellzyklusregulatoren 
(p21WAF1/CIP1, CyclinD1) und Regulatoren der Apoptose (Fas, Bim, Bcl-2 und Bcl-xl) 
beobachtet werden. Zusätzlich war die Zusammensetzung von JNK-Signalosomen verändert. 
All diese Veränderungen erhöhten die basale Apoptoserate der Zellen und verringerten ihre 
Proliferation unter normalen Wachstumsbedingungen. Nach Stimulation der Zellen mit Taxol 
oder Tunicamycin, verringerte MKK7γ1, aber nicht MKK7β1, den Zelltod und verstärkte 
gleichzeitig die Proliferation. 
Des Weiteren wurde die durch den Nervenwachstumsfaktor (nerve growth factor, 
NGF) eingeleitete Differenzierung von PC12-Zellen durch MKK7γ1 blockiert. 
Überexpression von MKK7γ1 verringerte die Proteinmengen und Phosphorylierung der NGF-
Rezeptoren (TrkA und p75) und einzelner Komponenten differenzierungsfördernder 
Signaltransduktionswege, wie den Extrazellulären Signal-regulierten Kinase 1/2 (ERK1/2) 
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und Phosphatidyl-Inositol-3-Kinase (PI3K). Außerdem verhinderte MKK7γ1 den 
Zelllzyklusarrest und machte die Zellen so anfällig gegenüber Taxol.  
Die Überexpression von MKK4 und MKK4∆ in PC12-Zellen bewirkte gegensätzliche 
Effekte. MKK4 verringerte die Viabilität der Zellen unter basalen Bedingungen und erhöhte 
die Überlebensrate der Zellen nach Taxol-Stimulation. Im Gegensatz dazu, erhöhte MKK4∆ 
die Anzahl lebender Zellen unter basalen Bedingungen, verstärkte jedoch den Taxol-
induzierten Zelltod. Somit sind einzelne MKK4 und MKK7 Spleißvarianten entscheidende 
Regulatoren von unterschiedlichen, teils auch gegensätzlichen JNK-Wirkungen in 
Abhängigkeit von der zellulären Umgebung. 
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8 Appendix 
8.1 Abbreviations and symbols 
A260, A280, A595 absorbance at 260, 280 or 595 nm, respectively 
Ala alanine (A) 
aa amino acid(s) 
AKT  protein kinase B 
AP-1 activator protein 1 
APS ammonium persulphate 
ASK apoptosis signal-regulating kinase 
ATF-2 activating transcription factor 2 
ATP adenosine triphosphate 
Bad Bcl-2-associated death promoter 
Bax Bcl-2-associated X protein 
Bcl-2 B cell lymphoma 2 
Bim Bcl-2-interacting mediator of cell death 
bp base pairs 
BrdU 5-bromo-2-deoxyuridine 
BS blocking solution 
BSA bovine serum albumin 
bsk basket 
CD common docking domain 
Cdk cyclin-dependent kinase 
cDNA complementary DNA 
CHAPS 3-[(3-cholamindopropyl)dimethyl-ammonio]-1-propanesulfonate 
ChIP chromatin immunoprecipitation 
cm centimeter 
CNS central nervous system 
CT cycle threshold 
d day(s) 
D docking domain 
DDW double-destilled water 
DEPC diethyl pyrocarbonate 
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DLK dual leucine zipper kinase 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP 2’-deoxynucleoside-5’-triphosphate 
dsDNA double-stranded deoxyribonucleic acid 
gDNA genomic deoxyribonucleic acid 
DTT dithiothreitol 
DUSP dual specificity phosphatase 
DVD domain of versatile docking 
E embryonic day(s) 
E. coli Escherichia coli 
e.g. exempli gratia 
ECL enhanced chemiluminescence 
ED glutamate/aspartate domain 
EDTA ethylenediaminetetraacetic acis 
EGFP enhanced green fluorescent protein 
EGTA ethylene glycol-bis(2-aminomethyl)-N,N,N’,N’-tetraacetic acid 
ELISA enzyme-linked immunosorbent assay
 
ER endoplasmatic reticulum 
ERK extracellular signal-regulated kinase 
Fas-l Fas-ligand 
FCS fetal calf serum 
Fig. figure 
g gram(s) 
GAPDH glycerinaldehyde-3-phosphate-dehydrogenase 
GFP green fluorescent protein 
GTP guanidine triphosphate 
h hour(s) 
H2A.z histone 2A variant z 
hep hemipterous 
HEPES N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
HRP horseradish peroxidase 
Ile isoleucine (I) 
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ID immunodepletion 
i.e. id est 
Ig immunglobulin 
IL interleukin 
IP immunoprecipitation 
JIP c-Jun N-terminal kinase-interacting protein 
JNK c-Jun N-terminal kinase 
JNKK c-Jun N-terminal kinase kinase 
kb kilobase 
kDa kilodalton 
l liter(s) 
LB Luria-Bertani medium 
LFU laminar flow unit 
Lys lysine (K) 
LZK leucine zipper-bearing kinase 
M molar (mol/l) 
MAP2K mitogen-activated protein kinase kinase 
MAP3K mitogen-activated protein kinase kinase kinase 
MAPK mitogen-activated protein kinase 
MEF mouse embryonic fibroblasts 
MEK mitogen-activated protein/extracellular signal-regulated kinase kinase 
MEKK mitogen-activated protein/extracellular signal-regulated kinase kinase 
mg milligram(s) 
min minute(s) 
MKK mitogen-activated protein kinase kinase 
MKKK mitogen.activated protein kinase kinase kinase 
MKP mitogen-activated protein kinase phosphatase 
ml milliliter(s) 
MLK mixed-lineage kinase 
mm millimeter(s) 
mM millimolar (mmol/l) 
MOPS 4-morpholino-propane-sulfonic acid 
mRNA messenger RNA 
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mV millivolt(s) 
ng nanogram(s) 
NGF nerve growth factor 
nm nanometer(s) 
OD600 optical density at 600 nm 
p probability 
p.a. pro analysis 
p21 p21WAF1/CIP1 
p75 p75 neutrophin receptor 
Pro proline (P) 
pAB primary antibody 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
pH potentia hydrogenii 
PI3K phosphatidyl-inositol-2-kinase 
PIPES piperazine-N,N’-bis(2-ethanesulfonic acid) 
PMSF phenyl-methyl sulfonyl fluoride 
POSH plenty of SH3 
PVDF polyvinylidene dufluoride 
QRT-PCR quantitative real time polymerase chain reaction 
r.t. room temperature 
rag recombination activating gene 
Ras rat sacroma viral oncogene homologue 
RCF relative centrifugal force  
rmax maximum radius 
RNA ribonucleic acid 
RNase ribonuclease 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute 
rRNA ribosomal ribonucleic acid 
RT reverse transcriptase; reverse transcription 
s second(s) 
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S Svedberg unit(s) 
sAB secondary antibody 
SAPK stress-activated protein kinase 
SCG10 super cervical ganglion 10 
SDS sodium dodecyl sulfate 
SEK stress-activated protein kinase/extracellular signal-regulated kinase kinase 
Ser serine (S) 
siRNA small interfering ribonucleic acid 
TA annealing/melting temperature of primers 
Tab. table 
TAK transforming growth factor β activated kinase 
TAO thousand-and-one amino acid protein kinase 
Taq Thermus aquaticus 
TAX taxol 
TBE Tris-boric acid-EDTA buffer 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Tween-20 
TEMED N,N,N’,N’-tetramethylethylenediamine 
Thr threonine (T) 
TM tunicamycin 
TNF-α tumour necrosis factor α 
Tris tris-(hydroxymethyl)-aminomethane 
TrkA tyrosine receptor kinase A 
Tyr tyrosine (Y) 
U unit(s) 
UV ultraviolet light 
vs versus 
v/v volume per volume 
w/v weight per volume 
ZAK sterile alpha motif and leucine zipper-containing kinase 
µg microgram(s) 
µl microliter(s) 
µm micrometer(s) 
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